NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Shekelle P, Maglione M, Bagley S, et al. Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Jan. (Comparative Effectiveness Reviews, No. 6.)

Cover of Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics

Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics [Internet].

Show details

Appendix DExcluded Articles

REJECTED: At Abstract

  1. Stroke and death associated with olanzapine. Prescrire Int. 2004 Dec; 13(74):226.
    Rec #: 243
  2. Aarnell G, Borjesson A Eder DN Olausson B Hetta J. Treatment resistant major depression - a comparison of fluoxetine/olanzapine combination therapy with venlafaxine. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum, June 23–27 2002, Montreal, Canada). 2002; 5(Suppl 1):S141. CODEN: RCT; ISSN: CN-00392863.
    Rec #: 947
  3. Albert, U.; Bergesio, C.; Pessina, E.; Maina, G., and Bogetto, F. Management of treatment resistant obsessive-compulsive disorder. Algorithms for pharmacotherapy. Panminerva Med. 2002 Jun; 44(2):83–91.
    Rec #: 483
  4. Alcántara Lapaz, A. G.; Morcillo Moreno, L., and Barcia Salorio, D. (Hosp General Universitario, Murcia, Spain). Risperidona en el tratamiento de trastornos afectivos. Bases fisiopatológicas y relaciones con otros trastornos europsiquiátricos. Anales De Psiquiatria. 1996 Mar; 12(3): 130–140; ISSN: 0213-0599 (Print).
    Rec #: 914
  5. Alexopoulos, G. S.; Silver, J. M., and Kahn, D. A. The expert consensus guideline series: treatment of agitation in older persons with dementia. Postgrad Med. 1998 Apr; 1–88.
    Rec #: 1209
  6. Allen, M. H.; Currier, G. W.; Hughes, D. H.; Reyes-Harde, M., and Docherty, J. P. The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgrad Med. 2001 May; (Spec No):1–88; quiz 89–90.
    Rec #: 178
  7. Allen, R. L.; Cooney, J. M., and Lawlor, B. A. The use of risperidone, an atypical neuroleptic, In Lewy Body disease. Int J Geriatr Psychiatry. 1994; 415–17.
    Rec #: 1331
  8. Allen, Robert M. (Rush-Presbyterian-St Luke’s Medical Ctr, Chicago, IL, US). Risperidone and obsessive-compulsive disorder. Psychiatric Annals. 1995 Sep; 25(9): 523–524; ISSN: 0048-5713 (Print).
    Rec #: 922
  9. Andersen SW, Tollefson GD Sanger T. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. 152nd Annual Meeting of the American Psychiatric Association. Washington DC, USA. 15–20th May, 1999. 1999. CODEN: RCT; ISSN: CN-00239267.
    Rec #: 968
  10. Andersen SW, Tollefson GD Sanger TM. DEPRESSIVE SIGNS AND SYMPTOMS IN SCHIZOPHRENIA: A PROSPECTIVE BLINDED TRIAL OF OLANZAPINE AND HALOPERIDOL CONFERENCE ABSTRACT. Schizophrenia Research (Abstracts of The VIIth International Congress on Schizohrenia Research, Santa Fe, New Mexcio USA. April 17–21 1999.). 1999; 1–3(269). CODEN: RCT; ISSN: CN-00278417.
    Rec #: 969
  11. Anderson, C.; Clark, W. R.; True, J.; Ereshefsky, L., and Miller, A. Risperidone, a novel antipsychotic, and weight change. Pharmacotherapy. 1993; 13:292.
    Rec #: 1452
  12. Anon. Study of aripiprazole in the treatment of patients with psychosis associated with dementia of the Alzheimer’s type. Clinical Trials Journal. 2003. CODEN: RCT; ISSN: CN-00452009.
    Rec #: 929
  13. Anwunah IJ, Mitropoulou V Bushnoe L Siever LJ. Risperidone treatment for schizotypal personality disorder. 51st Institute on Psychiatric Services; 1999 October 25th–November 2nd; New Orleans, LA, USA. 1999. CODEN: RCT; ISSN: CN-00320826.
    Rec #: 977
  14. Apeter, J. T.; Cantillon, M., and Goldstein, JM. Efficacy, safety, and tolerability of “Seroquel” (quetiapine fumarate) in elderly patients with psychotic disorders. Presented at the 36th Annual Meeting of the American College of Neuropsychopharmacology; Waikoloa, Hawaii.
    Rec #: 1140
  15. Aronson, S. M.; Lingam, V., and Stack, M. Risperidone in the treatment of the elderly psychiatirc patients. American Medical Directors Association 19th Annual Symposium; New Orleans, LA.
    Rec #: 1215
  16. Ayd FJ. Risperidone treatment for schizotypal personality disorder. International Drug Therapy Newsletter. 2001; 36(8):58. CODEN: CCT; ISSN: CN-00420887.
    Rec #: 955
  17. Baker RW, Ames D Umbricht D Chengappa KNR Schooler NR. Olanzapine’s impact on depressive and obsessive-compulsive symptoms in schizophrenia. Psychopharmacology Bulletin. 1995; 549. CODEN: RCT; ISSN: CN-00216181.
    Rec #: 992
  18. Ballard, C.; Lana, M.; Waite, T.; Bullock, R., and Bayly, A. The effectiveness of atypical antipsychotics for the treatment of agitation and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2002.
    Rec #: 159
  19. Barcia, D.; Giles, E.; Herraiz, M.; Morinigo, A.; Roca, M., and Rodriguez, A. [Risperidone in the treatment of psychotic, affective and behavioral symptoms associated to Alzheimer’s disease]. Actas Esp Psiquiatr. 1999 May–1999 Jun 30; 27(3):185–90.
    Rec #: 661
  20. Barker, M. J.; Benitez, J. G.; Ternullo, S., and Juhl, G. A. Acute oxcarbazepine and atomoxetine overdose with quetiapine. Vet Hum Toxicol. 2004 Jun; 46(3):130–2.
    Rec #: 305
  21. Bartzokis, G.; Freeman, T., and Roca, V. Risperidone in the treatment of chronic combat-related post traumatic stress disorder. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum, June 23–27 2002, Montreal, Canada). 2002; 5(Suppl 1):S130. CODEN: CCT; ISSN: CN-00392982.
    Rec #: 945
  22. Baskys, A. Quetiapine treatment of hallucinations and agitation of Lewy body disease (LBD): linking the unique receptor profile and neuroprotective pathways. 156th annual meeting of the American Psychiatric Association; San Francisco, CA.
    Rec #: 1030
  23. Baskys, A. and Davis, P. Atypical antipsychotic quetiapine in the treatment of the psychosis associated with Lewy body dementia. Presented at the 8th International Conference on Alzheimer’s Disease and Related Disorders; Stockholm, Sweden.
    Rec #: 1149
  24. Bech, Per (Frederiksborg General Hosp, Psychiatric Research Unit, Hillerod, Denmark E-mail: kd.af@ebep). The significance of delusions in depressive disorders. Current Opinion in Psychiatry. 2001 Jan; 14(1): 47–49 URL: http://www.co-psychiatry.com/; ISSN: 0951-7367 (Print).
    Rec #: 842
  25. Beck, Sarah; Paton, Carol; Euba, Rafael, and Goddard, Cait (Oxleas NHS Trust, Kent, United Kingdom). Atypical antipsychotics in the elderly. International Journal of Psychiatry in Clinical Practice. 2001 Dec; 5(4): 257–261 URL: http://www.tandf.co.uk/journals/md/13651501.html; ISSN: 1365-1501 (Print); 1471-1788 (Electronic).
    Rec #: 840
  26. Berkowitz, Alan (Pomerado Hospital Psychiatric Centers at San Diego, San Diego, CA, US). Ziprasidone for dementia in elderly patients: case review. Journal of Psychiatric Practice. 2003 Nov; 9(6): 469–473; ISSN: 1527-4160 (Print).
    Rec #: 806
  27. Berry, S. A. and Mahmoud, R. A. Normalization of olanzpine-associated abnormalities of insulin resistance and insulin release after switch to risperidone: the Risperidone Rescue Study (Poster). American College of Neuropsychopharmacology; Haiwaii.
    Rec #: 1446
  28. Bhanji, N. H. and Margolese, H. C. Extrapyramidal symptoms related to adjunctive nizatidine therapy in an adolescent receiving quetiapine and paroxetine. Pharmacotherapy. 2004 Jul; 24(7):923–5.
    Rec #: 280
  29. Blanchard MR. Risperidone in the treatment of behavioural disturbances in dementia. National Research Register. 2000. CODEN: RCT; ISSN: CN-00303024.
    Rec #: 964
  30. Boothby, H. (Mental Health Team for the Elderly, Bognor Regis, England). Anticholinergics in lewy body dementia: are they even worse than antidopaminergics? International Journal of Geriatric Psychiatry Vol. ISSN: 0885-6230 (Print); 1099-1166 (Electronic) DOI: 10.1002/(SICI)1099-1166(199607)11:7<660::AID-GPS461>3.0.CO;2-D.
    Rec #: 915
  31. Borison, R. L.; Davidson, M., and Berman, I. Risperidone treatment in elderly patients with schizophrenia or dementia. American Psychiatric Association 46th Institute of Hospital and Community Psychiatry.
    Rec #: 1212
  32. Borison, R. L.; Pathiraja, A. P.; Diamond, B. I., and Meibach, R. C. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull. 1992; 28(2):213–8.
    Rec #: 1300
  33. Bramble, David J. and Cosgrove, P. V. F. (Moore House CAMHS, United Kingdom; The Bristol Priority Clinic, Bath, United Kingdom). Parental assessments of the efficacy of risperidone in attention deficit hyperactivity disorder. Clinical Child Psychology & Psychiatry. 2002 Apr; 7(2): 225–233; ISSN: 1359-1045 (Print).
    Rec #: 778
  34. Brawman-Mintzer, O. Adjunctive risperidone for treatment resistant general anxiety disorders patient. Facing unmet needs: atypical antipsychotics for mood and anxiety. 156th APA Annual Meeting; San Francisco, CA. 2003.
    Rec #: 1069
  35. Brecher M, Clyde C Risperidone Study Group. Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia. Proceedings of the 8th Congress of the International Psychogeriatric Association: Jerusalem, Israel, August 17–22, 1997. 1997; 10. CODEN: RCT; ISSN: CN-00395630.
    Rec #: 990
  36. Brennan, R.; Lonegran, V., and Quilinan, T. et al. Case studies on the use of risperidone for the treatment of agitation of elderly patients with dementia. J Drug Assess. 1999; 2:247–53.
    Rec #: 1033
  37. Brodaty, H.; Katz, I.; DeDeyn, and Greenspan, A. Risperidone is effective in treating pyschotic symptomsin patients with psychosis of Alzheimer’s disease. Poster presented at the International College of Geriatric Psychopharmnacology Annual Meeting.; Basal, Switzeralnd.
    Rec #: 1493
  38. Brodaty H, Grossman F Bruynseels J Lyons B. Risperidone in the treatment of agitation and psychosis of dementia. International Psychogeriatrics. 2001; 13(Suppl 2):S108. CODEN: RCT; ISSN: CN-00395632.
    Rec #: 954
  39. Brown, E. S. Extrapyramidal side effects with low-dose risperidone. Canadian Journal of Psychiatry. 1997 Apr; 42(3): 325–326 URL: http://www.cpa-apc.org/Publications/cjpHome.asp; ISSN: 0706-7437 (Print).
    Rec #: 908
  40. Buchsbaum, M.; Hollander, E.; Pallanti, S.; Baldini-Rossi, N.; Platholi, J., and Sood, E. Positron emission tomography imaging of risperidone augmentation in SRI-refractory patients. Anxiety Disorders Association of America; Toronto, Canada. 2003.
    Rec #: 1067
  41. Bullock, R. and Saharan, A. Atypical antipsychotics: experience and use in the elderly. Int J Clin Pract. 2002 Sep; 56(7):515–25.
    Rec #: 465
  42. Burns, A.; Ko, G., and Grossman, F. Risperidone in the treatment of agitation, aggression and psychosis associated with dementia: pooled analysis including 1150 nursing home residents. Int J Neuropsychopharmacol. 2002; 5(1):892.
    Rec #: 1468
  43. Burns, A.; Lyons, B.; Ko, G., and Grossman, F. Risperidone in the treatment of agitation, aggression, and psychosis associated with dementia: poolled analysis including 1,150 nursing home residents. Annual Meeting of the American Psychiatric Association Institute on Psychiatric Services; Chicago, IL.
    Rec #: 1259
  44. Butterfield, M. I. (Department of Psychiatry (116A), VA Medical Center, Durham, NC, US). Olanzapine in the treatment-resistant, combat-related ptsd--a series of case reports: comment. Acta Psychiatrica Scandinavica. 2003 May; 107(5): 394–396 URL: http://www.blackwellmunksgaard.com/actapsych; ISSN: 0001-690X (Print); 1600-0447 (Electronic).
    Rec #: 804
  45. Bystritsky, A.; Ackerman, D. L., and Rosen, R. M. Augmentation os SSRI response in refractory OCD using adjunctive olanzapine: a placebo controlled trial. Fifth International Obsessive Compulsive Disorder Conference; Sardina, Italy.
    Rec #: 998
  46. Bystritsky A, Ackerman DL Rosen RM Vapnik T Gorbis E Maidment KM Saxen S. Augmentation of SSRIresponse in refractory ocd using adjunctive olanzapine:a placebo-controlled trial. 39th Annual Meeting of the American College of Neuropsychopharmacology. 2000; Dec 10–14; San Juan; Puerto Rico. 2000. CODEN: CCT; ISSN: CN-00352515.
    Rec #: 959
  47. Bystritsky A, Ackerman DL Rosen RM Vapnik T Gorbis E Maidment KM Saxena S. Augmentation of SSRI response in refractory OCD using adjunct olanzapine: a placebo-controlled trial. 2001 Annual Meeting of the American Psychiatric Association; 2001 May 5–10; New Orleans; LA, USA. 2001. CODEN: RCT; ISSN: CN-00335353.
    Rec #: 950
  48. Calabrese, J. R.; Bowden, C. L.; Mee-Lee, D., and et al. Lamotrigine or lithium in the maintenance treatment of bipolar I disorder [poster]. Annual meeting of the American Psychiatric Association; Philadelphia, PA.
    Rec #: 1396
  49. Calabrese, J. R.; Bowden, C. L., and Woyshville, M. J. Lithium and the anticonvulsants in the treatment of bipolar disorder. Raven Press. 1995; 1099–1111.
    Rec #: 1256
  50. Callaghan, J. T.; Cerimele, B. J.; Kassahun, K. J.; Nyhart, E. H. Jr; Hoyes-Beehler, P. J., and Kondraske, G. V. Olanzapine: interaction study with imipramine. J Clin Pharmacol. 1997 Oct; 37(10):971–8.
    Rec #: 716
  51. Carra, G.; Giacobone, C.; Pozzi, F.; Alecci, P., and Barale, F. [Prevalence of mental disorder and related treatments in a local jail: a 20-month consecutive case study]. Epidemiol Psichiatr Soc. 2004 Jan–2004 Mar 31; 13(1):47–54.
    Rec #: 187
  52. Carrey, N. J.; Wiggins, D. M., and Milin, R. P. Pharmacological treatment of psychiatric disorders in children and adolescents: focus on guidelines for the primary care practitioner. Drugs. 1996 May; 51(5):750–9.
    Rec #: 753
  53. Carson, W.; Marcus, R.; Jody, D., and et al. The effectiveness of switch to aripiprazole in the treatment of schizophrenia [poster]. Presented at the 40th American College of Neuropsychopharmacology Meeting; New York, NY.
    Rec #: 1341
  54. Carson, W.; Saha, A. R.; Iwanmoto, R., and et al. Meta-analysis of proactin effects with aripiprazole [poster]. XXIII CINP COngress; Montreal.
    Rec #: 1241
  55. Carson, W. H. and Kitagawa, H. Drug development for anxiety disorders: new roles for atypical antipsychotics. Psychopharmacol Bull. 2004 Winter; 38(1):38–45.
    Rec #: 284
  56. Cavazzoni P; Young C; PolzerJ, and et al. Incidence of cerebrovascular adverse events and mortality during antipsychotic clinical trials of elderly patients in dementia. Poster Presented at: 44th Annual New Clinical drug Evaluation Unit; Paris, France.
    Rec #: 1513
  57. Chan, W. C. and Lam, L. C. W. (Castle Peak Hosp, Psychogeriatric Dept, Tuen Mun, Hong Kong; Prince of Wales Hosp, Dept of Psychiatry, Shatin, Hong Kong). Response to onalaja and jainer. International Journal of Geriatric Psychiatry. 2002 Nov; 17(11): 1077 URL: http://www.interscience.wiley.com/jpages/0885-6230/; ISSN: 0885-6230 (Print); 1099-1166 (Electronic).
    Rec #: 828
  58. Chappell P, Sallee F. THE TOLERABILITY AND EFFICACY OF ZIPRASIDONE IN THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH TOURETTE’S SYNDROME (TS). 9th Congress of the Association of European Psychiatrists. Copenhagen, Denmark. 20–24th September 1998. 1998. CODEN: RCT; ISSN: CN-00279326.
    Rec #: 987
  59. Chopra, P.; Ng, C., and Schweitzer, I. Serotonin syndrome associated with fluoxetine and olanzapine. World J Biol Psychiatry. 2004 Apr; 5(2):114–5.
    Rec #: 304
  60. Chouinard, G.; Ross-Chouinard, A, and Annable, L. The extrapyramidal symptom rating scale. Can J Neurol Sci. 1980; 7:233.
    Rec #: 1430
  61. Chue, P.; Devos, E.; Duchesne, I., and et al. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection [poster]. Presented at the XXXII CINP Congress; Montreal, Canada.
    Rec #: 1356
  62. Citrome, L. and Volavka, J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry. 2002 Sep–2002 Oct 31; 10(5):280–91.
    Rec #: 1368
  63. Clark, W. S.; Street, J. S.; Sanger, T. M.; Feldman, P. D., and Breier, A. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer’s disease. 14th annual meeting of the American Association for Geriatric Psychiatry; San Francisco, CA. 2001.
    Rec #: 1091
  64. Comaty, Joseph E. and Advokat, Claire (Louisiana State U, Baton Rouge, LA, US). Indications for the use of atypical antipsychotics in the elderly. Journal of Clinical Geropsychology Special Issue: Management of Behavioral Problems in Late Life--Therapeutic Approaches and Related Issues. 2001 Oct; 7(4): 285–309 URL: http://www.wkap.nl/journalhome.htm/1079-9362; ISSN: 1079-9362 (Print).
    Rec #: 841
  65. Conn, D. K. and Simard, M. Case report: successful treatment of psychosis with olanzapine in a case of early dementia with Lewy bodies. International Journal of Geriatric Psychopharmacol. 2:47–49.
    Rec #: 1156
  66. Corey-Lisle, P. K.; Birnbaum, H.; Greenberg, P.; Marynchenko, M., and Dube, S. Economic impact of olanzapine plus fluoxetine combination therapy among patients treated for depression: a pilot study. Psychopharmacol Bull. 2003 Summer; 37(3):90–8.
    Rec #: 369
  67. Corya, S.; Andersen, S., and Dube, S. et al. Longterm olanzapine-fluoxetine use in major depressive disorder: interim data [Abstract P.1.028]. J Eur Coll Neuropsychopharmacol. 2002; 12(Suppl. 3):S182.
    Rec #: 1047
  68. Costa, e. Silva JA; Alvarez, N.; Mazzotti, G.; Gattaz, W. F.; Ospina, J.; Larach, V.; Starkstein, S.; Oliva, D.; Cousins, L.; Tohen, M.; Taylor, C. C.; Wang, J., and Tran, P. V. Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. J Clin Psychopharmacol. 2001 Aug; 21(4):375–81.
    Rec #: 1393
  69. Cozza, S. J. and Edison, D. L. Risperidone in adolescents. J Am Acad Child Adolesc Psychiatry. 1994 Oct; 33(8):1211.
    Rec #: 1176
  70. Cruz-Jentoft, A; Buron, J. A., and et al. Risperidone in the treatment of behavioural and psychological symptoms of dementia in patients diagnosed with vascualr or mixed -type dementia. Int J Psychiatry Clin Prac. 2005; 9(1):45–51.
    Rec #: 1474
  71. Czaplinski, A.; Steck, A. J., and Fuhr, P. [Tic syndrome]. Neurol Neurochir Pol. 2002 May–2002 Jun 30; 36(3):493–504.
    Rec #: 470
  72. Czekalla, J.; Kollack-Walker, S., and Beasley, C. M. Jr. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry. 2001; 62 Suppl 2:35–40.
    Rec #: 1401
  73. Daniel, D.; Reeves, K., and Harringan, E. P. The efficacy and safety of ziprasidone 80mg/day and 160mg/day in schizophrenia and schizaffective disorder. Schizophr Res. 1997; 24(1.2):77.
    Rec #: 1462
  74. Davidson, M. Long term efficacy, safety, and tolerability of risperidone in edlerly psychotic patients. Presented at 37th Annual Meeting of the American College of Neuropsychopharmacology; San Juan Puerto Rico.
    Rec #: 1137
  75. ---. Treatment of cognitive impairment in recent onset psychosis; a comparison of risperidone and haloperidol. Journal of the European College of Neuropsychopharmacology. 2993; 13(4):S334.
    Rec #: 1408
  76. Davis, P. and Baskys, A. Quetiapine effectively reduces psychotic symptoms in patients with Lewy Body dementia: an advantage of the unique pharmacological profile? Brain Aging. 2002; 2:49–53.
    Rec #: 1029
  77. De Deyn, P. P.; De Smedt, G., and Brecher, M. Efficacy and safety of resperidone in elderly patients with dementia: pooled results from phase III controlled trials. resented at the 11th Congress of the European College of Neuropsychopharmacology; Paris, France.
    Rec #: 1138
  78. De Deyn, P. P. and DeSmedt, G. Efficacy and safety of risperidone in elderly patients with dementia pooled results from phase III controlled trials. The 40th Annual meeting of the new clinical drug evaluation unit; 2000, Boca Raton, Florida, USA.
    Rec #: 235
  79. De Deyn Peter, Middelheim AZ De Smedt Goedele. Risperidone in the treatment of behavioral disturbances in dementia. 10th European College of Neuropsychopharmacology Congress. Vienna, Austria. 13th–17th September 1997. 1997. CODEN: RCT; ISSN: CN-00279793.
    Rec #: 989
  80. De Deyn PP, Brecher M DeSmedt G. Risperidone in 969 patients with dementia. XI World Congress of Psychiatry, Hamburg, August 6–11, 1999. 1999; Abstracts Volume II70. CODEN: RCT; ISSN: CN-00305355.
    Rec #: 976
  81. De Deyne, P. Risperidone in the treatment of behavioral disturbances in dementia. Poster presented at the Eighth Congress of the International Psychogeriatric Assoication; Jerusalem, Israel.
    Rec #: 1158
  82. De Deyne, P.; Jeste, D.; Auby, P.; Goyvaerts, H.; Brede, C.; Schneider, L.; Mintzer, J.; Iwamoto, I., and Carson, W. Arpiprazole treatment for psychosis in patients with alzheimer’s disease.; Prague. ECNPPoster presentation.
    Rec #: 1220
  83. De Smedt, G.; Lemmens, P., and Wyffels, V. Clinical Expert Report of risperidone in the treatment of behavioural disturbances in patients with dementia. Beeres: Janssen Research Foundation; 1997; Clinical Trial Reprt No. R-64766.
    Rec #: 1429
  84. DeDeyn PP and DeSmedt G. Risperidone in the treatment of behavioral disturbances in elderly patients with dementia. Poster. Eighth Congress of the International Psychogeriatric Association; Jerusalem, Israel.
    Rec #: 1521
  85. DeDeyn PP; Jeste DV; Mintzer JE, and et al. Aripiprazole in dementia of the Alzheimer’s type. Poster. 16th Annual Meeting of the American Association for Geriatric Psychiatry; Honolulu, Hawaii.
    Rec #: 1519
  86. Defilippi, J. L. and Crismon, M. L. Antipsychotic agents in patients with dementia. Pharmacotherapy. 2000 Jan; 20(1):23–33.
    Rec #: 640
  87. Demb, H. B. Risperidone in young children with pervasive developmental disorders and other developmental disabilities. J Child Adolesc Psychopharmacol. 1996 Spring; 6(1):79–80.
    Rec #: 104
  88. Devanand, D. P. and Levy, S. R. Neuroleptic treatment of agitation and psychosis in dementia. J Geriatr Psychiatry Neurol. 1995 Oct; 8 Suppl 1:S18–27.
    Rec #: 1195
  89. Devanand, D. P.; Michaels, K.; Sackeim, H. A.; Marder, K., and Mayeux, R. P. ANTIPSYCHOTICS IN THE TREATMENT OF DEMENTIA COMPLICATED BY PSYCHOSIS. 151st Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada. 30th May–4th June 1998. 1998; (No. 27D). CODEN: CCT; ISSN: CN-00279937.
    Rec #: 981
  90. Donnelly CL. Pharmacologic treatment approaches for children and adolescents with posttraumatic stress disorder. Child & Adolescent Psychiatric Clinics of North America. 2003; 12(2):251–269. CODEN: RCT; ISSN: CN-00477230.
    Rec #: 927
  91. Dube, S.; Andersen, S., and Paul, S. et al. Metaanalysis of olanzapine-fluoxetine use in treatment-resistant depression [Abstract P.1.021]. J Eur Coll Neuropsychopharmacol. 2002; 12(Suppl. 3):S179.
    Rec #: 1046
  92. Dube, S.; Andersen, S. W., and Sanger, T. M. Olanzapine-fluoxetine combination for pyschotic major depression. 155th annual meeting of the American Psychiatric Association; Philadelphia, PA.
    Rec #: 1223
  93. Dube, S.; Corya, S. A., and Andersen, S. W. et al. Efficacy of olanzapine/fluoxetine combination in treatment - resistant depression. 41st Annual Meeting, American College of Neuropsychopharmacology; San Juan, PR, Sout America.
    Rec #: 1263
  94. Dube S, Dube S Andersen SW Corya SA Sanger TM Tollefson GD. Olanzapine-fluoxetine for treatment-resistant depression. XII World Congress of Psychiatry, Aug 24–9, 2002, Yokohama, Japan. 2002; Abstract PO-46-47. CODEN: RCT; ISSN: CN-00431564.
    Rec #: 938
  95. Dube S, Dube S Andersen SW Sanger TM Tohen M Tollefson GD. Olanzapine-fluoxetine for psychotic depression. XII World Congress of Psychiatry, Aug 24–9, 2002, Yokohama, Japan. 2002; Abstract PO-46-46. CODEN: RCT; ISSN: CN-00431563.
    Rec #: 937
  96. Eerdekens, M.; Fleischhacker, W. W., and Xie, Y. Long-term safety of long-acting risperidone microspheres [poster]. Presented at the Collegium International Neuro-Pharmacologicum XXIII Congress; Montreal, Canada.
    Rec #: 1360
  97. Elliot, T. and Elliott, A. Quetiapine in the management of psychosis in dementia with Lewy bodies: preliminary findings of a pilot study. Presented at the Montreux meeting; Montreux, Switzerland.
    Rec #: 1148
  98. Elliott, T. J. A pilot study to evaluate the effectiveness of quetiapine in the management of psychosis in demential with Lewy bodies [abstract]. European and Mediterranean Regional Meeting; Rome, Italy. 2002.
    Rec #: 1028
  99. Emsley RA, Jones AM. Treatment of depressive symptoms in partially refractory schizophrenia: efficacy of quetiapine versus haloperidol. European Neuropsychopharmacology. 2001; 11(3):264. CODEN: RCT; ISSN: CN-00396647.
    Rec #: 956
  100. Eriksson, L.; Almqvist, A.; Mehnert, A.; Ingham, M., and et al. Treatment with long acting risperidone significantly reduces the need for institutional psychiatric care regardless of previous treatment [poster]. Presented at the 2004 Congress of the Collegium International Neuro-Psychopharmacology (CINP); Paris, France.
    Rec #: 1358
  101. Farah, A.; Beale, M. D., and Kellner, C. H. Risperidone and ECT combination therapy: a case series. Convuls Ther. 1995 Dec; 11(4):280–2.
    Rec #: 760
  102. Farragher, B. and Walsh, N. (Clondalkin Mental Health Service, Dublin, Ireland). Delayed onset of extrpyramidal side-effects on combining paroxetine with risperidone. Irish Journal of Psychological Medicine. 1997 Sep; 14(3): 117; ISSN: 0790-9667 (Print).
    Rec #: 904
  103. Fernandez, H. H. and Friedman, J. H. The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs. 1999; 11(6):467–483.
    Rec #: 1264
  104. Finkel, S. I. Managing the behavioral and psychological signs and symptoms of dementia. Int Clin Psychopharmacol. 1997 Sep; 12 Suppl 4:S25–8.
    Rec #: 726
  105. Frenchman, B.; Dang, J. C., and Prince, T. Effects of risperidone, haloperidol, and olanzapine on behavioral symptoms in nursing home patients. 11th annual meeting of the American Association for Geriatric Psychiatry; San Diego, CA. 1998.
    Rec #: 1093
  106. Frenchman, I. B. Risperidone, haloperidol, and olanzapine for the treatment of behavioral disturbances in nursing home patients: a retrospective analysis. Current Therapeutic Research. 2000 Oct; 61(10): 742–750 URL: http://www.currenttherapeuticres.com/; ISSN: 0011-393X (Print).
    Rec #: 863
  107. Frenchman, I. B.; Pierno, M., and Stenstrom. Comparison of atypical agents and haloperidol in nursing home patients. American Psychiatirc Association Annual Meeting: New Research Program & Abstracts. v. 208).
    Rec #: 1127
  108. Frenchman, I. B. and Prince, T. Effects of risperidone, haloperidol, and olanzapine on behavioral symptoms in nursing home patients. Presented at the 28th Annual Meeting of the Americna Society of Consultant Pharmacists; Philadelphia, PA.
    Rec #: 1135
  109. Fryburg, D. A.; O’Sullivan, R. L.; Siu, C., and Simpson, G. Insulin resistance in olanzapine- and ziprasidone-treated patients: interim results of a double-blind controlled 6-week trial. American Psychiatric Association; New Orleans, LA. 2001.
    Rec #: 1099
  110. Garnis-Jones, S.; Collins, S., and Rosenthal, D. Treatment of self-mutilation with olanzapine. J Cutan Med Surg. 2000 Jul; 4(3):161–3.
    Rec #: 1014
  111. Geirz, M.; An, A., and Jeste, D. V. Use of respiridone in th elderly (poster). Presented at the 9th Annual Meeting of American Association for Geriatric Psychiatry; Tucon, AZ.
    Rec #: 1136
  112. Geizer, M. and Ancill, R. J. Combination of risperidone and donepezil in Lewy body dementia. Can J Psychiatry. 1998 May; 43(4):421–2.
    Rec #: 706
  113. Gelenberg, A. J. and Jefferson, J. W. Lithium tremor. J Clin Psychiatry. 1995 Jul; 56(7):283–7.
    Rec #: 1273
  114. Gentile, S. Antipsychotic-associated weight gain. Ann Pharmacother. 2004 May; 38(5):903–4.
    Rec #: 335
  115. Geodon. Ziprasidone hydrochloride (package insert). Physician’s Desk Reference. Montvale, NJ: Thompason PDR; 2005; pp. 2609–15.
    Rec #: 1607
  116. Georgescu MJ, Nica-Udangiu L. Olanzapine in psychotic depression in parkinson’s disease. XI World Congress of Psychiatry, Hamburg, August 6–11, 1999. 1999; Abstracts Volume II246. CODEN: RCT; ISSN: CN-00305981.
    Rec #: 971
  117. Gerritsen, A. A.; de Jonghe-Rouleau, A. P., and Stienstra-Liem, L. H. [Neuroleptic malignant syndrome in users of risperidone]. Ned Tijdschr Geneeskd. 2004 Sep 11; 148(37):1801–4.
    Rec #: 259
  118. Gibson, P. J.; Ogostalick, A.; Zhu, B., and et al. Risperidone versus olanzapine: how population characteristics can confound results. Drug Benefit Trends. 2003; 15(1):38–46.
    Rec #: 1369
  119. Gierz, M.; An, A., and Jeste, D. V. Use of risperidone in the elderly. Ninth Annual Meeting of the American Association for Geriatric Psychiatry; Tucson, AZ.
    Rec #: 1213
  120. Ginsberg, David L. (Tisch Hospital, Department of Psychiatry, New York University Medical Center, New York City, NY, US). Olanzapine-associated pulmonary embolism. Primary Psychiatry. 2004 Feb; 11(2): 14–15 URL: http://www.primarypsychiatry.com/index.php3; ISSN: 1082-6319 (Print).
    Rec #: 790
  121. --- (Tisch Hospital’s Department of Psychiatry, New York University Medical Center, New York City, NY, US). Olanzapine-lnduced eruptive xanthomas. Primary Psychiatry. 2003 Dec; 10(12): 18–19 URL: http://www.primarypsychiatry.com/index.php3; ISSN: 1082-6319 (Print).
    Rec #: 777
  122. Glick, I. D.; Romano, S. J.; Simpson, G.; Horne, R. L.; Weiden, P.; Pigott, T., and Bari, M. Insulin resistance in olanzapine- and ziprasidone- treated patients: results of a double-blind, controlled 6-week trial. Annual Meeting of the American Psychiatric Association; New Orleans, LA. 2001.
    Rec #: 1100
  123. Goldberg, R. J. Long-term use of risperidone for the treatment of dementia-related behavioural disturbances in a nursing home population. International Journal of Geriatric Psychopharmacol. In press.
    Rec #: 1126
  124. Goldberg, R. J. Risperidone in dementia-related disturbed behavior in nursing home residents. Clinical Geriatric. 1996; 4:58–68.
    Rec #: 1216
  125. Golstein, J. M. and Brecher, M. (AstraZeneca Pharmaceuticals, Wilmington, DE, US). Clarification of anticholinergic effects of quetiapine. Journal of Clinical Psychiatry. 2000 Sep; 61(9): 680; ISSN: 0160-6689 (Print).
    Rec #: 874
  126. Goodman, M.; Koenigsberg, H. W.; New, A. S.; Mitropoulou, V.; Trestman, R. L.; Silverman, J., and Siever, L. J. Risperidone treatment of schizotypal personality disorder. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18–23rd; Philadelphia, PA, USA. 2002. CODEN: RCT; ISSN: CN-00429230.
    Rec #: 946
  127. Goodwin, F. K. and Jamison, K. R. Manic-depressive illness. Oxford University Press. 1990.
    Rec #: 1257
  128. Green, B. Focus on ziprasidone. Curr Med Res Opin. 2001; 17(2):146–50.
    Rec #: 520
  129. Greenspan A; Eerdekens M, and Mahmound R. Is there an increased rate of cerebrovascular events among dementia patients? Poster Presented at: 24th Congress of the Collegium Internationale Neuro-Psychoparmacologicum (CINP); Paris, France.
    Rec #: 1512
  130. Grohmann, R.; Schmidt, L. G.; Spiess-Kiefer, C., and Ruther, E. Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AMUP program. Psychopharmacology (Berl). 1989; 99 Suppl:S109–12.
    Rec #: 226
  131. Gunn, K. P.; Harringan, E. P., and Heym, J. The safety and tolerability of ziprasidone treatment. In: Brunello, N., Racagni, G., Langer, S.Z., et al..editors. Critical issues in the treatment of schizophrenia. Basal: Karger. 1995; 10:172–7.
    Rec #: 1464
  132. Gupta, M. A. and Gupta, A. K. Olanzapine is effective in the management of some self-induced dermatoses: three case reports. Cutis. 2000 Aug; 66(2):143–6.
    Rec #: 1015
  133. Gupta, S.; Masand, P. S.; Virk, S.; Schwartz, T.; Hameed, A.; Frank, B. L., and Lockwood, K. (U Buffalo, School of Medicine and Biomedical Sciences, Department of Psychiatry, Buffalo, NY, US; Duke U, Medical Ctr, Department of Psychiatry, Durham, NC, US; State U New York, Upstate Medical U, Syracuse, NY, US; State U New York, Upstate Medical U, Syracuse, NY, US; State U New York, Upstate Medical U, Syracuse, NY, US; U Buffalo, School of Medicine and Biomedical Sciences, Department of Psychiatry, Buffalo, NY, US; Global Research and Consulting, Olean, NY, US E-mail: ten.aihpleda@1atpugs). Weight decline in patients switching from olanzapine to quetiapine. Schizophrenia Research. 2004 Sep; 70(1): 57–62 URL: http://www.elsevier.com/locate/schres; ISSN: 0920-9964 (Print).
    Rec #: 792
  134. Gustafson, Y.; Lundstrom, M.; Bucht, G., and Edlund, A. [Delirium in old age can be prevented and treated]. Tidsskr Nor Laegeforen. 2002 Mar 20; 122(8):810–4.
    Rec #: 477
  135. Hamilton, S. P.; Klimchak, C., and Nunes, E. V. Treatment of depressed methadone maintenance patients with nefazodone. A case series. Am J Addict. 1998 Fall; 7(4):309–12.
    Rec #: 688
  136. Harry, P. [Acute poisoning by new psychotropic drugs]. Rev Prat. 1997 Apr 1; 47(7):731–5.
    Rec #: 735
  137. Harvey, P.; Simpson, G. M., and Loebel, A. Effect of ziprasidone vs olanzapine on cognition in schizophrenia: a double-blind study. Int J Neuropsychopharmacol. 2002; 5(Suppl 1):S125.
    Rec #: 227
  138. Hausmann, A. and Fleischhacker, W. W. (Innsbruck U Hosp, Dept of General Psychiatry, Innsbruck, Austria). Depression in patients with schizophrenia: prevalence and diagnostic and treatment considerations. CNS Drugs. 2000 Oct; 14(4): 289–299 URL: http://www.adis.com/page.asp?objectID=40; ISSN: 1172-7047 (Print).
    Rec #: 784
  139. Hock, C.; Wettstein, A.; Giannakopoulos, P.; Schupbach, B., and Muller-Spahn, F. [Diagnosis and therapy of behavior disorders in dementia]. Schweiz Rundsch Med Prax. 2000 Nov 16; 89(46):1907–13.
    Rec #: 595
  140. Hoehns, J. D.; Fouts, M. M.; Kelly, M. W., and Tu, K. B. Sudden cardiac death with clozapine and sertraline combination. Ann Pharmacother. 2001 Jul–2001 Aug 31; 35(7–8):862–6.
    Rec #: 549
  141. Iakovlev, V. A. [The new antipsychotic preparation Rispolept (risperidone)]. Voen Med Zh. 1999 Nov; 320(11):43–5.
    Rec #: 638
  142. Ilett, K. F.; Hackett, L. P.; Kristensen, J. H.; Vaddadi, K. S.; Gardiner, S. J., and Begg, E. J. Transfer of risperidone and 9-hydroxyrisperidone into human milk. Ann Pharmacother. 2004 Feb; 38(2):273–6.
    Rec #: 342
  143. Irizarry, M. C.; Binetti, T., and Gomez-Isla, T. Treatment of behavioral disturbances in dementia with risperidone. Neurology. 1996; 46: 218.
    Rec #: 1161
  144. Izrayelit, L. (Jacobi Medical Ctr, Bronx, NY, US). Schizoaffective disorder and ptsd successfully treated with olanzapine and supportive psychotherapy. Psychiatric Annals. 1998 Aug; 28(8): 424–426; ISSN: 0048-5713 (Print).
    Rec #: 893
  145. Jeste, D.; Glazer, W., and Morgenstern, H. Low incidence of tardive dyskinesia with quetiapine treatment of psychotic disorders in th elderly. Presented at the 13th Annual meeting of the American Association Geriatric Psychiatry; Miami, FL.
    Rec #: 1143
  146. Jeste, D. V. Comparison of conventional vs. atypical antipsychotic drugs: focus on elderly patients. Long-term Care Forum: psychotherapeutic management of the long-term care patient. Long Term Care Forum. 2002; 10–3.
    Rec #: 1258
  147. Jeste, D. V.; Glazer, W. M.; Morgenstern, H.; Pultz, J. A., and Yeung, P. P. Rarity of persistent tardive dyskinesia with quetiapine: treatment of psychotic disorders in the elderly. Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; Nashville, TN.
    Rec #: 1230
  148. Jeste, D. V.; Okamoto, A.; Napolitano, J.; Kane, J. M., and Martinez, R. A. Dr. Jeste and colleagues reply. American Journal of Psychiatry. 2001 Aug; 158(8): 1337 URL: http://ajp.psychiatryonline.org/; ISSN: 0002-953X (Print).
    Rec #: 856
  149. Jody, D.; Saha, A. R.; Iwamoto, T., and et al. Meta-analysis of weight effects with aripiprazole [poster]. XXIII CINP Congress; Montreal.
    Rec #: 1243
  150. Jones, A. M.; Rak, I. W.; Raniwalla, J.; Phung, D., and Melvin, K. Weight changes in patients treated with ‘Seroquel’ (quetiapine) (poster). Winter Workshop; Davos, Switzerland.
    Rec #: 1456
  151. Jones, B.; Wang, H.; David, S. R.; Nisivoccia, J. R.; Beasley, C. M., and Meehan, K. M. A double-blind, placebo-controlled study of short-acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia. 39th Annual Meeting of the American College of Neuropsychopharmacology. 2000; Dec 10–14; San Juan; Puerto Rico. 2000. CODEN: RCT; ISSN: CN-00353050.
    Rec #: 958
  152. Jones, M. and Huizar, K. Quetiapine monotherapy for acute mania associated with bipolar disorder (STAMP 1 and STAMP2). 156th APA Annual Meeting; San Francisco, CA.
    Rec #: 1060
  153. Jones, R.; Lasser, R. A.; Bossie, C. A., and Conley, R. R. Clinical improvements with long-acting risperidone in patients previously receiving oral olanzapine [poster]. Presented at the 156th American Psychiatric Association Annual Meeting; San Francisco, CA.
    Rec #: 1354
  154. Juncos, J. L.; Jewart, D. R., and Gearing, M. Quetiapine treatment of psychosis symptoms in Lewy body dementia: long term experience in ten patients with three pathologically confirmed cases. Presented at the 125th annual meeting of the American Neurological Association; Boston, Mass.
    Rec #: 1150
  155. Kawashima, Shinji; Nakazawa, Tsuneyuki; Kishiro, Masaki; Seki, Norio; Hihara, Hiroo, and Ogura, Kiyoshi (Hasegawa Hosp, Mitaka, Japan). Translated title: a case of frontotemporal dementia with paraphilia. Seishin Igaku (Clinical Psychiatry). 1999 Apr; 41(4): 413–416; ISSN: 0488-1281 (Print).
    Rec #: 882
  156. Kearns, A. E.; Goff, D. C.; Hayden, D. L., and Daniels, G. H. Risperidone-associated hyperprolactinemia. Endocr Pract. 2000 Nov–2000 Dec 31; 6(6):425–9.
    Rec #: 1153
  157. Keck, P.; Corya, S.; Case, M., and Tohen, M. Analysis of treatment-emergent mania with olanzapine/fluoxetine combination. 156th APA Annual Meeting; San Francisco, CA.
    Rec #: 1055
  158. Keck, P. and Licht. Antipsychotic medications in the treatment of mood disorders. Bristol, England: Edward Arnold.
    Rec #: 1107
  159. Keck, P. E.; Reeves, K., and Harrigan, E. P. Ziprasidone in the acute treatment of patients with schizoaffective disorder: results from 2 double-blind, placebo-controlled, multicenter studies. J Clin Psychiatry. 2000; 21:27–35.
    Rec #: 1109
  160. Keck, P. E. Jr; Wilson, D. R.; Strakowski, S. M.; McElroy, S. L.; Kizer, D. L.; Balistreri, T. M.; Holtman, H. M., and DePriest, M. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry. 1995 Oct; 56(10):466–70.
    Rec #: 763
  161. Kelly, D. L.; Conley, R. R.; Love, R. C.; Horn, D. S., and Ushchak, C. M. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol. 1998; 8(3):151–9.
    Rec #: 1133
  162. Kennedy JS; Deberdt W; Micca J, and et al. The effect of olanzapine of cognition in patients with Alzheimer’s disease without psychosis or agitation. Poster. International College of Geriatric Psychoneuropharmacology; Basel, Switzerland.
    Rec #: 1520
  163. Kinon, B. Improvement of comorbid depression with olanzapine versus ziprasidone treatment in patients with schizophrenia or schizoaffective disorder. Eleventh Biennial Winter Workshop on Schizophrenia; Feb 7–14, 2004. Davos, Switzerland. 2004.
    Rec #: 230
  164. Kirrane, R. M. (Stewart’s Hosp, Dublin, Ireland). Olanzapine-induced akathisia in ocd. Irish Journal of Psychological Medicine. 1999 Sep; 16(3): 118; ISSN: 0790-9667 (Print).
    Rec #: 879
  165. Kirwan Jeffrey, Brodaty Henry Ames David Snowdon John Woodward Michael Clarnette Roger Lee Emma. Risperidone in the treatment of agitation and psychosis of dementia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18–23rd; Philadelphia, PA, USA. 2002. CODEN: RCT; ISSN: CN-00421077.
    Rec #: 942
  166. Kondoh, Hitoshi and Asano, Hirotake (Sendai City Hosp, Dept of Psychiatry, Sendai, Japan; Sendai City Hosp, Dept of Psychiatry, Sendai, Japan). Translated title: a case of obsessive-compulsive disorder successfully treated with small dose of risperidone. Seishin Igaku (Clinical Psychiatry). 2002 Mar; 44(3): 302–304; ISSN: 0488-1281 (Print).
    Rec #: 835
  167. Kossoff, E. H. and Singer, H. S. Tourette syndrome: clinical characteristics and current management strategies. Paediatr Drugs. 2001; 3(5):355–63.
    Rec #: 559
  168. Kozma, C. M.; Engelhart, L.; Long, S.; Greenspan, A.; Mahmoud, R., and Baser, O. No evidence for relative stroke in elderly dementia patients treated with risperidone versus other antipsychotics. 2004.
    Rec #: 236
  169. Kropp, S.; Schlimme, J., and Schneider, U. (Hanover Medical School, Dept of Clincial Psychiatry & Psychotherapy, Germany). Psychotic depression, subcortical arteriosclerotic encephalopathy and holocaust-conditioned posttraumatic stress disorder. Australian & New Zealand Journal of Psychiatry Vol. ISSN: 0004-8674 (Print).
    Rec #: 853
  170. Kruglov, L. S. [Use of rispolept for psychotic symptoms in elderly patients with vascular psychoorganic syndrome]. Voen Med Zh. 2002 May; 323(5):63–7.
    Rec #: 480
  171. Kufferle, B.; Brucke, T.; Topitz-Schratzberger, A.; Tauscher, J.; Gossler, R.; Vesely, C.; Asenbaum, S.; Podreka, I., and Kasper, S. Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. Psychiatry Res. 1996 Nov 25; 68(1):23–30.
    Rec #: 747
  172. Kukopulos, A.; Reginaldi, D.; Laddomada, P.; Floris, G.; Serra, G., and Tondo, L. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol. 1980 Jul; 13(4):156–67.
    Rec #: 1274
  173. Kuntz, A. J.; Reams, S. G.; Sanger, T. M., and Beasley, C. M. Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders. 9th Biennial Winter Workshop on Schizophrenia; Davos, Switzerland. 1998.
    Rec #: 1086
  174. Kunwar, A. R.; Megna, J. L., and Gorman, J. M. (Dept of Psychiatry, SUNY Upstate Medical U, Syracuse, NY, US; Dept of Psychiatry & Dept of Internal Medicine, SUNY Upstate Medical U, Syracuse, NY, US; Dept of Psychiatry, Mount Sinai School of Medicine, NY, US). Ziprasidone substitution in a patient with risperidone-induced hyperprolactinemia. Journal of Psychiatric Practice. 2003 May; 9(3): 245–247; ISSN: 1527-4160 (Print).
    Rec #: 810
  175. Kurz, A.; Delius-Stute, H.; Rettig, K., and Schwalen, S. [Treatment of behavioral disorders in dementia with risperidone in psychogeriatric outpatients]. MMW Fortschr Med. 2003 Oct 16; 145(42):55.
    Rec #: 358
  176. Lacro, J. P.; Vanderswag, H.; Polichar, D.; Claigiuri, M.; Plamer, B., and Jeste, D. A randomized, double-blind comparison of risperidone vs haloperidol in older patients with schizophrenia or schizoaffective disorder. New Clinical Drug Evaluation Unit 41st Annual Meeting; Phoenix, AZ.
    Rec #: 1336
  177. Lam, Y. W. F. Concurrent donepezil, risperidone treatment appears to be safe. Brown University Psychopharmacology Update. 2004; 15(4):2–3.
    Rec #: 1409
  178. Lane, L. M.; Burns, P. R.; Sanger, T. M.; Beasley, C. M. Jr., and Tollefson, G. D. Olanzpine in the treatment of elderly patients with schizophrenia and related psychotic disorders. 11th Annual Meeting of the European College of Neuropsychopharmacology; Paris, France. 1998.
    Rec #: 1101
  179. Lavretsky, H. and Sultzer, D. An open-label study of risperidone for the treatment of agitation in dementia. 149th Annual Meeting of the American Psychiatirc Association; New York, NY.
    Rec #: 1214
  180. Lee, D. W. No significant difference in the risk of diabetes mellitus during treatment with typical veruss atypical antipsychotics. Results from a large observation trial. Drug Benefit Trends. 2002; 46–51.
    Rec #: 239
  181. Lee, T. W.; Tsai, S. J., and Hwang, J. P. Severe cardiovascular side effects of olanzapine in an elderly patient: case report. Int J Psychiatry Med. 2003; 33(4):399–401.
    Rec #: 310
  182. Lemmens, P.; De Deyn, P., and De Smedt, G. Risperidone in the treatment of behavioral disturbances in dementia. 36th Annual Meeting of the American College of Neuropsychopharmacology; Kamuela, HI. December 8–12, 1997.
    Rec #: 1210
  183. Li, X.; Jackson, W.; May, R.; Tolbert, L., and Baxter, L. Risperidone as adjunctive treatment for SSRI-refrarctory obsessive-compulsive disorder. Biol Psychiatry. 2002; 51:51.
    Rec #: 1065
  184. Lieberman, J. A. Safety considerations in the use of atypical antipsychotics. Primary Care Companion Reports. 2003 Oct; 3(3):1–10.
    Rec #: 1385
  185. Lindenmayer, J. P. (Yeshiva U, Albert Einstein Coll of Medicine-Bronx Psychiatric Ctr, Schizophrenia Research Unit, US). Risperidone: efficacy and side effects. Journal of Clinical Psychiatry Monograph Series Vol. ISSN: 0742-1915 (Print).
    Rec #: 923
  186. Listernick, R. A nine-year-old girl with new-onset tics. Pediatr Ann. 2003 Feb; 32(2):76–9.
    Rec #: 424
  187. Lodge, P.; Tanner, M., and McKeogh, M. M. Risperidone in the management of agitation in HIV dementia. Palliat Med. 1998 May; 12(3):206–7.
    Rec #: 694
  188. Lombroso, P. J.; Scahill, L.; King, R. A.; Lynch, K. A., and et al. (Yale U, School of Medicine, Child Study Ctr, New Haven, CT, US). “Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report”: errata. Journal of the American Academy of Child & Adolescent Psychiatry. 1996 Mar; 35(3): 394; ISSN: 0890-8567 (Print).
    Rec #: 917
  189. Lott, R. S.; Kerrick, J. M., and Cohen, S. A. Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. Psychopharmacol Bull. 1996; 32(4):721–9.
    Rec #: 1293
  190. Loy, Rebekah; Tariot, Pierre N., and Rosenquist, Klara. Alzheimer’s disease: behavioral management.
    Rec #: 876
  191. Madhusoodanan, S.; Brenner, R.; Araujo, L., and Abaza, A. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry. 1995 Nov; 56(11):514–8.
    Rec #: 762
  192. Madhusoodanan, S.; Brenner, R., and Cohen, C. I. (State U New York, Health Science Ctr, Brooklyn, NY, US). Role of atypical antipsychotics in the treatment of psychosis and agitation associated with dementia. CNS Drugs. 1999 Aug; 12(2): 135–150 URL: http://www.adis.com/page.asp?objectID=40; ISSN: 1172-7047 (Print).
    Rec #: 883
  193. Magnuson WG. Childhood onset psychotic disorders:characterization and treatment with atypical neuroleptics/Treatment of childhood onset psychotic disorders with olanzapine or clozapine. National Institutes of Health (Http:, Www.Clinicaltrials.Gov/ Accessed 16th Feb 2001). 2001. CODEN: CCT; ISSN: CN-00324655.
    Rec #: 951
  194. Mandoki, M. Olanzapine in the treatment of early onset schizophrenia in children and adolescents. Biol Psychiatry. 1997; 41 (suppl 7S):22S.
    Rec #: 1205
  195. Mandoki, M. W. Risperidone treatment of children and adolescents: increased risk of extrapyramidal side effects? Journal of Adolescence Psychopharmacol. 1995; 5:49–67.
    Rec #: 1202
  196. Marciniak, B. H. and Guay, D. R. P. Risperidone in the long-term care population. Consult Pharm. 1995; 10:1374–78.
    Rec #: 1160
  197. Mark, T. L. Preferences among antipsychotic medications given particular clinical scenarios. Schizophr Res. 2004 Jan 1; 66(1):71–3.
    Rec #: 1370
  198. Markowitz, J. S. and DeVane, C. L. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration. J Clin Psychopharmacol. 1999 Jun; 19(3):289–91.
    Rec #: 667
  199. Martin, A.; Landau, J.; Leebens, P.; Ulizio, K.; Cicchetti, D.; Scahill, L., and Leckman, J. F. Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol. 2000 Winter; 10(4):259–68.
    Rec #: 1319
  200. Martin-Cook, K.; Hynan, L. S.; Rice-Koch, K.; Svetlik, D. A., and Weiner, M. F. Responsiveness of the Quality of Life in Late-Stage Dementia Scale to Psychotropic Drug Treatment in Late-Stage Dementia. Dement Geriatr Cogn Disord. 2004 Nov 29; 19(2–3):82–85.
    Rec #: 247
  201. Masan, P. S. Atypical antipsychotics in the treatment of affective symptoms: a review. Ann Clin Psychiatry. 2004 Jan–2004 Mar 31; 16(1):3–13.
    Rec #: 311
  202. Matur, Z. and Ucok, A. Quetiapine treatment in a patient with Tourette’s syndrome, obsessive-compulsive disorder and drug-induced mania. Isr J Psychiatry Relat Sci. 2003; 40(2):150–2.
    Rec #: 376
  203. Mavrogiorgou, P. and Hegerl, U. [Drug treatment of obsessive-compulsive disorder. With proper drugs and some patience many patients can be helped]. MMW Fortschr Med. 1999 Sep 30; 141(39):32–4, 37.
    Rec #: 616
  204. McDougle, C. J.; Brodkin, E. S.; Yeung, P. P., and et al. Risperidone in adults with autism or pervasive developmental disorder. J Child Adolesc Psychopharmacol. 1995; 5:273–82.
    Rec #: 1326
  205. McDougle, C. J.; Goodman, W. K., and Price, L. H. Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. J Clin Psychiatry. 1994 Mar; 55 Suppl:24–31.
    Rec #: 775
  206. McNeely, M. Case study: atypical antipsychotic use associated with severe hyperglycemia. Clinical Psychiatry. 1998; 44:778–83.
    Rec #: 1374
  207. Meehan, K. M.; Wang, H.; David, S. R.; Nisivoccia, J. R.; Jones, B.; Beasley, C. M.; Feldman, P. D., and Breier, A. A double-blind, placebo-controlled study of short-acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia. 14th annual meeting of the American Association for Geriatric Psychiatry; San Francisco, CA. 2001.
    Rec #: 1094
  208. Mendelowitz, A. J. The utility of intramuscular ziprasidone in the management of acute psychotic agitation. Ann Clin Psychiatry. 2004 Jul–2004 Sep 30; 16(3):145–54.
    Rec #: 256
  209. Merritt, R.; Cipriani, A.; Rendell, J., and Geddes, J. Quetiapine alone or in combination for acute mania. Cochrane Database Syst Rev. 2003.
    Rec #: 161
  210. Mintzer, J.; Meehan, K.; Wang, H.; David, S.; Nisivoccia, J.; Jones, B.; Beasley, C. Jr.; Feldman, P., and Breier, A. A double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia. Proceedings of the 8th International Conference on Alzheimer’s Disease and Related Disorders; 2002 July 20–25, Stockholm, Sweden. 2002; Abstract No 133. CODEN: CCT; ISSN: CN-00404274.
    Rec #: 930
  211. Mintzer, J. E.; Madhusoodanan, S., and Brenner, R. (Medical U of South Carolina, Dept of Psychiatry, Charleston, SC, US). Risperidone in dementia. Psychiatric Annals. 2000 Mar; 30(3): 181–187; ISSN: 0048-5713 (Print).
    Rec #: 868
  212. Mitchell M, Earley W Bari MA Riesenberg RA Marquez E Kurtz D Falk D Taylor CC Cavazzoni P. A preliminary study of the pharmacokinetics and tolerability of higher dose oral olanzapine (20, 30, or 40mg/day) in stable patients with serious mental disorders. Journal of the European College of Neuropsychopharmacology. 2003; 13(4):S315. CODEN: RCT; ISSN: CN-00478408.
    Rec #: 925
  213. Moller, H. J.; Pelzer, E.; Kissling, W.; Riehl, T., and Wernicke, T. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study. Pharmacopsychiatry. 1991 Nov; 24(6):185–9.
    Rec #: 1294
  214. Moretti, R.; Torre, P.; Antonello, R. M.; Cattaruzza, T.; Cazzato, G., and Bava, A. Olanzapine as a possible treatment for anxiety due to vascular dementia: an open study. Am J Alzheimers Dis Other Demen. 2004 Mar–2004 Apr 30; 19(2):81–8.
    Rec #: 318
  215. Mortimer A. Randomised prospective parallel group comparison of clozapine vs olanzapine in the reduction of suicidality in patients with schizophrenia/schizoaffective disorder. National Research Register. 2002; 1. CODEN: RCT; ISSN: CN-00433811.
    Rec #: 940
  216. Mullen JA, Sajatovic M Sweitzer D. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychotic disorders. 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12–16; Acapulco, Mexico. 1999. CODEN: RCT; ISSN: CN-00433882.
    Rec #: 970
  217. Muller-Siecheneder F, Hillert A Benkert O. Risperidone in the treatment of patients with a combined psychotic and depressive syndrome. Pharmacopsychiatry. 1995; 28201. CODEN: RCT; ISSN: CN-00283144.
    Rec #: 993
  218. Myers, J. E. and Thase, M. E. Risperidone: review of its therapeutic utility in depression. Psychopharmacol Bull. 2001 Autumn; 35(4):109–29.
    Rec #: 177
  219. No authorship indicated. Mania due to ziprasidone augmentation of a selective serotonin reuptake inhibitor. Primary Psychiatry. 2004 Jan; 11(1): 17–18 URL: http://www.primarypsychiatry.com/index.php3; ISSN: 1082-6319 (Print).
    Rec #: 791
  220. Oh, B. H.; Lee, J. H.; Cheon, J. S., and Yoo, K. J. Newer neuroleptic treatment for behavioural and psychological symptoms of dementia. J Can Geriatr Soc. 2001; 4(1):24–7.
    Rec #: 1480
  221. Ohaeri, J. U. Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder. East Afr Med J. 2000 Feb; 77(2):86–92.
    Rec #: 631
  222. Okada, Takashi (Kouai Hosp, Takatsuki, Japan). Translated title: convulsions induced by withdrawal of risperidone. Seishin Igaku (Clinical Psychiatry). 1998 Nov; 41(11): 1205–1208; ISSN: 0488-1281 (Print).
    Rec #: 891
  223. Olie, J. P. and Bayle, F. J. [New chemotherapy approaches to psychoses]. Encephale. 1997 Apr; 23 Spec No 2:2–9.
    Rec #: 734
  224. Opolka, J. L.; Rascati, K. L.; Brown, C. M., and Gibson, P. J. Role of ethnicity in predicting antipsychotic medication adherence. Ann Pharmacother. 2003 May; 37(5):625–30.
    Rec #: 1362
  225. Pacher, P. and Kecskemeti, V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des. 2004; 10(20):2463–75.
    Rec #: 277
  226. Panagiotis, B.; Maria, G., and Aris, L. (U of Ioannina Medical School, Dept of Psychiatry, Greece). Development of obsessive and depressive symptoms during risperidone treatment. British Journal of Psychiatry Vol 174 (Jun 1999): 559. ISSN: 0007-1250 (Print).
    Rec #: 889
  227. Papakostas, G.; Petersen, T., and Worthington, J. et al. Ziprasidone augmentation for major depressive disorder refractory to SSRIs [Abstract NR248]. 156th APA Annual Meeting; San Francisco, CA.
    Rec #: 1050
  228. Parsa, M.; Greenway, H., and Bastini, B. Quetiapine in the treatment of the psychosis in patients with Parkinson’s disease and dementia (Lewy body disease variatn). Annual meeting of the American Neurological Association; Chicago, IL.
    Rec #: 1151
  229. Parsa, M. A.; Poggi, E. V., and Barte, L. et al. Treatment of dementia patients with psychotic and behavioral symptoms with quetiapine and donepezil [poster]. Presented at the 154th annual meeting of the American Psychiatric Association; New Orleans, LA. 2001.
    Rec #: 1027
  230. Parsa M, Poggi E Barte L. Treatment of dementia patients with psychotic and behavioural symptoms with quetiapine and donepezil. Journal of the European College of Neuropsychopharmacology (Abstracts of the 13th ECNP Congress, Munich, September 9–13, 2000). 2000; 10(Suppl 3):S302. CODEN: CCT; ISSN: CN-00308302.
    Rec #: 966
  231. Pellegrino M. A 10-week, double-blind, comparative study evaluation of the effectiveness of Risperidone versus Olanzapine to placebo in patients with Alzheimer’s Dementia. Centerwatch. 2000. CODEN: CCT; ISSN: CN-00303176.
    Rec #: 957
  232. Perenyi, A.; Arato, M.; Bagdy, G.; Frecska, E., and Szucs, R. Tiapride in the treatment of tardive dyskinesia: a clinical and biochemical study. J Clin Psychiatry. 1985 Jun; 46(6):229–31.
    Rec #: 1192
  233. Peris, M. and Szerman, N. Long-term treatment of obsessive compulsive disorder: effectieness of serotonin reuptake inhibitors and olanzapine. J Eur Coll Neuropsychopharmacol. 2002; 12(Suppl 3):S357.
    Rec #: 1068
  234. Peto, R.; Pike, M. C.; Armitage, P.; Breslow, N. E.; Cox, D. R.; Howard, S. V.; Mantel, N.; McPherson, K.; Peto, J., and Smith, P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan; 35(1):1–39.
    Rec #: 1313
  235. Philipp, M.; Lesch, O. M.; Schmauss, M.; Dose, M., and Glaser, T. [Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia]. Psychiatr Prax. 2003 May; 30 Suppl 2:S94–6.
    Rec #: 378
  236. Pollak, P. [Psychic disorders]. Rev Neurol (Paris). 2002; 158(122):125–131.
    Rec #: 413
  237. Potenza, M. N. and McDougle, C. J. (Connecticut Mental Health Ctr, Abraham Ribicoff Research Facilities, Clinical Neuroscience Research Unit, New Haven, CT, US). Potential of atypical antipsychotics in the treatment of nonpsychotic disorders. CNS Drugs. 1998 Mar; 9(3): 213–232 URL: http://www.adis.com/page.asp?objectID=40; ISSN: 1172-7047 (Print).
    Rec #: 903
  238. Prado, N.; Kramerginsberg, E., and Kremen, N. Open-label risperidone in dementia with agitation/psychosis. American Journal of Geriatric Psychiatry. 1996; 4:376.
    Rec #: 1206
  239. Rabe-Jablonska, J. [Obsessive-compulsive disorders in adolescents with diagnosed schizophrenia]. Psychiatr Pol. 2001 Jan–2001 Feb 28; 35(1):47–57.
    Rec #: 571
  240. Raheja, R. K.; Bharwani, I., and Penetrante, A. E. Efficacy of risperidone for behavioral disorders in the elderly: a clinical observation. J Geriatr Psychiatry Neurol. 1995 Jul; 8(3):159–61.
    Rec #: 769
  241. Rainer, M. K.; Mucke, H. A.; Masching, A. J.; Haushofer, M.; Karger, M.; Kasper, S., and Kurz, A. [State of the Art Management of BPSD in Dementia.]. Psychiatr Prax. 2005 Jan; 32(1):31–38.
    Rec #: 242
  242. Raj, Y. P. Psychopharmacology of borderline personality disorder. Curr Psychiatry Rep. 2004 Jun; 6(3):225–31.
    Rec #: 167
  243. Raja, Michele and Azzoni, Antonella (Ospedale Santo Spirito in Sassia, Servizio Psichiatrico di Diagnosi e Cura, Rome, Italy; Ospedale Santo Spirito in Sassia, Servizio Psichiatrico di Diagnosi e Cura, Rome, Italy E-mail: ti.loi@ossur.ajar). Valproate and quetiapine overdose with benign outcome: a case report. International Journal of Psychiatry in Clinical Practice. 2002 Sep; 6(3): 173–174 URL: http://www.tandf.co.uk/journals/md/13651501.html; ISSN: 1365-1501 (Print); 1471-1788 (Electronic).
    Rec #: 831
  244. Rak, I. W.; Jones, A. M.; Raniwalla, J.; Phung, D., and Melvin, K. Weight changes in patients treated with Seroquel (quetiapine). 2000; 41, 206 (abstract B83).
    Rec #: 1458
  245. Rein, W. and L’Heritier, C. Treatment-emergent tardive dyskinesia in the long-term teratment of schizophrenia: a comparison of amisulpride and haloperidol (abstract). 1999; 9, (282).
    Rec #: 1516
  246. Remington, G. and Adams, M. (Clark Inst of Psychiatry, Clinical Investigation Unit & Schizophrenia Research Program, Toronto, ON, Canada). “Risperidone and obsessive-compulsive symptoms”: reply. Journal of Clinical Psychopharmacology. 1996 Feb; 16(1): 85–86 URL: http://www.psychopharmacology.com/; ISSN: 0271-0749 (Print).
    Rec #: 919
  247. Rendell, J. M.; Gijsman, H. J.; Bauer, M. S.; Goodwin, G. M., and Geddes, J. R. Risperidone alone or in combination for acute mania. Cochrane Database Syst Rev. 2003.
    Rec #: 162
  248. Reyntjens, A.; Heylen, S., and Gelders, Y. Risperidone in the treatment of behavioral symptoms in psychogeriatic patients: a pilot clinical investigation. Psychopharmacol. 1988; 96 (suppl):335.
    Rec #: 1211
  249. Riva, E.; Nobili, A., and Trecate, F. [“Judicious” use of neuroleptic drugs in the treatment of behavioral symptoms in the course of Alzheimer disease]. Recenti Prog Med. 1998 Nov; 89(11):598–603.
    Rec #: 687
  250. Rogers, T.; de Leon, J., and Atcher, D. Possible interaction between warfarin and quetiapine. J Clin Psychopharmacol. 1999 Aug; 19(4):382–3.
    Rec #: 655
  251. Roychoudhury, K.; Demb, H. B., and Rose, F. Use of olanzapine in children with developmental disabilities and challenging behaviors. J. Invetigational Med. 1999; 9(Suppl. 5):S287–88.
    Rec #: 1325
  252. Rubin, M. Use of atypical antipsychotics in children with mental retardation, autism and other developmental disabilities. Psychiatric Ann. 1997; 27(3):219–20.
    Rec #: 1324
  253. Sachs, G. Risperidone and haloperidol in mood disorders. American Psychiatric Association Annual Meeting; Washington, DC. 2000.
    Rec #: 1111
  254. Sachs, G. S. Safety and efficacy of risperidone vs placebo as add-on therapy to mood stabilizers in the treatment of manic phase of bipolar disorder. Presented at the 38th Annual Meeting of the American College of Neuropsychopharmarcology; Acapulco, Mexico.
    Rec #: 1198
  255. Safranko, Ivan (Newcastle Mater Hosp, Dept of Psychiatry, Newcastle, Australia). Comment on “emergence of compulsive symptoms with olanzapine treatment”: reply to dr. Mahendran. Australian & New Zealand Journal of Psychiatry Vol. ISSN: 0004-8674 (Print).
    Rec #: 819
  256. Sajatovic, M.; Brescan, D.; Perez, D., and DiGiovanni, S. Quetiapine in neuroleptic-dependent mood disorders. Annual Meeting of the AMerican College of Neuropsychopharmacology; Acapulco, Mexico. 1999.
    Rec #: 1112
  257. Sajatovic M, Mullen JA Sweitzer D. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients wth psychotic disorders. 40th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU); 2000 May 30 – Jun 2; Boca Raton, Florida. 2000. CODEN: RCT; ISSN: CN-00433865.
    Rec #: 962
  258. Sakkas, P.; Liappas, J., and Christodoulou, G. N. (U Athens, Eginition Hosp, Dept of Psychiatry, Athens, Greece). Tardive dyskinesia due to risperidone. European Psychiatry. 1998 Apr; 13(2): 107–108 URL: http://www.elsevier.com/inca/publications/store/5/0/5/8/1/4/; ISSN: 0924-9338 (Print).
    Rec #: 896
  259. Salzman, C. Treatment of agitation in the elderly. Meltzer, H. Y. ed. Psychopharmacology: the third generation of progress. New York: Raven Press; 1987; pp. 1167–76.
    Rec #: 1232
  260. Sandor, P. (Toronto Hosp, Dept of Psychiatry, Tourette’s Syndrome Clinic, ON, Canada). Clinical management of tourette’s syndrome and associated disorders. Canadian Journal of Psychiatry. 1995 Dec; 40(10): 577–583 URL: http://www.cpa-apc.org/Publications/cjpHome.asp; ISSN: 0706-7437 (Print).
    Rec #: 921
  261. Sanger, T.; Tohen, M., and Jacobs, T. Long-term olanzapine treatment of mania: improvement in mood symptoms and cognitive function. New Research Program and Abstracts of the 152nd Annual Meeting of the American Psychiatric Association; Washington, D.C.
    Rec #: 1199
  262. Santarlasci, B. and Messori, A. Clinical trial response and dropout rates with olanzapine versus risperidone. Ann Pharmacother. 2003 Apr; 37(4):556–63.
    Rec #: 1361
  263. Santosh, P. J. and Baird, G. Pharmacotherapy of target symptoms in autistic spectrum disorders. Indian J Pediatr. 2001 May; 68(5):427–31.
    Rec #: 557
  264. Sasson, Y.; Zohar, J.; Chopra, M.; Lustig, M.; Iancu, I., and Hendler, T. Olanzapine treatment for schizophrenia patients with refractory OCD: an open-label case series. Fifth International Obsessive Compulsive Disorder Conference; Sardina, Italy.
    Rec #: 999
  265. Saxe, T. Risperidone questioned as dementia first-line treatment. Geriatrics. 2004 Feb; 59(2):11; author reply 11–2.
    Rec #: 338
  266. Saxena, Sanjaya and Bystritsky, Alexander. “Risperidone may worsen fluoxetine-treated ocd”: reply. Journal of Clinical Psychiatry. 1998 May; 59(5): 256; ISSN: 0160-6689 (Print).
    Rec #: 895
  267. Schar, V.; Leonhardt, M.; Agelink, A., and Klieser, E. Risperidone in the treatment of patients with delusional depression. Pharmacopsychiatry. 1995; 28:210.
    Rec #: 1045
  268. Schneider, L.; Yeung, P., and Sweitzer, D. Effects of SEROQUEL(quetiapine) on reducing hostility and psychosis in patients with Alzheimer’s disease. Presented at the 152nd annual meeting of the American Psychiatric Ssoication; Washington, DC.
    Rec #: 1144
  269. Schneider, L.; Yeung, P. P., and Sweitzer, D. Quetiapine may reduce hostility in patients with psychoses related Alzheimer’s disease. Presented at the 7th International Congress on Schizophrenia Research; Santa Fe, NM.
    Rec #: 1147
  270. Schneider, L. S.; Ismail, M. S.; Dagerman, K.; Davis, S.; Olin, J.; McManus, D.; Pfeiffer, E.; Ryan, J. M.; Sultzer, D. L., and Tariot, P. N. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer’s disease trial. Schizophr Bull. 2003; 29(1):57–72.
    Rec #: 205
  271. Schneider, L. S.; Pollock, V. E., and Lyness, S. A. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990 May; 38(5):553–63.
    Rec #: 1000
  272. Schulz, S. C. Pharmacotherapy for borderline personality disorder: new opportunities. 156th Annual Meeting of the American Psychiatric Association; San Francisco, CA.
    Rec #: 1276
  273. Schulz, S. C. and Camlin, K. Treatment of borderline personality disorder: potential of the new antipsychotic medications. J Pract Psychiatry Behav Health. 1999; 5:247–55.
    Rec #: 1113
  274. Schulz, S. C.; Camlin, K. L.; Berry, S., and Friedman, L. Risperidone for borderline personality disorder: a double-blind study. 37th Annual Meeting of the American College of Neuropsychopharmacology; San Juan, PR.
    Rec #: 1275
  275. Schwalen, S. Risperidone: effects on slee-wake cycle disturbances in demential. 10th Congress of the INternational Psychogeriatric Association; Nice, France.
    Rec #: 1034
  276. Sharma, V. Atypical antipsychotics and suicide in mood and anxiety disorders. Bipolar Disord. 2003; 5 Suppl 2:48–52.
    Rec #: 349
  277. Shelton, R. C. Atypical antipsychotics: treatment of depression. 152nd Annual Meeting of the American Psychiatric Association. Washington DC, USA. 15–20th May, 1999. 1999. CODEN: RCT; ISSN: CN-00284545.
    Rec #: 967
  278. Shelton, R. C.; Tohen, M.; Stahl, S.; Jacobs, T.; Gannon, K. S., and Tollefson, G. D. The study of olanzapine plus fluoxetine in treatment-resistant major depressive disorder without psychotic features. Schizophrenia Research (Xth Biennial Winter Workshop on Schizophrenia. Davos, Switzerland. February 5–11, 2000). 2000; Number 1 - Special Issue. CODEN: CCT; ISSN: CN-00266793.
    Rec #: 965
  279. Shelton, R. C.; Tohen, M., and Stahl, S. et al. The study of olanzapine plus fluoxetine is treatment-resistant major depressive disorder without psychiatric features. Schizophr Res. 2000; 41:193.
    Rec #: 1114
  280. Shi L, Namjoshi M Yu X Baker RW Tohen $AB M. Olanzapine improves health-related quality of life in patients with bipolar depression. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum, June 23–27 2002, Montreal, Canada). 2002; 5(Suppl 1):S109. CODEN: RCT; ISSN: CN-00394567.
    Rec #: 935
  281. Simeon, J. G.; Carrey, N. J., and Wiggins, D. M. Risperidone effects in treatment-resistant adolescents: preliminary case reports. Journal of Child Adolescents Psychopharmacol. 1995; 5(69–79).
    Rec #: 1203
  282. Simpson, G. M.; O’Sullivan, M. D., and Siu, C. Ziprasidone versus olanzapine in schizophrenia: results of a double-blind trail. American Psychiatric Association Annual Meeting; New Orleans, LA. abstract NR252.
    Rec #: 1459
  283. Sinoff, G. and Berger, S. I. (Carmel Medical Ctr, Dept of Geriatrics, Haifa, Israel E-mail: li.ten.noisivten@ffonis). “Awakenings”--a transient phenomenon with risperidone. Clinical Gerontologist. 2001; 23(3–4): 21–26 URL: http://www.haworthpressinc.com/store/product.asp?sku=J018; ISSN: 0731-7115 (Print).
    Rec #: 844
  284. Siris, S. G. On diagnosing depression among patients with schizophrenia. Essent Psychopharmacol. 2004; 6(1):65–72.
    Rec #: 1611
  285. Smith, D. A. and Beier, M. T. Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc. 2004 Mar–2004 Apr 30; 5(2):129–32.
    Rec #: 330
  286. Soloff, Paul. A 27-year-old woman with chronic depression and suicidal ideation. Psychiatric Annals. 2003 Dec; 33(12): 766–772; ISSN: 0048-5713 (Print).
    Rec #: 802
  287. Spiller, H. A.; Dunaway, M. D., and Cutino, L. Massive gabapentin and presumptive quetiapine overdose. Vet Hum Toxicol. 2002 Aug; 44(4):243–4.
    Rec #: 472
  288. Stamenkovic M, Schindler SD Aschauer HN Kasper S. Olanzapine in Gilles de la Tourette Syndrome patients CONFERENCE ABSTRACT. 11th European College of Neuropsychopharmacology Congress. Paris, France. 31st October – 4th November 1998. 1998. CODEN: CCT; ISSN: CN-00284766.
    Rec #: 986
  289. Stauffer, V. L.; Beasley, C.; Liu-Seifer, H., and et al. Overall treatment effectiveness as meaured by time continuing on antipsychotic therapy. Schizophrenia Bulletin. 2005; 31:504.
    Rec #: 1371
  290. Stein, Dan J.; Hawkridge, Susan; Bouwer, Colin, and Emsley, Robin A. “Possible dose-response relationship for risperidone in obsessive-compulsive disorder”: reply. Journal of Clinical Psychiatry. 1998 Mar; 59(3): 134; ISSN: 0160-6689 (Print).
    Rec #: 902
  291. Stein, Murray B.; Kline, Neal A., and Matloff, Jeffrey L. “Adjunctive olanzapine for ssri-resistant combat-related ptsd: a double-blind, placebo-controlled study”: reply. American Journal of Psychiatry. 2003 Jun; 160(6): 1190 URL: http://ajp.psychiatryonline.org/; ISSN: 0002-953X (Print).
    Rec #: 782
  292. Stephenson, C. M. and Pilowsky, L. S. Psychopharmacology of olanzapine. A review. Br J Psychiatry Suppl. 1999; (38):52–8.
    Rec #: 617
  293. Street J, Clark WS Gannon KS Mitan S Kadam D Sanger T Tamura R Tollefson GD. Olanzapine reduces psychosis and behavioral disturbances associated with Alzheimer’s disease. Journal of the European College of Neuropsychopharmacology. 1999; 9(Suppl 5):S331. CODEN: RCT; ISSN: CN-00319954.
    Rec #: 974
  294. Street J, Clark WS Gannon KS Sanger T Breier A. Reduction of psychotic symptoms in patients with Lewy Body-like symptoms treated with olanzapine. Journal of the European College of Neuropsychopharmacology. 1999; 9(Suppl 5):S331. CODEN: RCT; ISSN: CN-00319958.
    Rec #: 975
  295. Street, J. S.; Clark, W. S.; Gannon, K. S.; Mitan, S.; Sanger, T. M., and Tollefson, G. D. Olanzapine in the treatment of psychosis and behavioral disturbances associated with alzheimer’s disease. 152nd Annual Meeting of the American Psychiatric Association. Washington DC, USA. 15–20th May, 1999. 1999. CODEN: RCT; ISSN: CN-00284848.
    Rec #: 972
  296. Street, J. S.; Clark, W. S.; Juliar, B. I.; Feldman, P. D.; Kadam, D. I., and Breirer, A. Long-term efficacy of olanzapine in the control of psychotic and behavioural symptoms in patients with alzheimer’s dementia. International Journal of Neuropsychopharmacology. 2000; 3(Suppl 1):S356. CODEN: RCT; ISSN: CN-00404366.
    Rec #: 963
  297. Street, J. S.; Tollefson, G. D., and Tohen, M. et al. Olanzapine for psychotic conditions in the elderly. Psychiatr Ann. 2000; 30(3):191–6.
    Rec #: 1120
  298. Sultzer, D. L. Psychosis and antipsychotic medications in Alzheimer’s disease: clinical management and research perspectives. Dement Geriatr Cogn Disord. 2004; 17(1–2):78–90.
    Rec #: 1284
  299. Sun, T. F.; Lin, P. Y., and Wu, C. K. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases. Chang Gung Med J. 2001 Sep; 24(9):587–92.
    Rec #: 133
  300. Svetska, J. Risperidone treatment of behavioral and psychotic symptoms of dementia-prospective open postmarking study. Psychiatrie. 2002; 6(2):78083.
    Rec #: 1483
  301. Tandon, R.; Stock, E.; Kujawa, M., and et al. Broad effectiveness trial with aripiprazole [poster]. Presented at the 55th Institute on Psychiatric Services Meeting; Boston, MA.
    Rec #: 1342
  302. Tanigawa, Masamichi; Shiroma, Seigo; Koja, Sunao; Tamura, Yoshiki, and Miyazato, Yoshikazu (Miyazato Hosp, Dept of Psychiatry, Nago, Japan; Miyazato Hosp, Dept of Psychiatry, Nago, Japan; Miyazato Hosp, Dept of Psychiatry, Nago, Japan; Miyazato Hosp, Dept of Psychiatry, Nago, Japan; Miyazato Hosp, Dept of Psychiatry, Nago, Japan). Translated title: improvement of bpsd by donepezil hydrochloride and risperidone in a patient with senile dementia of the alzheimer type. Seishin Igaku (Clinical Psychiatry). 2003 Jan; 45(1): 84–86; ISSN: 0488-1281 (Print).
    Rec #: 815
  303. Tariot, P.; Gaile, S. E.; Castelli, N. A., and Porsteinsson, A. P. Treatment of agitation in dementia. New Dir Ment Health Serv. 1997 Winter; (76):109–23.
    Rec #: 712
  304. Tariot, P.; Salzman, C., and Yeung, P. et al. Clinical improvement and tolerability is maintained long-term in elderly patients with psychotic disorders treated with quetiapine. Annual Meeting of the American College of Neuropsychopharmacology; Acapulco, Mexico. 1999.
    Rec #: 1117
  305. Tariot, P.; Schneider, L.; Katz, I.; Mintzer, J., and Street, J. Quetiapine in nursing home residents with alzheimer’s dementia and psychosis (poster). Annual Meeting of the American Association of Geriatric Psychiatry; February 24–27, 2002, Orlando, FL. 2002.
    Rec #: 232
  306. Tariot, P. N. Treatment strategies for agitation and psychosis in dementia. J Clin Psychiatry. 1996; 57 Suppl 14:21–9.
    Rec #: 757
  307. The Expert Consensus Panel for Agitation in Dementia. Treatment of agitation in older persons with dementia. Postgrad Med. 1998; Spec:1–88.
    Rec #: 1330
  308. Tohen M. Olanzapine and olanzapine+fluoxetine in the treatment of bipolar depression. XII World Congress of Psychiatry, Aug 24–9, 2002, Yokohama, Japan. 2002; Abstract S-15-2. CODEN: RCT; ISSN: CN-00431560.
    Rec #: 934
  309. Tohen, M. Use of antipsychotics in bipolar disorder. Bipolar Disorder. 1999; 1:18.
    Rec #: 1200
  310. Tohen, M.; Chengappa, K. N. R.; Suppes, T., and et al. Olanzapine combined with lithium or valproate in prevention of recurrence in bipolar disorder: an 18-month study [poster]. 11th Biennial Winter Workshop on Schizophrenia; Davos, Switzerland.
    Rec #: 1366
  311. Tohen, M.; Shelton, R., and Tollefson, G. D. Olanzapine plus fluoxetine: double-blind and open-label results in treatment-resistant major depressive disorder. 12th annual meeting of the European College of Neuropsychopharmacology; London, England.
    Rec #: 1152
  312. Tohen, M.; Vieta, E., and Calabrese, J. et al. Olanzapine/fluoxetine combination and olanzapine in the treatment of bipolar depression. 156th APA Annual Meeting; San Francisco, CA.
    Rec #: 1056
  313. Tohen, M.; Vieta, E.; Ketter, T., and et al. Olanzapine and olanzapine-fluoxetine combination (OFC) in the treatment of bipolar depression [poster]. APA 2002; Philadelphia, PA.
    Rec #: 1395
  314. Tohen, M.; Zarate, C. A. Jr; Centorrino, F.; Hegarty, J. I.; Froeschl, M., and Zarate, S. B. Risperidone in the treatment of mania. J Clin Psychiatry. 1996 Jun; 57(6):249–53.
    Rec #: 1168
  315. Tohen, M. F.; Marneros, A., and Bowden, C. L. Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12-month trial. Bipolar Disord. 2002; 4:135.
    Rec #: 1222
  316. Tollefson, G.; Beasley, C.; Tran, P., and Sanger, T. Olanzapine: An Exciting Atypical Antipsychotic The Clinical Experience CONFERENCE ABSTRACT. 8th European College of Neuropsychopharmacology Congress. Venice, Italy. 30th September - 4th October, 1995. 1995. CODEN: RCT; ISSN: CN-00285093.
    Rec #: 991
  317. Tollefson, G.; Gannon, K.; Jacobs, T.; Shelton, R.; Tohen, M., and Stahl, S. The study of olanzapine plus fluoxetine in treatment-resistant major depressive disorder without psychotic features. XI World Congress of Psychiatry, Hamburg, August 6–11, 1999. 1999; Abstracts Volume II133. CODEN: RCT; ISSN: CN-00309665.
    Rec #: 978
  318. Tollefson, G. D.; Sanger, T. M.; Lu, Y., and Thieme, M. E. (Eli Lilly & Co, Lilly Research Labs, Indianapolis, IN, US). “Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol”: erratum. Archives of General Psychiatry. 1998 Nov; 55(11): 1052; ISSN: 0003-990X (Print).
    Rec #: 892
  319. Tollefson, G. D.; Shelton, R.; Tohen, M.; Stahl, S.; Jacobs, T.; Buras, W.; Gannon, K. S., and Spencer, K. A. Efficacy of olanzapine, fluoxetine and combination therapy in treatment-resistant major depressive disorder without psychotic features. 11th European College of Neuropsychopharmacology Congress. Paris, France. 31st October - 4th November 1998. 1998. CODEN: RCT; ISSN: CN-00285106.
    Rec #: 985
  320. Tollefson, G. D.; Shelton, R. C.; Tohen, M. F.; Stahl, S. M.; Jacobs, L., and Gannon, K. S. The study of olanzapine plus fluoxetine in treatment-resistant MDD without psychotic features. 152nd Annual Meeting of the American Psychiatric Association. Washington DC, USA. 15–20th May, 1999. 1999. CODEN: RCT; ISSN: CN-00285107.
    Rec #: 979
  321. Tollefson GD. A BLINDED TRIAL ON THE COURSE AND RELATIONSHIP OF DEPRESSIVE SYMPTOMS IN SCHIZOPHRENIA. XXIst Collegium Internationale Neuro-Psychopharmacologicum, Glasgow, Scotland. 12th–16th July, 1998. 1998. CODEN: RCT; ISSN: CN-00240299.
    Rec #: 980
  322. Tollefson GD, Sanger TM Andersen SW. Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol. 11th European College of Neuropsychopharmacology Congress. Paris, France. 31st October - 4th November 1998. 1998. CODEN: RCT; ISSN: CN-00216367.
    Rec #: 982
  323. Tome MB, Isaac M. Effect on HPA of olanzapine, pindolol, dexamethasone and antidepressants in resistant depression. 11th European College of Neuropsychopharmacology Congress. Paris, France. 31st October - 4th November 1998. 1998. CODEN: RCT; ISSN: CN-00285115.
    Rec #: 984
  324. Tran, P. V. ; Lu, Y., and Sanger, T. Olanzapine in the treatment of schizoaffective disorder. 36th annual meeting of the New Cinical Drug Evaluation Unit; Boca Raton, FL.
    Rec #: 1224
  325. Trequattrini, A.; Attala, T.; Spadoni, L., and Ciappi, F. (Dipartimento Tutela della Salute Mentale, ASL 1 Umbria, Città di Castello, Italy; Dipartimento Tutela della Salute Mentale, ASL 1 Umbria, Città di Castello, Italy; Dipartimento Tutela della Salute Mentale, ASL 1 Umbria, Città di Castello, Italy; Dipartimento Tutela della Salute Mentale, ASL 1 Umbria, Città di Castello, Italy). Olanzapina nel trattamento dei disturbi psicocomportamentali in soggetti affetti da demenza tipo alzheimer. Giornale Di Neuropsicofarmacologia. 2003; 25(3): 105–113; ISSN: 0391-9048 (Print).
    Rec #: 803
  326. Tsolaki, M.; Symeonides, G., and Kazis, A. (3rd Department of Neurology, Aristotle University of Thessaloniki, Greece; 3rd Department of Neurology, Aristotle University of Thessaloniki, Greece; 3rd Department of Neurology, Aristotle University of Thessaloniki, Greece). Translated title: olanzapine induced diabetic ketoacidosis. Psychiatriki. 2002 Jul-2002 Sep 30; 13(3): 222–227; ISSN: 1105-2333 (Print).
    Rec #: 820
  327. Vanden Borre, R.; Vermote, R.; Buttens, M., and et al. Risperidone as an add-on therapy in behavioural disturbances in mental retardation: A double-blind placebo controlled cross-over study. Acta Psychiatr Scand. 1993; 87:167–71.
    Rec #: 1328
  328. Vanderzeypen, F.; Bier, J. C.; Genevrois, C.; Mendlewicz, J., and Lotstra, F. [Frontal dementia or dementia praecox? A case report of a psychotic disorder with a severe decline]. Encephale. 2003 Mar-2003 Apr 30; 29(2):172–80.
    Rec #: 372
  329. Vavrusova, L. Quetiapine in the treatment of non-psychotic depression. Int J Neuropsychopharmacol. 2002; 5(Suppl. 1).
    Rec #: 1051
  330. Verhoeven, W. M. A.; Marijnissen, G.; Van Ooy, J. M.; Tuiner, S.; Van Den Berg, Y. W. M. M.; Pepplinkhuizen, L., and Fekkes, D. (Vincent van Gogh Inst for Psychiatry, Dept of Biological Psychiatry, Venray, Netherlands). Dysperceptions and serotonergic parameters in borderline personality disorders: effects of treatment with risperidone. New Trends in Experimental & Clinical Psychiatry. 1999 Jan-1999 Mar 31; 15(1): 9–16; ISSN: 0393-5310 (Print).
    Rec #: 884
  331. Veser F, Zealburg J Veser B Zhu Y Gharabawi G. Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology. 2002; 12(Supplement 3):S313. CODEN: RCT; ISSN: CN-00421264.
    Rec #: 939
  332. Vieta, E. (U of Barcelona, Hosp Clinic, August Pi i Sunyer Biomedical Inst (IDIBAPS), Barcelona, Spain E-mail: se.bu.cinilc@ateive). Atypical antipsychotics in the treatment of mood disorders. Current Opinion in Psychiatry. 2003 Jan; 16(1): 23–27 URL: http://www.co-psychiatry.com/; ISSN: 0951-7367 (Print).
    Rec #: 813
  333. Vieta, E.; Herraiz, M., and Fernandez, A. Efficacy and safety of resperidon in bipolar disorders. New Research Program and Abstracts of the 152nd Annual Meeting of the American Psycihatric Association.; Washington D.C.
    Rec #: 1197
  334. Wancata, J. (U Vienna, Dept of Psychiatry, Vienna, Austria). Risperidone for non-cognitive symptoms of dementia. International Journal of Psychiatry in Clinical Practice. 2000 Sep; 4(3): 249–251 URL: http://www.tandf.co.uk/journals/md/13651501.html; ISSN: 1365-1501 (Print); 1471–1788 (Electronic).
    Rec #: 869
  335. Watanabe, H.; Tominaga, K.; Ogino, A.; Sekino, K., and Aoba, A. [Dementia induced by antipsychotic drugs]. Nippon Rinsho. 2004 Jan; 62 Suppl:466–9.
    Rec #: 329
  336. Watanabe, Y. and Matsubara, T. [Delusional depression]. Nippon Rinsho. 2001 Aug; 59(8):1546–9.
    Rec #: 546
  337. Watson, P. B. Uses of olanzapine. Australian & New Zealand Journal of Psychiatry Vol. ISSN: 0004-8674 (Print).
    Rec #: 832
  338. Weizman, R. and Weizman, A. Use of atypical antipsychotics in mood disorders. Curr Opin Investig Drugs. 2001 Jul; 2(7):940–5.
    Rec #: 521
  339. Welner, M. Risperidone plus a monoamine oxidase inhibitor for agitated depression crisis. J Clin Psychopharmacol. 1996 Dec; 16(6):460–1.
    Rec #: 746
  340. White, R. E.; Travers, J.; Edell, W. S.; Adams, B. E., and Jensik, S. E. Effectiveness of atypical antipsychotic medications for maladaptive behaviors in geropsychiatric inpatients.
    Rec #: 1350
  341. Wijkstra, J.; Lijmer, J., and Nolen, W. A. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev. 2003.
    Rec #: 160
  342. Wilner KD, Demattos S Anziano RJ Apseloff G Gerber N. Lack of CYP2D6 Inhibition by Ziprasidone in Healthy Volunteers CONFERENCE ABSTRACT. 150th Annual Meeting of the American Psychiatric Association. San Diego, California, USA. 17–22 May, 1997. 1997. CODEN: CCT; ISSN: CN-00285667.
    Rec #: 988
  343. Wilson, J. G.; Pinkerton, A, and Miller, M. J. An Assessment of tardive dyskinesia in elderly patients treated with haloperidol, risperidone and olanzapine. In: American Psychiatric Association Annual Meeting: New Research Program & Abstracts; Washington, DC. v. 264).
    Rec #: 1130
  344. Woodward, M.; Brodaty, H.; Ames, D.; Clarnette, R.; Kirwan, J.; Lee, E.; Lyons, B., and Grossman, F. Risperidone in the treatment of agitation and psychosis of dementia [abstract]. Internal Medicine Journal. 2003; 33(5–6):A30. CODEN: RCT; ISSN: CN-00476666.
    Rec #: 928
  345. Woodward, M.; Brodaty, H., and Ames, D. et al. Risperidone in the treatment of agitation and psychosis of dementia. International College of Geriatric Psychoneuropharmacology General Program and Scientific Abstracts; Waikoloa, HI.
    Rec #: 1032
  346. Woodward, M.; Brodaty, H., and Lee, E. Risperidone in the treatment of agitation and psychosis of dementia: A multicentre, double-blind, placebo controlled study. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, 2002 Apr 3–6, Geneva. 2002; 255. CODEN: RCT; ISSN: CN-00386102.
    Rec #: 943
  347. Yatham, L.; Binder, C.; Kusumakar, V., and Riccardelli, R. Risperidone added to mood stabilizers in mania: is there a difference in effect depending on mood stabilizer? J Eur Coll Neuropsychopharmacol. 2002; 12(Suppl. 3 ):S202.
    Rec #: 1052
  348. Yatham, L. N. Mood stabilization and the role of antipsychotics. Int Clin Psychopharmacol. 2002 Aug; 17 Suppl 3:S21–7.
    Rec #: 430
  349. Zajecka, J. M. and Weisler, S. A et al. Divalproex sodium vs. olanzapine for the treatment of mania in bipolar disorder. 39th ACNP Annual Meeting; San Juan, Puerto Rico.
    Rec #: 997
  350. Zhao, Q.; Xie, C.; Pesco-Koplowitz, L.; Jia, X., and Parier, J. L. Pharmacokinetic and safety assessments of concurrent administration of risperidone and donepezil. J Clin Pharmacol. 2003 Feb; 43(2):180–6.
    Rec #: 425
  351. Zhao, Z.; Damler, R. M., and Jackson, E. A. Atypical antipsychotic treatment adherence and persistence in a state Medicaid program. Value in Health. 2004; 7(3):264.
    Rec #: 1364
  352. Zhao, Z.; Tunis, S., and Lage, M. Medication treatment patterns following initiation on olanzapine versus risperidone. CNS Drugs. 2002; 22 (11):741–9.
    Rec #: 1363
  353. Zhong, X.; Sweitzer, D.; Russo, J.; Potter, L., and Mullen, J. A comparison of the efficacy and safety of quetiapine and risperidone (poster). American Psychiatric Association Annual Meeting; May 17–22, 2003 San Francisco, CA. 2003.
    Rec #: 228
  354. Zuddas, A.; Di Martino, A.; Muglia, P., and Cianchetti, C. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol. 2000 Summer; 10(2):79–90.
    Rec #: 135

REJECTED: Foreign Language Article

  1. Mirsal, Hasan; Kalyoncu, Ayhan; Pektas, Özkan; Tan, Devran, and Beyazyürek, Mansur (Baliki Rum Hastanesi Anatolia Klinikleri, Istanbul, Turkey; Baliki Rum Hastanesi Anatolia Klinikleri, Istanbul, Turkey; Baliki Rum Hastanesi Anatolia Klinikleri, Istanbul, Turkey; Maltepe U Tip Fakültesi Psikiyatri Anabilim Dali, Balikli Rum Hastanesi Anatolia Klinikleri, Istanbul, Turkey E-mail: moc.enilnorepus@lasrimh). Tedaviye dirençli majör depresyonu olan yasli hastalarda olanzapin ekleme tedavisi: bir açik çalisma. Klinik Psikofarmakoloji Bülteni. 2003; 13(1): 1–5; ISSN: 1017-7833 (Print).
    Rec #: 814

REJECTED: Duplicate Article

  1. Breder C/Swanink R; Marcus R, and et al. Dose-ranging study of ariprprazole in patients with Alzheimer’s dementia. Poster. American Psychiatric Association Annual Meeting ; New York, NY.
    Rec #: 1593
  2. De Deyn, P. P.; Carrasco, M. M.; Deberdt, W.; Jeandel, C.; Hay, D. P.; Feldman, P. D.; Young, C. A.; Lehman, D. L., and Breier, A. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 2004 Feb; 19(2):115–26.
    Rec #: 1407
  3. Denys, D.; Van Megen, H., and Westenberg, H. A double-blind, placebo controlled study of quetiapine addition in treatment refractory patients with OCD. 156th APA Annual Meeting; San Francisco, CA. 2003.
    Rec #: 1070
  4. Katz, I. R.; Jeste, D. V.; Mintzer, J. E.; Clyde, C.; Napolitano, J., and Brecher, M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999 Feb; 60(2):107–15.
    Rec #: 881
  5. Katz, I. R.; Schneider, L., and Kozma, C. et al. Risk of falls in dementia patients: analysis of a randomized, double-blind risperidone trial. 2nd Annual Meeting, International Congress of Geriatric Psychoneuropharmacology; Barcelona, Spain.
    Rec #: 1036
  6. Research Units on Pediatric Psychopharmacology Autism Network. A double-blind placebo-controlled trial of risperidone in children with autistic disorder. N Engl J Medicine. 2002; 347(5):314–321.
    Rec #: 1084
  7. Tohen, M; Vieta, E.; Ketter, T.; Centorino, F.; Calabrese, J.; Sachs, G.; Bowden, C.; Mitchel, P.; Risser, R.; Baker, R. W.; Evans, A. R.; Dubé, S.; Tollefson, G., and Breier, A. Olanzapine in the treatment of bipolar depression. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum, June 23–27 2002, Montreal, Canada). 2002; 5(Suppl 1):S109. CODEN: RCT; ISSN: CN-00394722.
    Rec #: 936
  8. Tollefson, G. D.; Sanger, T. M.; Lu, Y., and Thieme, M. E. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. [erratum appears in Arch Gen Psychiatry 1998 Nov;55(11):1052]. Archives of General Psychiatry. 1998; 55(3):250–8; ISSN: CN-00148645.
    Rec #: 983

REJECTED: Condition

  1. Medication developments in the treatment of mental illness. Behav Healthc Tomorrow. 2003 Dec; 12(6):13–4.
    Rec #: 352
  2. Ad-Dab'bagh, Y.; Greenfield, B.; Milne-Smith, J., and Freedman, H. Inpatient treatment of severe disruptive behaviour disorders with risperidone and milieu therapy. Can J Psychiatry. 2000 May; 45(4):376–82.
    Rec #: 1004
  3. Allain, H.; Tessier, C.; Bentue-Ferrer, D.; Tarral, A.; Le Breton, S.; Gandon, M., and Bouhours, P. Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers. Psychopharmacology (Berl). 2003 Feb; 165(4):419–29.
    Rec #: 446
  4. Allison, D. B.; Mentore, J. L.; Heo, M.; Chandler, L. P.; Cappelleri, J. C.; Infante, M. C., and Weiden, P. J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999 Nov; 156(11):1686–96.
    Rec #: 1451
  5. Aman, M. G.; De Smedt, G.; Derivan, A.; Lyons, B., and Findling, R. L. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002 Aug; 159(8):1337–46.
    Rec #: 1076
  6. Ananth, J. and Kenan, J. Tardive dyskinesia associated with olanzapine monotherapy. J Clin Psychiatry. 1999; 60(12):870.
    Rec #: 1089
  7. Ananth, J.; Venkatesh, R.; Burgoyne, K., and Gunatilake, S. Atypical antipsychotic drug use and diabetes. Psychother Psychosom. 2002 Sep-2002 Oct 31; 71(5):244–54.
    Rec #: 1387
  8. Arango C. Expanding the therapeutic options for behavioural disorders. 18th ECNP Congress; Amsterdam, The Netherlands.
    Rec #: 1590
  9. Arvantis, L. A.; Miller, B. G., and Seroquel Trial 13 Study Group. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidon and placebo. Biol Psychiatry. 1997; 42:233–46.
    Rec #: 1461
  10. Atmaca, M.; Kuloglu, M.; Tezcan, E.; Ustundag, B., and Kilic, N. Nizatidine for the treatment of patients with quetiapine-induced weight gain. Hum Psychopharmacol. 2004 Jan; 19(1):37–40.
    Rec #: 347
  11. Bagnall, A.; Lewis, R. A., and Leitner, M. L. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2000; (4):CD001945.
    Rec #: 157
  12. Baker, R. W.; Ames, D.; Umbricht, D. S.; Chengappa, K. N., and Schooler, N. R. Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo. Psychopharmacol Bull. 1996; 32(1):89–93.
    Rec #: 759
  13. Baker, R. W. ; Kinon, B. J.; Liu, H.; Richey, A.; Hill, A. L.; Bergstrom, R. F. P., and Schuh, L. M. Effectiveness of rapid initial dose escalation of oral olanzapine for acute agitation. 2002; 53, 193.
    Rec #: 1254
  14. Balit, C. R.; Isbister, G. K.; Hackett, L. P., and Whyte, I. M. Quetiapine poisoning: a case series. Ann Emerg Med. 2003 Dec; 42(6):751–8.
    Rec #: 362
  15. Barbui, C.; Danese, A.; Guaiana, G.; Mapelli, L.; Miele, L.; Monzani, E., and Percudani, M. Prescribing second-generation antipsychotics and the evolving standard of care in Italy. Pharmacopsychiatry. 2002 Nov; 35(6):239–43.
    Rec #: 176
  16. Bastiaens D. Pediatric Experience with aripiprazole.
    Rec #: 1585
  17. Beasley, C. M.; Dellva, M. A.; Tamura, R. N.; Morgenstern, H.; Glazer, W. M.; Ferguson, K., and Tollefson, G. D. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry. 1999 Jan; 174:23–30.
    Rec #: 1228
  18. Beasley, C. M. Jr; Hamilton, S. H.; Crawford, A. M.; Dellva, M. A.; Tollefson, G. D.; Tran, P. V.; Blin, O., and Beuzen, J. N. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997 May; 7(2):125–37.
    Rec #: 1317
  19. Beasley, C. M. Jr; Sanger, T.; Satterlee, W.; Tollefson, G.; Tran, P., and Hamilton, S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl). 1996 Mar; 124(1–2):159–67.
    Rec #: 1298
  20. Beasley, C. M. Jr; Tollefson, G.; Tran, P.; Satterlee, W.; Sanger, T., and Hamilton, S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996 Feb; 14(2):111–23.
    Rec #: 1282
  21. Bellnier, T. J. Continuum of care: stabilizing the acutely agitated patient. Am J Health Syst Pharm. 2002 Sep 1; 59(17 Suppl 5):S12–8.
    Rec #: 466
  22. Benedetti, F.; Cavallaro, R., and Smeraldi, E. Olanzapine-induced neutropenia after clozapine-induced neutropenia. Lancet. 1999 Aug 14; 354(9178):567.
    Rec #: 1416
  23. Beresford, T. P.; Clapp, L.; Martin, B.; Wiberg, J. L.; Alfers, J., and Beresford, H. F. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol. 2005 Aug; 25(4):363–6.
    Rec #: 1565
  24. Bever, K. A. and Perry, P. J. Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy. Am J Health Syst Pharm. 1998 May 15; 55(10):1003–16.
    Rec #: 705
  25. Biederman, J.; McDonnell, M. A.; Wozniak, J.; Spencer, T.; Aleardi, M.; Falzone, R., and Mick, E. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr. 2005 Feb; 10(2):141–8.
    Rec #: 1569
  26. Biswas, A.; Mittal, P.; Chaturvedi, S., and Prasad, A. Risperidone induced cytopenias. J Assoc Physicians India. 2000 Nov; 48(11):1122–3.
    Rec #: 572
  27. Blin, O.; Azorin, J. M., and Bouhours, P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol. 1996 Feb; 16(1):38–44.
    Rec #: 1299
  28. Bonanno, D. G.; Davydov, L., and Botts, S. R. Olanzapine-induced diabetes mellitus. Ann Pharmacother. 2001 May; 35(5):563–5.
    Rec #: 1382
  29. Bonelli, R. M. Olanzapine-associated seizure. Ann Pharmacother. 2003 Jan; 37(1):149–50.
    Rec #: 441
  30. Bonzalez; Sofuoglu M; Martell B; Poling P, and Kosten TR. Open-label pilot study evaluating dose tolerability of aripiprazole in cocaine dependent patients.
    Rec #: 1591
  31. Bouchard, R. H.; Merette, C.; Pourcher, E.; Demers, M. F.; Villeneuve, J.; Roy-Gagnon, M. H.; Gauthier, Y.; Cliche, D.; Labelle, A.; Filteau, M. J.; Roy, M. A., and Maziade, M. Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group. J Clin Psychopharmacol. 2000 Jun; 20(3):295–304.
    Rec #: 1301
  32. Brown, D.; McEvoy, J.; Saha, A. R.; Carson, W. H., and Stock, E. Aripiprazole in patients with first episode schizophrenia. International Congress on Schizophrenia Research; 2003.
    Rec #: 1582
  33. Brown, R. N. ; Taylor, M. J.; Wilder, H., and Geddes, J. Aripiprazole alone or in combination for acute mania. Cochrane Database Syst Rev. 2004; (2).
    Rec #: 158
  34. Brylewski, J. and Duggan, L. Antipsychotic medication for challenging behaviour in people with learning disability. Cochrane Database Syst Rev. 1998; CD000377.
    Rec #: 155
  35. Buckley, P. F. Second-generation antipsychotic medications in the treatment of mood disorders: focus on aripiprazole. Drugs Today (Barc). 2005 Jan; 41(1):5–11.
    Rec #: 1573
  36. Buitelaar, J. K. Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol. 2000 Spring; 10(1):19–26.
    Rec #: 101
  37. Buitelaar, J. K.; van der Gaag, R. J.; Cohen-Kettenis, P., and Melman, C. T. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001 Apr; 62(4):239–48.
    Rec #: 102
  38. Buse, J. B.; Cavazzoni, P.; Hornbuckle, K.; Hutchins, D.; Breier, A., and Jovanovic, L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol. 2003 Feb; 56(2):164–70.
    Rec #: 1390
  39. Caligiuri, M. R.; Jeste, D. V., and Lacro, J. P. Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging. 2000 Nov; 17(5):363–84.
    Rec #: 591
  40. Capel, M. M.; Colbridge, M. G., and Henry, J. A. Overdose profiles of new antipsychotic agents. Int J Neuropsychopharmacol. 2000 Mar; 3(1):51–54.
    Rec #: 567
  41. Caro, J. J.; Ward, A.; Levinton, C., and Robinson, K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry. 2002 Dec; 63(12):1135–9.
    Rec #: 215
  42. Carroll, Nancy B.; Boehm, Kathryn E., and Strickland, R. Todd. Chorea and tardive dyskinesia in a patient taking risperidone. Journal of Clinical Psychiatry. 1999 Jul; 60(7): 485–487; ISSN: 0160-6689 (Print).
    Rec #: 885
  43. Carson, W.; Saha, A. R.; Iwamoto, T., and et al. Meta-analysis of prolactin effects with aripiprazole [abstracts no. P.4.E.028]. 2002 Jun; 5, (Suppl 1): S186.
    Rec #: 1244
  44. Casey, D. E.; Carson, W. H.; Saha, A. R.; Liebeskind, A.; Ali, M. W.; Jody, D., and Ingenito, G. G. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003 Apr; 166(4):391–9.
    Rec #: 1237
  45. Cavallaro, R.; Mistretta, P.; Cocchi, F.; Manzato, M., and Smeraldi, E. Differential efficacy of risperidone versus haloperidol in psychopathological subtypes of subchronic schizophrenia. Hum Psychopharmacol. 2001 Aug; 16(6):439–448.
    Rec #: 1302
  46. Ceskova, E. and Svestka, J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry. 1993 Jul; 26(4):121–4.
    Rec #: 1303
  47. Chen, N. and Davis, J. M. Meta-analysis of the efficacy and side effects of olanzapine. Schizophrenia Research. 2001; 49(1–2):222.
    Rec #: 1394
  48. Chouinard, G.; Jones, B.; Remington, G.; Bloom, D.; Addington, D.; MacEwan, G. W.; Labelle, A.; Beauclair, L., and Arnott, W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993 Feb; 13(1):25–40.
    Rec #: 1304
  49. Chouinard, G.; Kopala, L.; Labelle, A.; Beauclair, L.; Johnson, S. V., and Singh, K. I. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group. Can J Psychiatry. 1998 Dec; 43(10):1018–25.
    Rec #: 1424
  50. Chue, P.; Eerdekens, M.; Augustyns, I.; Lachaux, B.; Molcan, P.; Eriksson, L.; Pretorius, H., and David, A. S. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005 Jan; 15(1):111–7.
    Rec #: 1352
  51. Clark, C. and Burge, M. R. Diabetes mellitus associated with atypical anti-psychotic medications. Diabetes Technol Ther. 2003; 5(4):669–83.
    Rec #: 1410
  52. Clark Wr; Findling RL; Blumer JL; Kauffman R; Batterson JR; Gilbert DL; Bramer S, and Marcus R. Aripiprazole in pediatric conduct disorder: A pilot study. APNA Pediatric.
    Rec #: 1583
  53. Claus, A.; Bollen, J.; De Cuyper, H.; Eneman, M.; Malfroid, M.; Peuskens, J., and Heylen, S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand. 1992 Apr; 85(4):295–305.
    Rec #: 1305
  54. Cohen, L. S. Quetiapine in treatment-resistant obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2003 Jun; 42(6):623–4.
    Rec #: 385
  55. Conley, R. R. and Mahmoud, R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001 May; 158(5):765–74.
    Rec #: 1098
  56. Crawford, A. M.; Beasley, C. M. Jr, and Tollefson, G. D. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res. 1997 Jul 25; 26(1):41–54.
    Rec #: 1318
  57. Croke, S.; Buist, A.; Hackett, L. P.; Ilett, K. F.; Norman, T. R., and Burrows, G. D. Olanzapine excretion in human breast milk: estimation of infant exposure. Int J Neuropsychopharmacol. 2002 Sep; 5(3):243–7.
    Rec #: 460
  58. Csernansky, J. and Okamoto, A. Risperidone Vs. Haloperidol for prevention of relapse in schizphrenia and schizoaffective disorders: a long-term double-blind comparison. 55th Annual Scientific Convention and Program of the Society of Biological Psychiatry.; Chicago, Il.
    Rec #: 1334
  59. Curtis, R. C. and Resch, D. S. Case of pick's central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J Clin Psychopharmacol. 2000 Jun; 20(3):384–5.
    Rec #: 623
  60. Czobor, P.; Volavka, J.; Sheitman, B.; Lindenmayer, J. P.; Citrome, L.; McEvoy, J.; Cooper, T. B.; Chakos, M., and Lieberman, J. A. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol. 2002 Jun; 22(3):244–51.
    Rec #: 1447
  61. Daniel, D.; Stern, R., and Kramer, T. Switching from Olanzappine to Ziprasidone: an interim analysis of a 6-week study. Presented at the 152nd APA; Washington, DC.
    Rec #: 1288
  62. Daniel, D. G.; Potkin, S. G.; Reeves, K. R.; Swift, R. H., and Harrigan, E. P. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl). 2001 May; 155(2):128–34.
    Rec #: 558
  63. Daniel, D. G.; Zimbroff, D. L.; Swift, R. H., and Harrigan, E. P. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int Clin Psychopharmacol. 2004 Jan; 19(1):9–15.
    Rec #: 319
  64. Davies, A.; Adena, M. A.; Keks, N. A.; Catts, S. V.; Lambert, T., and Schweitzer, I. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clin Ther. 1998 Jan-1998 Feb 28; 20(1):58–71.
    Rec #: 1454
  65. Davis, J. M.; Chen, N., and Glick, I. D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003 Jun; 60(6):553–64.
    Rec #: 1402
  66. Davis, M. P.; Khawam, E.; Pozuelo, L., and Lagman, R. Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project. Expert Rev Anticancer Ther. 2002 Aug; 2(4):365–76.
    Rec #: 417
  67. DelBello MP; Sabin A; Barzman DH; Kowatch RA; Gernert EH; Rappaport KB; Delgado S, and Pathak S. Aripiprazole for Pediatric Bipolar Disorder: A retrospective Chart Review.
    Rec #: 1586
  68. Dewa, C. S.; Remington, G.; Herrmann, N.; Fearnley, J., and Goering, P. How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience. Clin Ther. 2002 Sep; 24(9):1466–76.
    Rec #: 458
  69. Dolder, C. R.; Lacro, J. P.; Dunn, L. B., and Jeste, D. V. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry. 2002 Jan; 159(1):103–8.
    Rec #: 1351
  70. Duggal, Harpreet S. (Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, US). Letter to the editor. Risperidone-induced obsessive-compulsive symptoms in two children. Journal of Child & Adolescent Psychopharmacology. 2004 Spring; 14(1): 155–156 URL: http://www.liebertpub.com/CAP/default1.asp; ISSN: 1044-5463 (Print).
    Rec #: 794
  71. Dunlop, B. W.; Sternberg, M.; Phillips, L. S.; Andersen, J., and Duncan, E. Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics. Psychopharmacol Bull. 2003 Summer; 37(3):99–117.
    Rec #: 368
  72. Duran-Ferreras, E.; Chacon-Pena, J. R., and Duran-Quintana, J. A. [The role of olanzapine in Parkinsonian dopaminergic psychosis]. Rev Neurol. 2002 Oct 1-2002 Oct 15; 35(7):691–6.
    Rec #: 455
  73. Edgell, E. T.; Andersen, S. W.; Johnstone, B. M.; Dulisse, B.; Revicki, D., and Breier, A. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics. 2000 Dec; 18(6):567–79.
    Rec #: 193
  74. Edleman, R. J. Risperidone side effects. J Am Acad Child Adolesc Psychiatry. 1996 Jan; 35(1):4–5.
    Rec #: 1190
  75. Eerdekens, M.; Van Hove, I.; Remmerie, B., and Mannaert, E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res. 2004 Sep 1; 70(1):91–100.
    Rec #: 1359
  76. Emsley, R. A. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull. 1999; 25(4):721–9.
    Rec #: 1306
  77. Emsley, R. A.; Raniwalla, J.; Bailey, P. J., and Jones, A. M. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol. 2000 May; 15(3):121–31.
    Rec #: 1286
  78. Feeney, Daniel J. and Klykylo, William (Wright State U, School of Medicine, Dayton, OH, US). “Td from risperidone?”: Reply. Journal of the American Academy of Child & Adolescent Psychiatry. 1997 Jul; 36(7): 867; ISSN: 0890-8567 (Print).
    Rec #: 906
  79. Feldman, P. D.; Kaiser, C. J.; Kennedy, J. S.; Sutton, V. K.; Tran, P. V.; Tollefson, G. D.; Zhang, F., and Breier, A. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. J Clin Psychiatry. 2003 Sep; 64(9):998–1004.
    Rec #: 364
  80. Findling RL; Blumer JL/Kauffman R; Batterson JR; Gilbert DL; Bramer SL; Marcus RN; Iwamoto T, and Carson WH. Pharmacokinetic effects of aripiprazole in children and adolescents with conduct disorder. XXIVth Collegium Internationale Neuro-psychopharmacologicum Congress; Paris, France.
    Rec #: 1589
  81. Findling RL; Krauffman R; Batterson JR; Sallee FR; Auby P; Nylias M; Mallikaarjun S; Forbes RA, and Carson WH. Tolerability of Aripiprazole in children and adolescents wiht major psychiatric diagnoses. American Academy of Child and Adolescent Psychiatry; Toronto, Canada.
    Rec #: 1588
  82. Findling RLL; BLumer JL; Kauffman R, and Batterson JR. Aripiprazole in pediatric conduct disorder: A pilot Study. 16th ECNP Congress; Prague, Czech Republic.
    Rec #: 1584
  83. Fleminger, S.; Greenwood, R. J., and Oliver, D. L. Pharmacological management for agitation and aggression in people with acquired brain injury. Cochrane Database Syst Rev. 2003; (1):CD003299.
    Rec #: 156
  84. Flynn, Sean W.; Altman, Siemion; MacEwan, G. William; Black, Lori L.; Greenidge, Lori L., and Honer, William G. (U British Columbia, Dept of Psychiatry, Vancouver, BC, Canada). Prolongation of clozapine-induced granulocytopenia associated with olanzapine. Journal of Clinical Psychopharmacology. 1997 Dec; 17(6): 494–495 URL: http://www.psychopharmacology.com/; ISSN: 0271-0749 (Print).
    Rec #: 905
  85. Fras, I. and Major, L. F. Clinical experience with risperidone. J Am Acad Child Adolesc Psychiatry. 1995 Jul; 34(7):833.
    Rec #: 1177
  86. Fric, M. and Laux, G. [Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics]. Psychiatr Prax. 2003 May; 30 Suppl 2:S97–101.
    Rec #: 377
  87. Friedman, J. H.; Fernandez, H. H.; Jacques, C., and Goldstein, J. M. Quetiapine for the treatment of dopamimetic psychosis in parkinson's disease. Annual Meeting of the American College of Neuropsychopharmacology; Acapulco, Mexico.
    Rec #: 1434
  88. Furmaga, K. M.; DeLeon, O. A.; Sinha, S. B.; Jobe, T. H., and Gaviria, M. Psychosis in medical conditions: response to risperidone. Gen Hosp Psychiatry. 1997 May; 19(3):223–8.
    Rec #: 731
  89. Gabriel, Adel. A case of resistant trichotillomania treated with risperidone-augmented fluvoxamine. Canadian Journal of Psychiatry. 2001 Apr; 46(3): 285–286 URL: http://www.cpa-apc.org/Publications/cjpHome.asp; ISSN: 0706-7437 (Print).
    Rec #: 839
  90. Gatta, B.; Rigalleau, V., and Gin, H. Diabetic ketoacidosis with olanzapine treatment. Diabetes Care. 1999 Jun; 22(6):1002–3.
    Rec #: 1376
  91. Geddes, J.; Freemantle, N.; Harrison, P., and Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000 Dec 2; 321(7273):1371–6.
    Rec #: 1307
  92. Gillman, P. Ken (PsychoTropical Research Unit, Mt Pleasant, QLD, Australia). Comments on “serotonin syndrome during treatment with paroxetine and risperidone.”. Journal of Clinical Psychopharmacology. 2001 Jun; 21(3): 344–345 URL: http://www.psychopharmacology.com/; ISSN: 0271-0749 (Print).
    Rec #: 850
  93. Gilmore, J. A.; Kinon, B. J., and Zhao, Z. Rigorous criteria for treatment response differentiated efficacy of olanzapine versus haloperidol in patients with schizophrenia. 2002; 53, 177.
    Rec #: 1251
  94. Goff, D. C.; Posever, T., and Herz, L. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1998; 18(4):296–304.
    Rec #: 1463
  95. Goldstein, J. M. The new generation of antipsychotic drugs: how atypical are they? Int J Neuropsychopharmacol. 2000 Dec; 3(4):339–349.
    Rec #: 1421
  96. Gossen, D.; de Suray, J. M.; Vandenhende, F.; Onkelinx, C., and Gangji, D. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci. 2002; 4(2):E11.
    Rec #: 476
  97. Guille, C.; Sachs, G. S., and Ghaemi, S. N. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2000 Sep; 61(9):638–42.
    Rec #: 1172
  98. Guitierrez-Esteinou, R. and Grebb, J. A. Risperidone: An analysis of the first three years in general use. Int Clin Psychopharmacol. 1997; 12(Suppl 4):S3–10.
    Rec #: 1431
  99. Gupta, S.; Chohan, M., and Madhusoodanan, S. Treatment of Acute Mania With Aripiprazole in an Older Adult With Noted Improvement in Coexisting Parkinson's Disease. Prim Care Companion J Clin Psychiatry. 2004; 6(1):50–51.
    Rec #: 1567
  100. Gupta, S. and Masand, P. Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders. Ann Clin Psychiatry. 2004 Jul-2004 Sep 30; 16(3):155–66.
    Rec #: 1571
  101. Gupta, S.; Steinmeyer, C.; Frank, B.; Madhusoodanan, S.; Lockwood, K.; Lentz, B., and Keller, P. Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy. Am J Ther. 2003 Sep-2003 Oct 31; 10(5):348–55.
    Rec #: 1388
  102. Haddad, P. M.; Helleweil, J. S., and Wieck, A. Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports. J Psychopharmacol. 2001 Dec; 15(4):293–5.
    Rec #: 518
  103. Hagger, C.; Mitchell, D.; Wise, A. L., and Schultz, S. C. Effects on oral Ziprasidone and Riseridone on cognitive functioning in patient with Schizoprenia or schizo affective disorder: preliminary data. Eur Neuropsycho-Pharmacology. 1997; 71(supl 2):219.
    Rec #: 1164
  104. Hanna, G. L.; Fluent, T. E., and Fischer, D. J. Separation anxiety in children and adolescents treated with risperidone. J Child Adolesc Psychopharmacol. 1999; 9(4):277–83.
    Rec #: 110
  105. Herrmann, N.; Mamdani, M., and Lanctot, K. L. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004 Jun; 161(6):1113–5.
    Rec #: 306
  106. Horrigan, J. P.; Barnhill, L. J., and Kohli, R. R. (U North Carolina, Developmental Neuropharmacology Clinic, Chapel Hill, NC, US ). Adderall, the atypicals, and weight gain. Journal of the American Academy of Child & Adolescent Psychiatry. 2001 Jun; 40 (6): 620; ISSN: 0890-8567 (Print).
    Rec #: 848
  107. Huffman, J. C. and Fricchione, G. L. Catatonia and psychosis in a patient with AIDS: treatment with lorazepam and aripiprazole. J Clin Psychopharmacol. 2005 Oct; 25(5):508–10.
    Rec #: 1562
  108. Huttunen, M. O.; Piepponen, T.; Rantanen, H.; Larmo, I.; Nyholm, R., and Raitasuo, V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand. 1995 Apr; 91(4):271–7.
    Rec #: 1309
  109. Jeste, D. V.; Rockwell, E.; Harris, M. J.; Lohr, J. B., and Lacro, J. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry. 1999 Winter; 7(1):70–6.
    Rec #: 684
  110. Jody, D.; Saha, A. R.; Iwamoto, T., and et al. Meta-analysis of weight effects with aripiprazole [abstracts P.4.E.030]. 2002 Jun; 5, (Suppl 1.): S186.
    Rec #: 1245
  111. Jones, B. D.; Purdon, S. E.; Labelle, A., and Finlayson, R. Risperidone treatment for severe negative symptoms. Can J Psychiatry. 1994 Aug; 39(6):381.
    Rec #: 774
  112. Jonnalagada, J. Rao and Norton, John W. (U Mississippi Coll of Medicine, Jackson, MS, US). Acute dystonia with quetiapine. Clinical Neuropharmacology. 2000 Jul-2000 Aug 31; 23(4): 229–230 URL: http://www.clinicalneuropharm.com/; ISSN: 0362-5664 (Print).
    Rec #: 860
  113. Juncos, J.; Yeung, P.; Sweitzer, D.; Arvanitis, L., and Nemeroff, C. SEROQUEL (quetiapine) improves psychotic symptoms associated with parkinson's disease. American Psychiatric Association's Annual Meeting; Washington, D.C.
    Rec #: 1437
  114. Juncos, J. L.; Evatt, M. L.; Jewart, R. D.; Roberts, V. J.; Potter, L. S.; Jou, H., and Yeung, P. Long-term quetiapine treatment for psychosis in patients with Parkinson's disease who failed treatment with other atypical antipsychotics. American Psychiatric Association Annual Meeting; Chicago, IL.
    Rec #: 1435
  115. Juncos, J. L.; Roberts, V. J.; Evatt, M. L.; Jewart, R. D.; Wood, C. D.; Potter, L. S.; Jou, H. C., and Yeung, P. P. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord. 2004 Jan; 19(1):29–35.
    Rec #: 1346
  116. Kane, J. M.; Carson, W. H.; Saha, A. R.; McQuade, R. D.; Ingenito, G. G.; Zimbroff, D. L., and Ali, M. W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002 Sep; 63(9):763–71.
    Rec #: 1239
  117. Kane, J. M.; Leucht, S.; Carpenter, D., and Docherty, J. P. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003; 64 Suppl 12:5–19.
    Rec #: 361
  118. Kastrup, A.; Schlotter, W.; Plewnia, C., and Bartels, M. Treatment of tics in tourette syndrome with aripiprazole. J Clin Psychopharmacol. 2005 Feb; 25(1):94–6.
    Rec #: 1587
  119. Keck, P. E. Jr; Versiani, M.; Potkin, S.; West, S. A.; Giller, E., and Ice, K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003 Apr; 160(4):741–8.
    Rec #: 1604
  120. Kinon, B. J. and Gilmore, J. A. Prevalence of hyperprolactinemia in a large cohort of patients with schizophrenia treated with conventional antipsychotic drugs or risperidone. 2002; 53, 198–9.
    Rec #: 1255
  121. Kinon, B. J.; Jeste, D. V.; Kollack-Walker, S.; Stauffer, V., and Liu-Seifert, H. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Sep; 28(6):985–96.
    Rec #: 1249
  122. Kinon, B. J.; Stauffer, V. L.; Wang, L., and Thi, K. T. Olanzapine improves tardive dyskinesia in patients with schizophrenia. 2002; 53, 190.
    Rec #: 1253
  123. Kleinberg, D. L.; Davis, J. M., and de Coster, R. Prolactin levels and adverse events in patients treated with risperidone. Journal of Clinical Psychopharmacol. 1999 Feb; 19:57–61.
    Rec #: 1124
  124. Koller, E. A.; Cross, J. T.; Doraiswamy, P. M., and Schneider, B. S. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003 Jun; 23(6):735–44.
    Rec #: 1412
  125. Koller, E. A. and Doraiswamy, P. M. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002 Jul; 22(7):841–52.
    Rec #: 1411
  126. Konrad, C.; Schormair, C.; Eikelmann, B., and Telger, K. [Risperidone after clozapine in therapy refractory schizoaffective psychosis--a case report]. Psychiatr Prax. 1997 Mar; 24(2):88–9.
    Rec #: 738
  127. Koro, C. E.; Fedder, D. O.; L'Italien, G. J.; Weiss, S. S.; Magder, L. S.; Kreyenbuhl, J.; Revicki, D. A., and Buchanan, R. W. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002 Aug 3; 325(7358):243.
    Rec #: 1392
  128. Kumra, S.; Herion, D.; Jacobsen, L. K.; Briguglia, C., and Grothe, D. Case study: risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry. 1997 May; 36(5):701–5.
    Rec #: 1187
  129. Kumra, S.; Jacobsen, L. K.; Lenane, M.; Karp, B. I.; Frazier, J. A.; Smith, A. K.; Bedwell, J.; Lee, P.; Malanga, C. J.; Hamburger, S., and Rapoport, J. L. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry. 1998 Apr; 37(4):377–85.
    Rec #: 1183
  130. Lane, H. Y.; Lin, Y. C., and Chang, W. H. Mania induced by risperidone: dose related? J Clin Psychiatry. 1998 Feb; 59(2):85–6.
    Rec #: 1167
  131. Lantz MS and Buchalter EN. Improvement in Tardive Dyskinesia in Elderly patients on Aripiprazole.
    Rec #: 1579
  132. Larson, M. F. and Hauser, A. ( Adolescent Assessment Unit, Cambridge Health Alliance, Harvard Medical School, Somerville, MA, US; Adolescent Assessment Unit, Cambridge Health Alliance, Harvard Medical School, Somerville, MA, US). Possible ziprasidone-induced mania. Journal of the American Academy of Child & Adolescent Psychiatry. 2003 Sep; 42(9): 1012; ISSN: 0890-8567 (Print).
    Rec #: 801
  133. Lean, M. E. and Pajonk, F. G. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care. 2003 May; 26(5):1597–605.
    Rec #: 1413
  134. Lebovitz, H. E. Metabolic consequences of atypical antipsychotic drugs. Psychiatr Q. 2003 Fall; 74(3):277–90.
    Rec #: 1389
  135. Lemmens, P; Brecher, M., and Van-Baelen, B. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents:factors associated with extrapyramidal symptoms. Acta Psychiatric Scand. 1999 Mar; 160–70.
    Rec #: 1123
  136. Leucht, S.; Pitschel-Walz, G.; Abraham, D., and Kissling, W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999 Jan 4; 35(1):51–68.
    Rec #: 1227
  137. Leucht, S.; Wahlbeck, K.; Hamann, J., and Kissling, W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003 May 10; 361(9369):1581–9.
    Rec #: 1231
  138. Lieberman, J. A.; Stroup, T. S.; McEvoy, J. P.; Swartz, M. S.; Rosenheck, R. A.; Perkins, D. O.; Keefe, R. S. E.; Davis, S. M.; Davis, C. E.; Lebowitz, B. D.; Severe, J., and Hsiao, J. K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 Sep 22; 353(12):1209–23.
    Rec #: 1507
  139. Liebzeit, K. A.; Markowitz, J. S., and Caley, C. F. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol. 2001 Feb; 11(1):25–32.
    Rec #: 1439
  140. Llorca, P. M.; Devos, E.; Eerdekens, M.; Duchesne, I.; Leal, A., and Mehnert, A. Re-hospitalization rates with long-acting risperidone injection are lower than those reported for other antipsychotics [poster]. Presented at the XXXII CINP Congress; Montreal, Canada.
    Rec #: 1357
  141. London, J. A. Mania associated with olanzapine. J Am Acad Child Adolesc Psychiatry. 1998 Feb; 37(2):135–6.
    Rec #: 1191
  142. Lopez-Meza, E.; Ruiz-Chow, A., and Ramirez-Bermudez, J. Aripiprazole in psychosis associated with Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2005 Summer; 17(3):421–2.
    Rec #: 1574
  143. Lusskin, S. I.; Cancro, R.; Chuang, L., and Jacobson, J. Prolactin elevation with ziprasidone. Am J Psychiatry. 2004 Oct; 161(10):1925.
    Rec #: 263
  144. Lykes, W. C. and Cueva, J. E. Risperidone in children with schizophrenia -letter-. J Am Acad Child Adolesc Psychiatry. 1996 Apr; 35(4):405–6.
    Rec #: 1182
  145. Mabini, R.; Wergowske, G., and Baker, F. M. Galactorrhea and gynecomastia in a hypothyroid male being treated with risperidone. Psychiatr Serv. 2000 Aug; 51(8):983–5.
    Rec #: 614
  146. Mackay, F. J.; Wilton, L. V.; Pearce, G. L.; Freemantle, S. N., and Mann, R. D. The safety of risperidone: a post-marketing study on 7,684 patients. Hum Psychopharmacol. 1998; 13(6):413–18.
    Rec #: 238
  147. Madhusoodanan, S.; Brecher, M.; Brenner, R.; Kasckow, J.; Kunik, M.; Negron, A. E., and Pomara, N. Risperidone in the treatment of elderly patients with psychotic disorders. Am J Geriatr Psychiatry. 1999 Spring; 7(2):132–8.
    Rec #: 1297
  148. Madhusoodanan, S.; Brenner, R.; Suresh, P.; Concepcion, N. M.; Florita, C. D.; Menon, G.; Kaur, A.; Nunez, G., and Reddy, H. Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann Clin Psychiatry. 2000 Mar; 12(1):11–8.
    Rec #: 629
  149. Mahendran, R. Obsessional symptoms associated with risperidone treatment. Aust N Z J Psychiatry. 1998 Apr; 32(2):299–301.
    Rec #: 1080
  150. Mahmoud, R.; Gianfrancesco, F.; Grogg, A., and Nasrallah, H. A. Differential effects of antipsychotics on type 2 diabetes: findings from a large health plan database. Proceedings of the 39th Annual meeting of the American College of Neuropsychopharmacology; San Juan, Puerto Rico.
    Rec #: 1445
  151. Mahmoud, R. A.; Engelhart, L. M.; Janagap, C. C.; Oster, G., and Ollendorf, D. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder - symptoms, quality of life and resource use under customary clinical care. Clinical Drug Investigation. 2004; 24(5):275–86.
    Rec #: 1337
  152. Marder, S. R. and Meibach, R. C. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994 Jun; 151(6):825–35.
    Rec #: 1311
  153. McDougle, C. J.; Holmes, J. P.; Carlson, D. C.; Pelton, G. H.; Cohen, D. J., and Price, L. H. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry. 1998 Jul; 55(7):633–41.
    Rec #: 121
  154. McLean, A. J. The use of the dopamine-receptor partial agonist aripiprazole in the treatment of restless legs syndrome. Sleep. 2004 Aug 1; 27(5):1022.
    Rec #: 1564
  155. McQuade R; Sanchez R; Carson W; Kostic D; Abou-Gharbia N; Iwamoto T, and Hardy S. Efficacy of aripiprazole versus placebo in acute mania: pooled analysis.
    Rec #: 1556
  156. Meehan, K.; Zhang, F.; David, S.; Tohen, M.; Janicak, P.; Small, J.; Koch, M.; Rizk, R.; Walker, D.; Tran, P., and Breier, A. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001 Aug; 21(4):389–97.
    Rec #: 1465
  157. Melkersson, K. I.; Hulting, A. L., and Brismar, K. E. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 2000 Oct; 61(10):742–9.
    Rec #: 1450
  158. Meyer, J. M. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry. 2001; 62 Suppl 27:27–34; discussion 40–1.
    Rec #: 1448
  159. ---. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002 May; 63(5):425–33.
    Rec #: 1414
  160. Min, S. K.; Rhee, C. S.; Kim, C. E., and Kang, D. Y. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J. 1993 Jun; 34(2):179–90.
    Rec #: 1312
  161. Mir, S. and Taylor, D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol. 2001 Mar; 16(2):63–73.
    Rec #: 1440
  162. Mishra, A.; Moore, P. B., and Hobbs, R. Does quetiapine have mood altering properties? J Psychopharmacol. 2004 Jun; 18(2):281–4.
    Rec #: 290
  163. Moore, N. C. and Shukla, P. Risperidone overdose. American Journal of Psychiatry. 1997 Feb; 154(2): 289–290; ISSN: 0002-953X (Print).
    Rec #: 911
  164. Mueck-Weymann, Michael; Rechlin, Thomas; Ehrengut, Franz; Rauh, Robert; Acker, Jens; Dittmann, Ralf W.; Czekalla, Jörg; Joraschky, Peter, and Musselman, Dominique (Dresden U of Technology, Dept of Psychotherapy & Psychosomatic Medicine, Dresden, Germany; Dept of Psychiatry, Rendsburg, Germany; Dept of Internal Medicine, Neumarkt, Germany; U Erlangen, Inst of Physiology & Cardiology, Erlangen, Germany; U Ulm, Dept of Psychiatry, Revensburg-Weissenau, Germany; Lilly Germany, Inc., Bad Homburg, Germany; Lilly Germany, Inc., Bad Homburg, Germany; Dresden U of Technology, Dept of Psychotherapy & Psychosomatic Medicine, Dresden, Germany; Emory U, Dept of Psychiatry, Atlanta, GA, US E-mail: ed.bew@kceum.leahcim). Effects of olanzapine and clozapine upon pulse rate variability. Depression & Anxiety. 2002; 16(3): 93–99; ISSN: 1091-4269 (Print).
    Rec #: 826
  165. Muench, J. and Carey, M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J Am Board Fam Pract. 2001 Jul-2001 Aug 31; 14(4):278–82.
    Rec #: 1383
  166. Naumann, R.; Felber, W.; Heilemann, H., and Reuster, T. Olanzapine-induced agranulocytosis. Lancet. 1999 Aug 14; 354(9178):566–7.
    Rec #: 1417
  167. Osser, D. N.; Najarian, D. M., and Dufresne, R. L. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry. 1999 Nov; 60(11):767–70.
    Rec #: 1154
  168. Ostbye, T.; Curtis, L. H.; Masselink, L. E.; Hutchison, S.; Wright, A.; Dans, P. E.; Schulman, K. A., and Krishnan, R. R. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2004 Sep 16.
    Rec #: 221
  169. Owens, D. G. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry. 1994 May; 55 Suppl:29–35.
    Rec #: 1457
  170. Padla, D. Quetiapine resolves psychotic depression in an adolescent boy. J Child Adolesc Psychopharmacol. 2001 Summer; 11(2):207–8.
    Rec #: 153
  171. Palenzona, S.; Meier, P. J.; Kupferschmidt, H., and Rauber-Luethy, C. The clinical picture of olanzapine poisoning with special reference to fluctuating mental status. J Toxicol Clin Toxicol. 2004; 42(1):27–32.
    Rec #: 168
  172. Patel, N. C.; Sierk, P.; Dorson, P. G., and Crismon, L. Experience with ziprasidone. J Am Acad Child Adolesc Psychiatry. 2002 May; 41(5):495.
    Rec #: 486
  173. Penn, J. V.; Martini, J., and Radka, D. Weight gain associated with risperidone. J Clin Psychopharmacol. 1996 Jun; 16(3):259–60.
    Rec #: 1185
  174. Peuskens, J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995 Jun; 166(6):712–26; discussion 727–33.
    Rec #: 1314
  175. Peuskens, J.; De Hert, M., and Jones, M. The clinical value of risperidone and olanzapine: A meta-analysis of efficacy and safety. Int J Psychiatry Clin Prac. 2001; 5(3):179–187.
    Rec #: 231
  176. Philipp, M.; Lesch, O. M.; Schmauss, M.; Dose, M., and Glaser, T. [Comparative Efficacy of Flupentixol and Risperidone on Schizophrenic Negative Symptoms]. Psychiatr Prax. 2003 May; 30(Suppl 2):94–96.
    Rec #: 379
  177. Pijnenburg, Y. A.; Sampson, E. L.; Harvey, R. J.; Fox, N. C., and Rossor, M. N. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatry. 2002; 18(1):67–72.
    Rec #: 1489
  178. Poewe, W. and Seppi, K. Treatment options for depression and psychosis in Parkinson's disease. J Neurol. 2001 Sep; 248 Suppl 3:III12–21.
    Rec #: 534
  179. Potkin, S. G.; Saha, A. R.; Kujawa, M. J.; Carson, W. H.; Ali, M.; Stock, E.; Stringfellow, J.; Ingenito, G., and Marder, S. R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003 Jul; 60(7):681–90.
    Rec #: 1236
  180. Precourt, A.; Dunewicz, M.; Gregoire, G., and Williamson, D. R. Multiple complications and withdrawal syndrome associated with quetiapine/venlafaxine intoxication. Ann Pharmacother. 2005 Jan; 39(1):153–6.
    Rec #: 249
  181. Procyshyn, R. M.; Pande, S., and Tse, G. New-onset diabetes mellitus associated with quetiapine. Can J Psychiatry. 2000 Sep; 45(7):668–9.
    Rec #: 1442
  182. Purdon, S. E.; Lit, W.; Labelle, A., and Jones, B. D. Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry. 1994 Sep; 39(7):400–5.
    Rec #: 128
  183. Quintana, H. and Keshavan, M. Case study: risperidone in children and adolescents with schizophrenia. Journal American Acad Child Adolescent Psychiatry. 1995; 34:1292–96.
    Rec #: 1204
  184. Rassam, S. and Srinivasa, R. Respiratory depression after accidental risperidone overdose. Am J Emerg Med. 2002 Oct; 20(6):570.
    Rec #: 459
  185. Ravin, D. S. and Levenson, J. W. Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother. 1997 Jul-1997 Aug 31; 31(7–8):867–70.
    Rec #: 1295
  186. Renshaw PF, Yurgelun-Todd DA Wei H Charles HC Tohen M Lieberman JA. Olanzapine induced reductions in frontal lobe lactate levels correlate with treatment response in first episode psychosis. Schizophrenia Research. 2003; 60301. CODEN: RCT; ISSN: CN-00454033.
    Rec #: 926
  187. Revicki, D. A.; Genduso, L. A.; Hamilton, S. H.; Ganoczy, D., and Beasley, C. M. Jr. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res. 1999 Aug; 8(5):417–26.
    Rec #: 651
  188. Roberts, M. D. Risperdal and parkinsonian tremor. J Am Acad Child Adolesc Psychiatry. 1999 Mar; 38(3):230.
    Rec #: 675
  189. Rowan, A. B. and Malone, R. P. Tics with risperidone withdrawal. J Am Acad Child Adolesc Psychiatry. 1997 Feb; 36(2):162–3.
    Rec #: 1188
  190. Saha, A.; Ali, M. W.; Ingenito, G. G., and et al. Safety and tolerability of aripiprazole at doses higher than 30 mg [abstract no. P.4E.026]. 2002 Jun; 5, (Suppl 1): S185.
    Rec #: 1246
  191. Sajatovic, M.; DiGiovanni, S. K.; Bastani, B.; Hattab, H., and Ramirez, L. F. Risperidone therapy in treatment refractory acute bipolar and schizoaffective mania. Psychopharmacol Bull. 1996; 32(1):55–61.
    Rec #: 1170
  192. Schmidt, A. W.; Lebel, L. A.; Howard, H. R. Jr, and Zorn, S. H. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001 Aug 17; 425(3):197–201.
    Rec #: 1608
  193. Schotte, A.; Janssen, P. F.; Gommeren, W.; Luyten, W. H.; Van Gompel, P.; Lesage, A. S.; De Loore, K., and Leysen, J. E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar; 124(1–2):57–73.
    Rec #: 1085
  194. Segal, J.; Berk, M., and Brook, S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol. 1998 May-1998 Jun 30; 21(3):176–80.
    Rec #: 1171
  195. Sharma, R.; Trappler, B.; Ng, Y. K., and Leeman, C. P. Risperidone-induced neuroleptic malignant syndrome. Ann Pharmacother. 1996 Jul-1996 Aug 31; 30(7–8):775–8.
    Rec #: 1189
  196. Shayegan, D. K. and Stahl, S. M. Atypical antipsychotics and receptor binding: enhancing cognition and mood. 157th Annual Meeting of the American Psychiatric Association; New York, NY, USA. 2004 May 1-2004 May 6.
    Rec #: 1609
  197. Sheitman, B. B.; Bird, P. M.; Binz, W.; Akinli, L., and Sanchez, C. Olanzapine-induced elevation of plasma triglyceride levels. Am J Psychiatry. 1999 Sep; 156(9):1471-2.
    Rec #: 1155
  198. Shiwach, R. S. and Carmody, T. J. Prolactogenic effects of risperidone in male patients--a preliminary study. Acta Psychiatr Scand. 1998 Jul; 98(1):81–3.
    Rec #: 699
  199. Sourander, A. Risperidone for treatment of childhood schizophrenia. Am J Psychiatry. 1997 Oct; 154(10):1476.
    Rec #: 1180
  200. Stahl, S. M. and Shayegan, D. K. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003; 64 Suppl 19:6–12.
    Rec #: 1603
  201. Staller, J. A. Aripiprazole in an adult with Asperger disorder. Ann Pharmacother. 2003 Nov; 37(11):1628–31.
    Rec #: 1566
  202. Stanniland, C. and Taylor, D. Tolerability of atypical antipsychotics. Drug Saf. 2000 Mar; 22(3):195–214.
    Rec #: 1418
  203. Sternlicht, H. C. and Wells, S. R. Risperidone in childhood schizophrenia. J Am Acad Child Adolesc Psychiatry. 1995 May; 34(5):540.
    Rec #: 1178
  204. Stock, E.; Saha, A.; Brunell, R., and et al. Meta-analysis of cardiac safety with aripiprazole [poster]. XXIII CINP Congress; Montreal.
    Rec #: 1242
  205. Stoner, Steven C.; Dubisar, Beth M.; Khan, Rintu, and Farrar, Cynthia D. (U Missouri, Kansas City School of Pharmacy, Kansas City, MO, US; Northwest Missouri Psychiatric Rehabiltation Ctr, St Joseph, MO, US; Northwest Missouri Psychiatric Rehabiltation Ctr, St Joseph, MO, US; Northwest Missouri Psychiatric Rehabiltation Ctr, St Joseph, MO, US). Severe hypertriglyceridemia associated with olanzapine. Journal of Clinical Psychiatry. 2002 Oct; 63(10): 948–949; ISSN: 0160-6689 (Print).
    Rec #: 827
  206. Taylor, D. M.; Young, C. L.; Mace, S., and Patel, M. X. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry. 2004 Aug; 65(8):1076–83.
    Rec #: 1355
  207. Thorpe, L. The treatment of psychotic disorders in late life. Can J Psychiatry. 1997 Jun; 42 Suppl 1:19S–27S.
    Rec #: 729
  208. Tohen, M.; Jacobs, T., and Gannon, K. S. et al. Olanzapine acute and long term efficacy in bipolar I patients. Schizophr Res. 2000; 41:192–3.
    Rec #: 1116
  209. Tollefson, B. D.; Beasley, C. M.; Tamura, R. N.; Tran, P. V., and Potvin, J. H. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 1997; 154(9):1248–1254.
    Rec #: 1090
  210. Tomlinson, W. C. Risperidone and mania. American Journal of Psychiatry. 1996; 153:132–33.
    Rec #: 1207
  211. Tran, P. V.; Hamilton, S. H.; Kuntz, A. J.; Potvin, J. H.; Andersen, S. W.; Beasley, C. Jr, and Tollefson, G. D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997 Oct; 17(5):407–18.
    Rec #: 1104
  212. Turgay, A.; Binder, C.; Snyder, R., and Fisman, S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics. 2002 Sep; 110(3):e34.
    Rec #: 1229
  213. Van Bellinghen, M. and De Troch, C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol. 2001 Spring; 11(1):5–13.
    Rec #: 134
  214. Velligan, D. I.; Newcomer, J.; Pultz, J.; Csernansky, J.; Hoff, A. L.; Mahurin, R., and Miller, A. L. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res. 2002 Jan 15; 53(3):239–48.
    Rec #: 194
  215. Velligan, D. I.; Prihoda, T. J.; Sui, D.; Ritch, J. L.; Maples, N., and Miller, A. L. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry. 2003 May; 64(5):524–31.
    Rec #: 196
  216. Verma, S.; Orengo, C. A.; Kunik, M. E.; Hale, D., and Molinari, V. A. Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients. Int J Geriatr Psychiatry. 2001 Feb; 16(2):223–7.
    Rec #: 583
  217. Vieta, E.; Reinares, M.; Corbella, B.; Benabarre, A.; Gilaberte, I.; Colom, F.; Martinez-Aran, A.; Gasto, C., and Tohen, M. Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol. 2001 Oct; 21(5):469–73.
    Rec #: 1039
  218. Von Hayek, D.; Huttl, V.; Reiss, J.; Schweiger, H. D., and Fuessl, H. S. [Hyperglycemia and ketoacidosis associated with olanzapine]. Nervenarzt. 1999 Sep; 70(9):836–7.
    Rec #: 1380
  219. Warsi, M.; Sattar, S. P.; Bhatia, S. C., and Petty, F. Aripiprazole reduces alcohol use. Can J Psychiatry. 2005 Mar; 50(4):244.
    Rec #: 1581
  220. Weiden, P. J.; Simpson, G. M.; Potkin, S. G., and O'Sullivan, R. L. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003 May; 64(5):580–8.
    Rec #: 1613
  221. Weigmann, H.; Gerek, S.; Zeisig, A.; Muller, M.; Hartter, S., and Hiemke, C. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 2001 Aug; 23(4):410–3.
    Rec #: 552
  222. White, R. E. and Gianfrancesco, F. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database.
    Rec #: 1433
  223. Windhaber, J.; Urbanits, S., and Grisold, W. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology. 2000 Apr 11; 54(7):1543–4.
    Rec #: 633
  224. Wirshing, D. A.; Marshall, B. D. Jr; Green, M. F.; Mintz, J.; Marder, S. R., and Wirshing, W. C. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry. 1999 Sep; 156(9):1374–9.
    Rec #: 1315
  225. Wirshing, D. A.; Pierre, J. M.; Eyeler, J.; Weinbach, J., and Wirshing, W. C. Risperidone-associated new-onset diabetes. Biol Psychiatry. 2001 Jul 15; 50(2):148–9.
    Rec #: 1444
  226. Wirshing, D. A.; Spellberg, B. J.; Erhart, S. M.; Marder, S. R., and Wirshing, W. C. Novel antipsychotics and new onset diabetes. Biol Psychiatry. 1998 Oct 15; 44(8):778–83.
    Rec #: 1375
  227. Wirshing, D. A.; Wirshing, W. C.; Kysar, L.; Berisford, M. A.; Goldstein, D.; Pashdag, J.; Mintz, J., and Marder, S. R. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999 Jun; 60(6):358–63.
    Rec #: 1449
  228. Wirshing, W. C. Movement disorders associated with neuroleptic treatment. J Clin Psychiatry. 2001; 62 Suppl 21:15–8.
    Rec #: 541
  229. Wirtz, H. S.; Kinon, B. J.; Zhao, Z., and Barber, B. L. Acute response to olanzapine but note to risperidone predicts the likelihood of continued improvement over time in patients with schizophrenia. 2002; 53, 181.
    Rec #: 1252
  230. Woerner, M. G.; Sheitman, B. B.; Lieberman, J. A., and et al. Tardive dyskensia induced by risperidone? Am J Psychiatry. 1996; 153:843.
    Rec #: 1329
  231. Wolters, E. C.; Jansen, E. N.; Tuynman-Qua, H. G., and Bergmans, P. L. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology. 1996 Oct; 47(4):1085–7.
    Rec #: 1083
  232. Wong, D. C. and Curtis, L. A. Are 1 or 2 dangerous? Clozapine and olanzapine exposure in toddlers. J Emerg Med. 2004 Oct; 27(3):273–7.
    Rec #: 266
  233. Workman, R. H. Jr; Orengo, C. A.; Bakey, A. A.; Molinari, V. A., and Kunik, M. E. The use of risperidone for psychosis and agitation in demented patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1997 Fall; 9(4):594–7.
    Rec #: 721
  234. Worrel, J. A.; Marken, P. A.; Beckman, S. E., and Ruehter, V. L. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm. 2000 Feb 1; 57(3):238–55.
    Rec #: 183
  235. Worthington JW; Fava M; Hughes ME; Kinrys GD; Dording CM; Reese H, and Pollack MH. Aripiprazole as an aumentor of SSRIs in Mood and anxiery disorder patients.
    Rec #: 1592
  236. Wright, P.; Meehan, K.; Birkett, M.; Lindborg, S. R.; Taylor, C. C.; Morris, P., and Breier, A. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin Ther. 2003 May; 25(5):1420–8.
    Rec #: 1466
  237. Yatham, L. N.; Grossman, F.; Augustyns, I.; Vieta, E., and Ravindran, A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry. 2003 Feb; 182:141–7.
    Rec #: 1054
  238. Yeung, P. P.; Carson, W. H.; Saha, A., and et al. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia ad schizoaffective disorder: results of a placebo-controlled trial with risperidone [abstract no. P.2.040]. 2001 Oct; 1, (Suppl 3): S259–60.
    Rec #: 1240
  239. Zhang, X. Y.; Zhou, D. F.; Cao, L. Y.; Zhang, P. Y.; Wu, G. Y., and Shen, Y. C. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. Int Clin Psychopharmacol. 2001 Nov; 16(6):325–30.
    Rec #: 1316
  240. Zuddas, A. and Cianchetti, C. Efficacy of risperidone in idiopathic segmental dystonia. Lancet. 1996 Jan 13; 347(8994):127–8.
    Rec #: 1179
  241. Zuddas, A.; Pintor, M., and Cianchetti, C. Risperidone for negative symptoms. J Am Acad Child Adolesc Psychiatry. 1996 Jul; 35(7):838–9.
    Rec #: 1181

REJECTED: Topic

  1. [Schizophrenia and depression. Special aspects in the therapy of women]. Nervenarzt. 1998 Jul; 69(7 Suppl Besondere):1–8.
    Rec #: 698
  2. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002 Feb 26; 58(4):527–36.
    Rec #: 1077
  3. Ackerman, D. L. and Greenland, S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol. 2002 Jun; 22(3):309–17.
    Rec #: 1063
  4. Addington, D.; Addington, J., and Maticka-Tyndale, E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993 Dec; (22):39–44.
    Rec #: 1141
  5. Aguirre, Blaise (Lowell Youth Treatment Ctr, Lowell, MA, US). Fluoxetine and compulsive sexual behavior. Journal of the American Academy of Child & Adolescent Psychiatry. 1999 Aug; 38(8): 943; ISSN: 0890–8567 (Print).
    Rec #: 886
  6. Ahlfors, U. G.; Baastrup, P. C.; Dencker, S. J.; Elgen, K.; Lingjaerde, O.; Pedersen, V.; Schou, M., and Aaskoven, O. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatr Scand. 1981 Sep; 64(3):226–37.
    Rec #: 1269
  7. Alarcon, R. D.; Glover, S.; Boyer, W., and Balon, R. Proposing an algorithm for the pharmacological management of posttraumatic stress disorder. Ann Clin Psychiatry. 2000 Dec; 12(4):239–46.
    Rec #: 180
  8. Alexopoulos, G. S.; Gordon, J., and Zhang, D. A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder. 2004; 29, (Suppl. 1): S87.
    Rec #: 1484
  9. Askenasy, J. J. Approaching disturbed sleep in late Parkinson’s Disease: first step toward a proposal for a revised UPDRS. Parkinsonism Relat Disord. 2001 Oct; 8(2):123–31.
    Rec #: 547
  10. Avorn, J.; Dreyer, P.; Connelly, K., and Soumerai, S. B. Use of psychoactive medication and the quality of care in rest homes. Findings and policy implications of a statewide study. N Engl J Med. 1989 Jan 26; 320(4):227–32.
    Rec #: 1001
  11. Avorn, J.; Soumerai, S. B.; Everitt, D. E.; Ross-Degnan, D.; Beers, M. H.; Sherman, D.; Salem-Schatz, S. R., and Fields, D. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med. 1992 Jul 16; 327(3):168–73.
    Rec #: 1002
  12. Barnes, R.; Veith, R.; Okimoto, J.; Raskind, M., and Gumbrecht, G. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry. 1982 Sep; 139(9):1170–4.
    Rec #: 1406
  13. Bowden, C. L.; Calabrese, J. R.; McElroy, S. L.; Gyulai, L.; Wassef, A.; Petty, F.; Pope, H. G. Jr; Chou, J. C.; Keck, P. E. Jr; Rhodes, L. J.; Swann, A. C.; Hirschfeld, R. M., and Wozniak, P. J. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000 May; 57(5):481–9.
    Rec #: 1278
  14. Bridges-Parlet, S.; Knopman, D., and Steffes, S. Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind, baseline-treatment-controlled pilot study. J Geriatr Psychiatry Neurol. 1997 Jul; 10(3):119–26.
    Rec #: 1021
  15. Brown, E. S.; Khan, D. A., and Nejtek, V. A. The psychiatric side effects of corticosteroids. Ann Allergy Asthma Immunol. 1999 Dec; 83(6 Pt 1):495–503; quiz 503–4.
    Rec #: 1265
  16. Burke, W. J.; Pfeiffer, R. F., and McComb, R. D. Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci. 1998 Spring; 10(2):227–9.
    Rec #: 1280
  17. Coccaro, E. F.; Kramer, E.; Zemishlany, Z.; Thorne, A.; Rice, C. M. 3rd; Giordani, B.; Duvvi, K.; Patel, B. M.; Torres, J.; Nora, R., and et, a. l. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am J Psychiatry. 1990 Dec; 147(12):1640–5.
    Rec #: 1020
  18. Cummings, J. L.; Tractenberg, R. E.; Gamst, A.; Teri, L.; Masterman, D., and Thal, L. J. Regression to the mean: implications for clinical trials of psychotropic agents in dementia. Curr Alzheimer Res. 2004 Nov; 1(4):323–8.
    Rec #: 1602
  19. De Deyn, P. P. Treatment of Alzheimer’s disease. N Engl J Med. 2000 Mar 16; 342(11):821; author reply 821–2.
    Rec #: 635
  20. De Deyn, P. P. and Wirshing, W. C. Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. J Clin Psychiatry. 2001; 62 Suppl 21:19–22.
    Rec #: 540
  21. Devanand, D. P.; Marder, K.; Michaels, K. S.; Sackeim, H. A.; Bell, K.; Sullivan, M. A.; Cooper, T. B.; Pelton, G. H., and Mayeux, R. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer’s disease. Am J Psychiatry. 1998 Nov; 155(11):1512–20.
    Rec #: 1289
  22. Dilsaver, S. C.; Chen, Y. R.; Shoaib, A. M., and Swann, A. C. Phenomenology of mania: evidence for distinct depressed, dysphoric, and euphoric presentations. Am J Psychiatry. 1999 Mar; 156(3):426–30.
    Rec #: 1605
  23. Emsley, R. A.; Oosthuizen, P. P.; Joubert, A. F.; Roberts, M. C., and Stein, D. J. Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. J Clin Psychiatry. 1999 Nov; 60(11):747–51.
    Rec #: 1226
  24. Esparon, J.; Kolloori, J.; Naylor, G. J.; McHarg, A. M.; Smith, A. H., and Hopwood, S. E. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry. 1986 Jun; 148:723–5.
    Rec #: 1270
  25. Fagiolini, A.; Kupfer, D. J.; Houck, P. R.; Novick, D. M., and Frank, E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003 Jan; 160(1):112–7.
    Rec #: 1058
  26. Finkel, S. I. Behavioral and psychological symptoms of dementia: a current focus for clinicians, researchers, and caregivers. J Clin Psychiatry. 2001; 62 Suppl 21:3–6.
    Rec #: 1219
  27. Hollander, E.; Bienstock, C. A.; Koran, L. M.; Pallanti, S.; Marazziti, D.; Rasmussen, S. A.; Ravizza, L.; Benkelfat, C.; Saxena, S.; Greenberg, B. D.; Sasson, Y., and Zohar, J. Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychiatry. 2002; 63 Suppl 6:20–9.
    Rec #: 484
  28. Hori, K.; Oda, T.; Tominaga, I., and Inada, T. ‘Awakenings’ in demented patients. Psychiatry Clin Neurosci. 2003 Apr; 57(2):237.
    Rec #: 415
  29. Jeste, D. V.; Caligiuri, M. P.; Paulsen, J. S.; Heaton, R. K.; Lacro, J. P.; Harris, M. J.; Bailey, A.; Fell, R. L., and McAdams, L. A. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry. 1995 Sep; 52(9):756–65.
    Rec #: 1119
  30. Kane, J. M. The role of neuroleptics in manic-depressive illness. J Clin Psychiatry. 1988 Nov; 49 Suppl:12–4.
    Rec #: 1271
  31. Kane, J. M. and Smith, J. M. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982 Apr; 39(4):473–81.
    Rec #: 1272
  32. Klein, C.; Gordon, J.; Pollak, L., and Rabey, J. M. Clozapine in Parkinson’s disease psychosis: 5-year follow-up review. Clin Neuropharmacol. 2003 Jan-2003 Feb 28; 26(1):8–11.
    Rec #: 1423
  33. Lanctot, K. L.; Best, T. S.; Mittmann, N.; Liu, B. A.; Oh, P. I.; Einarson, T. R., and Naranjo, C. A. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry. 1998 Oct; 59(10):550–61; quiz 562–3.
    Rec #: 184
  34. Prien, R. F.; Caffey, E. M. Jr, and Klett, C. J. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry. 1972 Feb; 26(2):146–53.
    Rec #: 1268
  35. Reynolds, G. P. Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia. Acta Psychiatr Scand Suppl. 1994; 380:36–40.
    Rec #: 1420
  36. Richelson, E. Basic neuropharmacology of antidepressants relevant to the pharmacotherapy of depression. Clin Cornerstone. 1999; 1(4):17–30.
    Rec #: 190
  37. Shamrei, V. K.; Kolchev, A. I., and Dobrovol’skaia, N. V. [Effectiveness of rispolept in mental disorders in patients with Alzheimer and vascular types of dementia]. Voen Med Zh. 2002 Nov; 323(11):47–51.
    Rec #: 438
  38. Shulman, R. W.; Singh, A., and Shulman, K. I. Treatment of elderly institutionalized bipoloar patients with clozpine. Psychopharmacol Bull. 1997; 33:113–8.
    Rec #: 1115
  39. Sim, K.; Mahendran, R.; Siris, S. G.; Heckers, S., and Chong, S. A. Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression. Psychiatry Res. 2004 Dec 15; 129(2):141–7.
    Rec #: 1614
  40. Stein, M. D.; Solomon, D. A.; Herman, D. S.; Anthony, J. L.; Ramsey, S. E.; Anderson, B. J., and Miller, I. W. Pharmacotherapy plus psychotherapy for treatment of depression in active injection drug users. Arch Gen Psychiatry. 2004 Feb; 61(2):152–9.
    Rec #: 171
  41. Swann, A. C.; Bowden, C. L.; Morris, D.; Calabrese, J. R.; Petty, F.; Small, J.; Dilsaver, S. C., and Davis, J. M. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry. 1997 Jan; 54(1):37–42.
    Rec #: 1285
  42. Taiminen, T. J.; Syvalahti, E.; Saarijarvi, S.; Niemi, H.; Lehto, H.; Ahola, V., and Salokangas, R. K. Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. Int Clin Psychopharmacol. 1997 Jan; 12(1):31–5.
    Rec #: 1266
  43. Teri, L.; Logsdon, R. G.; Peskind, E.; Raskind, M.; Weiner, M. F.; Tractenberg, R. E.; Foster, N. L.; Schneider, L. S.; Sano, M.; Whitehouse, P.; Tariot, P.; Mellow, A. M.; Auchus, A. P.; Grundman, M.; Thomas, R. G.; Schafer, K., and Thal, L. J. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000 Nov 14; 55(9):1271–8.
    Rec #: 1023
  44. Toghni, H. and Murakami, M. The effect of ticlopidine on TIA compared with aspirin: a double blind twelve month and open 24 month follow-up study. Jpn J Med. 1987; 26:117–9.
    Rec #: 1122
  45. Vieta, E. Bipolar mixed states and their treatment. Expert Rev Neurother. 2005 Jan; 5(1):63–8.
    Rec #: 1606
  46. Warner, J.; Butler, R., and Prabhakaran, P. Dementia. Clin Evid. 2003 Jun; (9):1010-33.
    Rec #: 173

REJECTED: Population

  1. Grottick, A. J.; Montgomery, A. M., and Herberg, L. J. Rapid recovery of self-stimulation from depression produced by the atypical neuroleptic risperidone is not prevented by 5-HT2 receptor stimulation. Pharmacol Biochem Behav. 1997 Dec; 58(4):1045–9.
    Rec #: 723
  2. Perrone, J. A.; Chabla, J. M.; Hallas, B. H.; Horowitz, J. M., and Torres, G. Weight loss dynamics during combined fluoxetine and olanzapine treatment. BMC Pharmacol. 2004 Oct 21; 4(1):27.
    Rec #: 258
  3. Seager, M. A.; Huff, K. D.; Barth, V. N.; Phebus, L. A., and Rasmussen, K. Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity. Biol Psychiatry. 2004 Jun 1; 55(11):1103–9.
    Rec #: 307
  4. Zhang, W.; Perry, K. W.; Wong, D. T.; Potts, B. D.; Bao, J.; Tollefson, G. D., and Bymaster, F. P. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000 Sep; 23(3):250–62.
    Rec #: 1043

REJECTED: Study-Design - Case Series

  1. Aarsland, D.; Larsen, J. P.; Lim, N. G., and Tandberg, E. Olanzapine for psychosis in patients with Parkinson’s disease with and without dementia. J Neuropsychiatry Clin Neurosci. 1999 Summer; 11(3):392–4.
    Rec #: 657
  2. Adams, B. E.; Tunis, S. L., and Edell, W. S. Assessing antipsychotic effectiveness in dementia with the factor structure of the Psychogeriatric Dependency Rating Scale (PGDRS). J Am Med Dir Assoc. 2003 Mar-2003 Apr 30; 4(2):61–6.
    Rec #: 403
  3. Adli, M.; Rossius, W., and Bauer, M. [Olanzapine in the treatment of depressive disorders with psychotic symptoms]. Nervenarzt. 1999 Jan; 70(1):68–71.
    Rec #: 136
  4. Adson, D. E.; Kushner, M. G.; Eiben, K. M., and Schulz, S. C. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety. 2004; 19(2):121–6.
    Rec #: 326
  5. Agid, O. and Lerer, B. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology. J Clin Psychiatry. 1999 Jan; 60(1):55–6.
    Rec #: 679
  6. Ahearn, E. P.; Winston, E.; Mussey, M., and Howell, T. Atypical antipsychotics, improved intrusive symptoms in patients with posttraumatic stress disorder. Mil Med. 2003 Sep; 168(9):x–xi.
    Rec #: 373
  7. al-Mulhim, A.; Atwal, S., and Coupland, N. J. Provocation of obsessive-compulsive behaviour and tremor by olanzapine. Can J Psychiatry. 1998 Aug; 43(6):645.
    Rec #: 696
  8. Alevizos, B.; Lykouras, L.; Zervas, I. M., and Christodoulou, G. N. Risperidone-induced obsessive-compulsive symptoms: a series of six cases. J Clin Psychopharmacol. 2002 Oct; 22(5):461–7.
    Rec #: 464
  9. Alevizos, B.; Papageorgiou, C., and Christodoulou, G. N. Obsessive-compulsive symptoms with olanzapine. Int J Neuropsychopharmacol. 2004 Sep; 7(3):375–7.
    Rec #: 295
  10. Allen, R. L.; Walker, Z.; D’Ath, P. J., and Katona, C. L. Risperidone for psychotic and behavioural symptoms in Lewy body dementia. Lancet. 1995 Jul 15; 346(8968):185.
    Rec #: 768
  11. Alzaid, K. and Jones, B. D. A case report of risperidone-induced obsessive-compulsive symptoms. J Clin Psychopharmacol. 1997 Feb; 17(1):58–9.
    Rec #: 741
  12. Andrade, C. Risperidone may worsen fluoxetine-treated OCD. J Clin Psychiatry. 1998 May; 59(5):255–6.
    Rec #: 100
  13. Arias, F.; Soto, J.; Garcia, M.; Rodriguez-Calvin, J.; Morales, J., and Salgado, M. Efficacy and tolerance of risperidone addition in serotonin reuptake inhibitors (SRI) treatment for refractory obsessive-compulsive disorder. J Eur Coll NeuropsychopharmacolJ Eur Coll Neuropsychopharmacol. 2002; 12(Suppl. 3):S341.
    Rec #: 1066
  14. Arvanitis, L. A. and Rak, I. W. Efficacy, safety and tolerability of ‘Seroquel’ (quetiapine) in elderly subjects with psychotic disorders. Schizophr Res. 1997; 24:196.
    Rec #: 1332
  15. Bajjoka, I.; Patel, T., and O’Sullivan, T. Risperidone-induced neuroleptic malignant syndrome. Ann Emerg Med. 1997 Nov; 30(5):698–700.
    Rec #: 1131
  16. Bakaras, P.; Georgoussi, M., and Liakos, A. Development of obsessive and depressive symptoms during risperidone treatment. Br J Psychiatry. 1999 Jun; 174:559.
    Rec #: 642
  17. Baldwin, S. H. and Avery, E. Lewy body dementia. J Miss State Med Assoc. 2002 Apr; 43(4):107–8.
    Rec #: 1026
  18. Ballard, C.; Grace, J.; McKeith, I., and Holmes, C. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer’s disease. Lancet. 1998 Apr 4; 351(9108):1032–3.
    Rec #: 1025
  19. Bar, K. J.; Hager, F., and Sauer, H. Olanzapine- and clozapine-induced stuttering. A case series. Pharmacopsychiatry. 2004 May; 37(3):131–4.
    Rec #: 303
  20. Barbee, J. G.; Conrad, E. J., and Jamhour, N. J. Aripiprazole augmentation in treatment-resistant depression.
    Rec #: 1599
  21. Barbee, J. G.; Conrad, E. J., and Jamhour, N. J. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2004 Oct–2004 Dec 31; 16(4):189–94.
    Rec #: 1546
  22. ---. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry. 2004 Jul; 65(7):975–81.
    Rec #: 281
  23. Barkin, J. S.; Pais, V. M. Jr, and Gaffney, M. F. Induction of mania by risperidone resistant to mood stabilizers. J Clin Psychopharmacol. 1997 Feb; 17(1):57–8.
    Rec #: 1166
  24. Belzie, L. R. Risperidone for AIDS-associated dementia: a case series. AIDS Patient Care STDS. 1996 Aug; 10(4):246–9.
    Rec #: 563
  25. Benazzi, F. Severe depression with risperidone-induced EPS in an elderly schizoaffective patient. Can J Psychiatry. 1996 Apr; 41(3):196–7.
    Rec #: 754
  26. Benazzi, F. and Rossi, E. Mania induced by olanzapine. Hum Psychopharmacol Clin Exp. 1998; 13:585–6.
    Rec #: 1208
  27. Berkowitz, A. Ziprasidone for elderly dementia: A case series. 11th Congress of the International Psychogeriatric Association. 2003.
    Rec #: 1333
  28. Bettinger, T. L.; Mendelson, S. C.; Dorson, P. G., and Crismon, M. L. Olanzapine-induced glucose dysregulation. Ann Pharmacother. 2000 Jul–2000 Aug 31; 34(7–8):865–7.
    Rec #: 1381
  29. Bhadrinath, B. R. Olanzapine in Tourette syndrome. Br J Psychiatry. 1998 Apr; 172:366.
    Rec #: 1012
  30. Bhatara, V.; Alshari, M. G.; Warhol, P.; McMillin, J. M., and Bhatara, A. Coexistent hypothyroidism, psychosis, and severe obsessions in an adolescent: a 10-year follow-up. J Child Adolesc Psychopharmacol. 2004 Summer; 14(2):315–23.
    Rec #: 278
  31. Blanco Lopez, W.; Segui Diaz, M.; Arremberg Alarcon, J., and Castello Sabate, A. [What does olanzapine give us?]. Aten Primaria. 2001 Mar 31; 27(5):366–7.
    Rec #: 569
  32. Bogetto, F.; Bellino, S.; Vaschetto, P., and Ziero, S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res. 2000 Oct 30; 96(2):91–8.
    Rec #: 138
  33. Brecher, M.; Kane, J. M., and Okamoto, A. Low frequency of tardive dyskinesia in elderly patients with dementia exposed to risperidone for up tp one year. 151st Annual Meeting of the American Psychiatric Association; Toronto, Ontario.
    Rec #: 1129
  34. Brown, E. S.; Chamberlain, W.; Dhanani, N.; Paranjpe, P.; Carmody, T. J., and Sargeant, M. An open-label trial of olanzapine for corticosteroid-induced mood symptoms. J Affect Disord. 2004 Dec; 83(2–3):277–81.
    Rec #: 250
  35. Brown, E. S.; Nejtek, V. A.; Perantie, D. C., and Bobadilla, L. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord. 2002 Dec; 4(6):406–11.
    Rec #: 1344
  36. Bruun, R. D. and Budman, C. L. Risperidone as a treatment for Tourette’s syndrome. J Clin Psychiatry. 1996 Jan; 57(1):29–31.
    Rec #: 1005
  37. Budman, C. L.; Gayer, A.; Lesser, M.; Shi, Q., and Bruun, R. D. (New York U School of Medicine, North Shore University Hosp, Depts of Psychiatry & Neurology, New York, NY, US). An open-label study of the treatment efficacy of olanzapine for tourette’s disorder. Journal of Clinical Psychiatry. 2001 Apr; 62(4): 290–294; ISSN: 0160–6689 (Print).
    Rec #: 857
  38. Butterfield MI, PI (VA Medical Center, Durham NC). An open-lable pilot study of aripiprazole in PTSD; 2005 Sep 29.
    Rec #: 1601
  39. Caligiuri, M. P.; Lacro, J. P., and Jeste, D. V. Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychopharmacol. 1999 Aug; 19(4):322–8.
    Rec #: 656
  40. Canuso, C. M.; Pandina, G.; Bossie, C. A.; Loescher, A.; Turkoz, I., and Gharabawi, G. M. Cognitive effects of risperidone augmentation in resistant depression. 24th Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP); Paris, France.
    Rec #: 1481
  41. Casaer, P.; Crooneberghs, J. A.; Lagae, L., and et al. Risperidone in the treatment of childhood autistic disorder: an open pilot study. Acta Neuropschiatrica. 2002; 14:242–9.
    Rec #: 1504
  42. Centorrino, F.; Maclean, E.; Salvatore, P.; Kidwell, J. E.; Fogarty, K. V.; Berry, J. M., and Baldessarini, R. J. Ziprasidone: first year experience in a hospital setting. J Psychiatr Pract. 2004 Nov; 10(6):361–7.
    Rec #: 246
  43. Chengappa, K. N.; Sheth, S.; Brar, J. S.; Parepally, H.; Marcus, S.; Gopalani, A.; Palmer, A.; Baker, R. W., and Schooler, N. R. Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions. J Clin Psychiatry. 1999 Jun; 60(6):373–8.
    Rec #: 663
  44. Chopra, A.; Scheinthal, S. M., and Shah, C. Atypical antipsychotic drugs in the management of aggression in elderly patients with dementia in a special care unit. Journal of American Geriatric Society. 1998 Sep; 46:S98.
    Rec #: 1128
  45. Cohen, L. G.; Fatalo, A.; Thompson, B. T.; Di Centes Bergeron, G.; Flood, J. G., and Poupolo, P. R. Olanzapine overdose with serum concentrations. Ann Emerg Med. 1999 Aug; 34(2):275–8.
    Rec #: 662
  46. Connor, K. M.; Payne, V. M.; Gadde, K. M.; Zhang, W., and Davidson, J. R. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry. 2005 Jan; 66(1):49–51.
    Rec #: 1561
  47. Corya, S. A.; Andersen, S. W.; Detke, H. C.; Kelly, L. S.; Van Campen, L. E.; Sanger, T. M.; Williamson, D. J., and Dube, S. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry. 2003 Nov; 64(11):1349–56.
    Rec #: 357
  48. Coulson, B. S.; Fenner, S. G., and Almeida, O. P. Successful treatment of behavioural problems in dementia using a cholinesterase inhibitor: the ethical questions. Aust N Z J Psychiatry. 2002 Apr; 36(2):259–62.
    Rec #: 488
  49. Croarkin, P. E.; Jacobs, K. M., and Bain, B. K. Diabetic ketoacidosis associated with risperidone treatment? Psychosomatics. 2000 Jul–2000 Aug 31; 41(4):369–70.
    Rec #: 615
  50. Crocq, M. A.; Leclercq, P.; Guillon, M. S., and Bailey, P. E. Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment. Eur Psychiatry. 2002 Sep; 17(5):296–7.
    Rec #: 457
  51. D’Amico, G.; Cedro, C.; Muscatello, M. R.; Pandolfo, G.; Di Rosa, A. E.; Zoccali, R.; La Torre, D.; D’Arrigo, C., and Spina, E. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Jun; 27(4):619–23.
    Rec #: 406
  52. Dartnall, N. A.; Holmes, J. P.; Morgan, S. N., and McDougle, C. J. Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism. J Autism Dev Disord. 1999 Feb; 29(1):87–91.
    Rec #: 103
  53. David, D.; De Faria, L.; Lapeyra, O., and Mellman, T. A. Adjunctive risperidone treatment in combat veterans with chronic PTSD. J Clin Psychopharmacol. 2004 Oct; 24(5):556–9.
    Rec #: 273
  54. David, D.; Defaria, L.; Lapeyra, O., and Mellman, T. Adjunctive risperidone treatment in combat veterans with chronic PTSD. Annual Meeting of the American Psychiatric Association; Washington, DC.
    Rec #: 1061
  55. Davidson, M.; Borison, R., and Grebb, J. The tolorence and safety of risperidone in geraitric patients with behavioural disturbances.: Beerse: Janssen Research Foundation ; 1995; RIS-USA-34.
    Rec #: 1427
  56. Davis, R. and Risch, S. C. Ziprasidone induction of hypomania in depression? Am J Psychiatry. 2002 Apr; 159(4):673–4.
    Rec #: 496
  57. De Faria, L.; Lapeyra, O.; David, D., and Mellman, T. A. Sleep effects of adjunctive risperidone treatment in combat veterans with chronic PTSD [poster]. 24th Annual ADAA Meeting; Miami, FL.
    Rec #: 1496
  58. de Haan, L.; Beuk, N.; Hoogenboom, B.; Dingemans, P., and Linszen, D. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. J Clin Psychiatry. 2002 Feb; 63(2):104–7.
    Rec #: 502
  59. Debattista, C.; Solvason, H. B.; Belanoff, J., and Schatzberg, A. F. Treatment of psychotic depression. Am J Psychiatry. 1997 Nov; 154(11):1625–6.
    Rec #: 725
  60. Degner, D.; Bleich, S.; Kornhuber, J., and Ruther, E. Olanzapine treatment of obsessive-compulsive disorder. Can J Psychiatry. 2000 May; 45(4):393.
    Rec #: 626
  61. Dehning, S.; Riedel, M., and Muller, N. Aripiprazole in a patient vulnerable to side effects. Am J Psychiatry. 2005 Mar; 162(3):625.
    Rec #: 1563
  62. Denys, D.; van Megen, H., and Westenberg, H. Quetiapine addition to serotonin reputake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry. 2002 Aug; 63(8):700–3.
    Rec #: 469
  63. Deshauer, Dorian; Albuquerque, Joy; Alda, Martin, and Grof, Paul (Royal Ottawa Hosp, Ottawa, ON, Canada). Seizures caused by possible interaction between olanzapine and clomipramine. Journal of Clinical Psychopharmacology. 2000 Apr; 20(2): 283–284 URL: http://www.psychopharmacology.com/; ISSN: 0271–0749 (Print).
    Rec #: 866
  64. Detweiler, M. B. and Trinkle, D. B. Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report. J Clin Psychiatry. 2003 Jul; 64(7):851–2.
    Rec #: 382
  65. Diler, R. S.; Yolga, A.; Avci, A., and Scahill, L. Risperidone-induced obsessive-compulsive symptoms in two children. J Child Adolesc Psychopharmacol. 2003; 13 Suppl 1:S89–92.
    Rec #: 387
  66. Dion, Y.; Annable, L.; Sandor, P., and Chouinard, G. Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2002 Feb; 22(1):31–9.
    Rec #: 1146
  67. Doan, R. J. Risperidone for insomnia in PDDs. Can J Psychiatry. 1998 Dec; 43(10):1050–1.
    Rec #: 105
  68. Dodt, J. E.; Byerly, M. J.; Cuadros, C., and Christensen, R. C. Treatment of risperidone-induced obsessive-compulsive symptoms with sertraline. Am J Psychiatry. 1997 Apr; 154(4):582.
    Rec #: 736
  69. Dogu, O.; Sevim, S., and Kaleagasi, H. S. Seizures associated with quetiapine treatment. Ann Pharmacother. 2003 Sep; 37(9):1224–7.
    Rec #: 384
  70. Dryden-Edwards, R. C. and Reiss, A. L. Differential response of psychotic and obsessive symptoms to risperidone in an adolescent. J Child Adolesc Psychopharmacol. 1996 Summer; 6(2):139–45.
    Rec #: 106
  71. Dubbelman, Y. D.; Thung, F. H., and Heeringa, M. [Severe tardive dyskinesia during treatment with risperidone and fluoxetine]. Ned Tijdschr Geneeskd. 1998 Jun 27; 142(26):1508–11.
    Rec #: 693
  72. Duggal, H. S. and Fetchko, J. Serotonin syndrome and atypical antipsychotics. Am J Psychiatry. 2002 Apr; 159(4):672–3.
    Rec #: 497
  73. Duggal, Harpreet S.; Gates, Charlie, and Pathak, Praveen C. (Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, US; Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, US; Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, US). Olanzapine-induced neutropenia: mechanism and treatment. Journal of Clinical Psychopharmacology. 2004 Apr; 24(2): 234–235 URL: http://www.psychopharmacology.com/; ISSN: 0271–0749 (Print).
    Rec #: 795
  74. Duggal, Harpreet S.; Sivamony, Swapna, and Umapathy, Channamalappa. Pisa syndrome and atypical antipsychotics. American Journal of Psychiatry. 2004 Feb; 161(2): 373 URL: http://ajp.psychiatryonline.org/; ISSN: 0002–953X (Print).
    Rec #: 799
  75. Duran, J. C. ; Greenspan, A., and Diago, J. I. Evaluation of risperidone in the treatment of behavioural and psychological symptoms and sleep disorders associated with dementia. Presented at the Annual Meeting of the Amercian Geriatrics Society; Las Vegas, NV.
    Rec #: 1476
  76. Dwight, M. M.; Keck, P. E. Jr; Stanton, S. P.; Strakowski, S. M., and McElroy, S. L. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet. 1994 Aug 20; 344(8921):554–5.
    Rec #: 773
  77. Edell, W. S. and Rupnow, M. F. Inpatient length of stay and atypical antipsychotic use among elderly patients with psychiatric disorders and Alzheimer’s disease. Manag Care Interface. 2003 May; 16(5):64–7.
    Rec #: 405
  78. Edell, W. S. and Tunis, S. L. Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients. Am J Geriatr Psychiatry. 2001 Summer; 9(3):289–97.
    Rec #: 551
  79. Eidelman, I.; Seedat, S., and Stein, D. J. Risperidone in the treatment of acute stress disorder in physically traumatized in-patients. Depress Anxiety. 2000; 11(4):187–8.
    Rec #: 107
  80. Ellingrod, V. L.; Schultz, S. K.; Ekstam-Smith, K.; Kutscher, E.; Turvey, C., and Arndt, S. Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. Pharmacotherapy. 2002 Jan; 22(1):1–5.
    Rec #: 198
  81. Eren, Íbrahim; Özcankaya, Ramazan, and Altinyazar, Vesile (Department of Psychiatry, Süleyman Demirel University, Isparta, Turkey; Department of Psychiatry, Süleyman Demirel University, Isparta, Turkey; Department of Psychiatry, Süleyman Demirel University, Isparta, Turkey E-mail: moc.oohay@nereird). Risperidone-induced rabbit syndrome in mood disorder. European Psychiatry. 2004 Nov; 19(7): 452–453 URL: http://www.elsevier.com/inca/publications/store/5/0/5/8/1/4/; ISSN: 0924–9338 (Print).
    Rec #: 786
  82. Errico, J. R. and Yates, W. R. Aripiprazole and depression in schizoaffective disorder. Am J Psychiatry. 2005 Mar; 162(3):626–7.
    Rec #: 1551
  83. Fahy, S. and Fahy, T J. (University College Hosp, Dept of Psychiatry, Galway, Ireland). Induction of manic symptoms by novel antipsychotics. British Journal of Psychiatry Vol 176 (Jun 2000): 597. ISSN: 0007–1250 (Print).
    Rec #: 867
  84. Feeney, D. J. and Klykylo, W. Risperidone and tardive dyskinesia. J Am Acad Child Adolesc Psychiatry. 1996 Nov; 35(11):1421–2.
    Rec #: 748
  85. Fernandez, H. H.; Trieschmann, M. E.; Burke, M. A., and Friedman, J. H. Quetiapine for psychosis in Parkinson’s disease versus dementia with Lewy bodies. J Clin Psychiatry. 2002 Jun; 63(6):513–5.
    Rec #: 478
  86. Fertig, M. K.; Brooks, V. G.; Shelton, P. S., and English, C. W. Hyperglycemia associated with olanzapine. J Clin Psychiatry. 1998 Dec; 59(12):687–9.
    Rec #: 1378
  87. Filteau, M. J.; Leblanc, J., and Bouchard, R. H. Quetiapine reduces flashbacks in chronic posttraumatic stress disorder. Can J Psychiatry. 2003 May; 48(4):282–3.
    Rec #: 407
  88. Findling, R. L.; Maxwell, K., and Wiznitzer, M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull. 1997; 33(1):155–9.
    Rec #: 1011
  89. Finkel, S. I. Behavioral and psychological symptoms of dementia. Assisting the caregiver and managing the patient. Geriatrics. 2002 Nov; 57(11):44–6.
    Rec #: 1218
  90. Fisman, S. and Steele, M. Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol. 1996 Fall; 6(3):177–90.
    Rec #: 108
  91. Fisman, S.; Steele, M.; Short, J.; Byrne, T., and Lavallee, C. Case study: anorexia nervosa and autistic disorder in an adolescent girl. J Am Acad Child Adolesc Psychiatry. 1996 Jul; 35(7):937–40.
    Rec #: 1291
  92. Fitzgerald, K. D.; Stewart, C. M.; Tawile, V., and Rosenberg, D. R. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharmacol. 1999; 9(2):115–23.
    Rec #: 109
  93. Francobandiera, G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can J Psychiatry. 2001 May; 46(4):356–8.
    Rec #: 140
  94. ---. Quetiapine augmentation of sertraline in obsessive-compulsive disorder. J Clin Psychiatry. 2002 Nov; 63(11):1046–7.
    Rec #: 445
  95. Frenchman, I. B. and Prince, T. Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances. Int Psychogeriatr. 1997 Dec; 9(4):431–5.
    Rec #: 710
  96. Frischauf, E. Drug therapy in autism. J Am Acad Child Adolesc Psychiatry. 1997 May; 36(5):577.
    Rec #: 733
  97. Fujikawa, T.; Takahashi, T.; Kinoshita, A.; Kajiyama, H.; Kurata, A.; Yamashita, H., and Yamawaki, S. Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. Neuropsychobiology. 2004; 49(4):201–4.
    Rec #: 316
  98. Gaile, S. and Noviasky, J. A. Speech disturbance and marked decrease in function seen in several older patients on olanzapine. J Am Geriatr Soc. 1998 Oct; 46(10):1330–1.
    Rec #: 1121
  99. Galynker, I.; Khan, A.; Grebchenko, Y.; Ten, A.; Malaya, L.; Yanowitch, P., and Cohen, L. J. Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. J Clin Psychiatry. 2005 Apr; 66(4):544.
    Rec #: 1467
  100. Ganesan, V.; Kumar, T. C., and Khanna, S. Obsessive--compulsive disorder and psychosis. Can J Psychiatry. 2001 Oct; 46(8):750–4.
    Rec #: 535
  101. Gareri, P.; Cortoneo, A.; Marchisio, U.; Curcio, M., and De Sarro, G. Risperidone in the treatment of behavioral disorders in elderly patients with dementia. Arch Gerontol Geriatr. 2001 Jan; 33 Suppl 1:173–82.
    Rec #: 556
  102. Ghaemi, S. N.; Cherry, E. L.; Katzow, J. A., and Goodwin, F. K. Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disord. 2000 Sep; 2(3 Pt 1):196–9.
    Rec #: 141
  103. Ghaemi, S. N. and Katzow, J. J. The use of quetiapine for treatment-reistant bi-polar disroder: a case series. Annual Clinical Psychiatry. 1999; 11:137–40.
    Rec #: 1201
  104. Ghaemi, S. N. and Sachs, G. S. Long-term risperidone treatment in bipolar disorder: 6-month follow up. Int Clin Psychopharmacol. 1997 Nov; 12(6):333–8.
    Rec #: 1108
  105. Ghaemi, S. N.; Sachs, G. S.; Baldassano, C. F., and Truman, C. J. Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. Can J Psychiatry. 1997 Mar; 42(2):196–9.
    Rec #: 1169
  106. Giakas, W. J. Risperidone treatment for a Tourette’s disorder patient with comorbid obsessive-compulsive disorder. Am J Psychiatry. 1995 Jul; 152(7):1097–8.
    Rec #: 770
  107. Gleason, P. P. and Conigliaro, R. L. Neuroleptic malignant syndrome with risperidone. Pharmacotherapy. 1997 May–1997 Jun 30; 17(3):617–21.
    Rec #: 1132
  108. Goldberg, R. J. Weight variance associated with atypical neuroleptics in nursing home dementia patients. J Am Med Dir Assoc. 2001 Jan-2001 Feb 28; 2(1):26–8.
    Rec #: 401
  109. Goldberg, R. J. and Goldberg, J. Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. Int Psychogeriatr. 1997 Mar; 9(1):65–8.
    Rec #: 737
  110. Goldman, L. S. and Goveas, J. Olanzapine treatment of corticosteroid-induced mood disorders. Psychosomatics. 2002 Nov-2002 Dec 31; 43(6):495–7.
    Rec #: 1281
  111. Goldstein, L. E.; Sporn, J.; Brown, S.; Kim, H.; Finkelstein, J.; Gaffey, G. K.; Sachs, G., and Stern, T. A. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics. 1999 Sep-1999 Oct 31; 40(5):438–43.
    Rec #: 1379
  112. Gupta, S.; Al-Samarrai, S.; Masand, P. S.; Lentz, B. J.; Keller, P. J., and Droney, T. M. Real-World Outcomes of Once-Daily Risperidone Dosing. Prim Care Companion J Clin Psychiatry. 2000 Apr; 2(2):55–57.
    Rec #: 328
  113. Gupta, S.; Droney, T.; Al-Samarrai, S.; Keller, P., and Frank, B. (Research & Education Div of Psychiatric Network, Olean, NY, US). Olanzapine-induced weight gain. Annals of Clinical Psychiatry. 1998 Mar; 10(1): 39 URL: http://www.tandf.co.uk/journals/titles/10401237.asp; ISSN: 1040–1237 (Print).
    Rec #: 897
  114. Gupta, S.; Frank, B., and Madhusoodanan, S. Risperidone-associated galactorrhea in a male teenager. J Am Acad Child Adolesc Psychiatry. 2001 May; 40(5):504–5.
    Rec #: 565
  115. Gupta, S. C.; Jagadheesan, K.; Basu, S., and Paul, S. E. Risperidone-induced galactorrhoea: a case series. Can J Psychiatry. 2003 Mar; 48(2):130–1.
    Rec #: 416
  116. Hallmayer, J. F. Risperidone and borderline personality disorder. Curr Psychiatry Rep. 2003 Jul; 5(3):175–6.
    Rec #: 408
  117. Hamilton, Steven and Malone, Kevin (Columbia U, Dept of Psychiatry, New York, NY, US). Serotonin syndrome during treatment with paroxetine and risperidone. Journal of Clinical Psychopharmacology. 2000 Feb; 20(1): 103–105 URL: http://www.psychopharmacology.com/; ISSN: 0271–0749 (Print).
    Rec #: 861
  118. Hammer, M. B.; Deitsch, S. E.; Ulmer, H. G., and et al. Quetiapine treatment in post-traumatic stress disorder: a preliminary open trial of add-on therapy. Eur Neuropsychopharmacol. 2001; 11(Suppl):S263.
    Rec #: 1616
  119. Hamner, M. B.; Deitsch, S. E.; Brodrick, P. S.; Ulmer, H. G., and Lorberbaum, J. P. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol. 2003 Feb; 23(1):15–20.
    Rec #: 437
  120. Hansen, L. and Wilkinson, D. G. Drug induced akathisia, suicidal ideation and its treatment in the elderly. Int J Geriatr Psychiatry. 2001 Feb; 16(2):231–3.
    Rec #: 582
  121. Hardan, A.; Johnson, K.; Johnson, C., and Hrecznyj, B. Case study: risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry. 1996 Nov; 35(11):1551–6.
    Rec #: 111
  122. Heimann, S. W. High-dose olanzapine in an adolescent. J Am Acad Child Adolesc Psychiatry. 1999 May; 38(5):496–8.
    Rec #: 1292
  123. Hellerstein, D. J. Aripiprazole as an adjunctive treatment for refractory major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Dec; 28(8):1347–8.
    Rec #: 245
  124. ---. Aripiprazole as an adjunctive treatment for refractory major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Dec; 28(8):1347–8.
    Rec #: 1552
  125. Herrmann, N.; Rivard, M. F.; Flynn, M.; Ward, C.; Rabheru, K., and Campbell, B. Risperidone for the treatment of behavioral disturbances in dementia: a case series. J Neuropsychiatry Clin Neurosci. 1998 Spring; 10(2):220–3.
    Rec #: 704
  126. Hilger, E.; Barnas, C., and Kasper, S. Quetiapine in the treatment of borderline personality disorder. World J Biol Psychiatry. 2003 Jan; 4(1):42–4.
    Rec #: 429
  127. Hill, Russell C.; McIvor, Ronan J.; Wojnar-Horton, Richard E.; Hackett, L. Peter, and Ilett, Kenneth F. (Fremantle Hosp & Health Service, Dept of Pharmacy, Fremantle, WAU, Australia). Risperidone distribution and excretion into human milk: case report and estimated infant exposure during breast-feeding. Journal of Clinical Psychopharmacology. 2000 Apr; 20(2): 285–286 URL: http://www.psychopharmacology.com/; ISSN: 0271–0749 (Print).
    Rec #: 865
  128. Hillert, A.; Maier, W.; Wetzel, H., and Benkert, O. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome--a functional approach. Pharmacopsychiatry. 1992 Sep; 25(5):213–7.
    Rec #: 776
  129. Hirose, S. Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone. Psychiatry Clin Neurosci. 2001 Apr; 55(2):161–2.
    Rec #: 575
  130. Hirose, S. and Ashby, C. R. Jr. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry. 2002 Aug; 63(8):733–6.
    Rec #: 468
  131. Horrigan, J. P. and Barnhill, L. J. Risperidone and explosive aggressive autism. J Autism Dev Disord. 1997 Jun; 27(3):313–23.
    Rec #: 112
  132. Horrigan, J. P.; Barnhill, L. J., and Courvoisie, H. E. Olanzapine in PDD. J Am Acad Child Adolesc Psychiatry. 1997 Sep; 36(9):1166–7.
    Rec #: 1184
  133. Hough, D. W. Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder. J Clin Psychiatry. 2001 Apr; 62(4):296–7.
    Rec #: 561
  134. Hoy, J. S. and Alexander, B. Rabbit syndrome secondary to risperidone. Pharmacotherapy. 2002 Apr; 22(4):513–5.
    Rec #: 493
  135. Hoyberg, O. J.; Fensbo, C.; Remvig, J.; Lingjaerde, O.; Sloth-Nielsen, M., and Salvesen, I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993 Dec; 88(6):395–402.
    Rec #: 1308
  136. Hwang, J. P.; Yang, C. H.; Lee, T. W., and Tsai, S. J. The efficacy and safety of olanzapine for the treatment of geriatric psychosis. J Clin Psychopharmacol. 2003 Apr; 23(2):113–8.
    Rec #: 1422
  137. Hwang, J. P.; Yang, C. H.; Yu, H. C., and et al. The efficacy and safety of risperidone for the treatment of geriatric psychosis. J Clin Psychopharmacol. 2001; 21:583–87.
    Rec #: 1478
  138. Irizarry, M. C.; Ghaemi, S. N.; Lee-Cherry, E. R.; Gomez-Isla, T.; Binetti, G.; Hyman, B. T., and Growdon, J. H. Risperidone treatment of behavioral disturbances in outpatients with dementia. J Neuropsychiatry Clin Neurosci. 1999 Summer; 11(3):336–42.
    Rec #: 658
  139. Jackson, W. C.; Manning, J. S.; Connor, P. D., and Deardorff, O. G. Retrospective Study of Olanzapine in Depressive and Anxious States in Primary Care. Prim Care Companion J Clin Psychiatry. 2004; 6(5):199–202.
    Rec #: 257
  140. Jacobsen, F. M. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry. 1995 Sep; 56(9):423–9.
    Rec #: 113
  141. Jakovljevic, M.; Sagud, M., and Mihaljevic-Peles, A. Olanzapine in the treatment-resistant, combat-related PTSD--a series of case reports. Acta Psychiatr Scand. 2003 May; 107(5):394–6; discussion 396.
    Rec #: 410
  142. Jeanblanc, W. and Davis, Y. B. Risperidone for treating dementia-associated aggression. Am J Psychiatry. 1995 Aug; 152(8):1239.
    Rec #: 767
  143. Jeste, D. V.; Lacro, J. P.; Bailey, A.; Rockwell, E.; Harris, M. J., and Caligiuri, M. P. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc. 1999 Jun; 47(6):716–9.
    Rec #: 224
  144. Jeste, D. V.; Okamoto, A.; Napolitano, J.; Kane, J. M., and Martinez, R. A. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry. 2000 Jul; 157(7):1150–5.
    Rec #: 223
  145. Jonkers, F. and De Haan, L. Olanzapine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder. Psychopharmacology (Berl). 2002 Jun; 162(1):87–8. Rec #: 475
  146. Kaplan, A. and Hollander, E. Comorbidity in compulsive hoarding: a case report. CNS Spectr. 2004 Jan; 9(1):71–3.
    Rec #: 334
  147. Kaplan, M. Atypical antipsychotics for treatment of mixed depression and anxiety. J Clin Psychiatry. 2000 May; 61(5):388–9.
    Rec #: 621
  148. Karki, S. D. and Masood, G. R. Combination risperidone and SSRI-induced serotonin syndrome. Ann Pharmacother. 2003 Mar; 37(3):388–91.
    Rec #: 419
  149. Kasper, S. Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety. 2004; 20(1):44–7.
    Rec #: 268
  150. Kato, K.; Wada, T.; Kawakatsu, S., and Otani, K. Improvement of both psychotic symptoms and Parkinsonism in a case of dementia with Lewy bodies by the combination therapy of risperidone and L-DOPA. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan; 26(1):201–3.
    Rec #: 503
  151. Kawahara, T.; Ueda, Y., and Mitsuyama, Y. A case report of refractory obsessive-compulsive disorder improved by risperidone augmentation of clomipramine treatment. Psychiatry Clin Neurosci. 2000 Oct; 54(5):599–601.
    Rec #: 114
  152. Ke, C. L.; Yen, C. F.; Chen, C. C.; Yang, S. J.; Chung, W., and Yang, M. J. Obsessive-compulsive symptoms associated with clozapine and risperidone treatment: three case reports and review of the literature. Kaohsiung J Med Sci. 2004 Jun; 20(6):295–301.
    Rec #: 292
  153. Keck, M. E.; Muller, M. B.; Binder, E. B.; Sonntag, A., and Holsboer, F. Ziprasidone-related tardive dyskinesia. Am J Psychiatry. 2004 Jan; 161(1):175–6.
    Rec #: 348
  154. Keshavan, M.; Shad, M.; Soloff, P., and Schooler, N. Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr Res. 2004 Nov 1; 71(1):97–101.
    Rec #: 267
  155. Ketter, T. A.; Winsberg, M. E.; DeGolia, S. G.; Dunai, M.; Tate, D. L., and Strong, C. M. Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states. J Clin Psychiatry. 1998 Feb; 59(2):83–5.
    Rec #: 1398
  156. Khouzam, H. R. Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine. Depress Anxiety. 2000; 11(2):80–2.
    Rec #: 627
  157. Khouzam, H. R. and Donnelly, N. J. Remission of self-mutilation in a patient with borderline personality during risperidone therapy. J Nerv Ment Dis. 1997 May; 185(5):348–9.
    Rec #: 732
  158. Khullar, A.; Chue, P., and Tibbo, P. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci. 2001 Jan; 26(1):55–9.
    Rec #: 152
  159. Kinon, B. J.; Targum, S. D., and Basson, B. R. Olanzapine in the management of behavioral distrubances and/or psychosis in demented nursing home patients. Academy of Psychosomatic Medicine, 47th Annual Meeting; Palm Springs, CA.
    Rec #: 1323
  160. Kiraly, S. J.; Gibson, R. E.; Ancill, R. J., and Holliday, S. G. Risperidone: treatment response in adult and geriatric patients. Int J Psychiatry Med. 1998; 28(2):255–63.
    Rec #: 697
  161. Knopf, U.; Hubrich-Ungureanu, P., and Thome, J. [Paroxetine augmentation with risperidone in therapy-resistant depression]. Psychiatr Prax. 2001 Nov; 28(8):405–6.
    Rec #: 115
  162. Koek, R. J. and Kessler, C. C. Probable induction of mania by risperidone. J Clin Psychiatry. 1996 Apr; 57(4):174–5.
    Rec #: 755
  163. Konig, F.; von Hippe, C.; Petersdorff, T.; Neuhoffer-Weiss, M.; Wolfersdorf, M., and Kaschka, W. P. First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression. Neuropsychobiology. 2001; 43(3):170–4.
    Rec #: 142
  164. Kopala, L. and Honer, W. G. Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry. 1994 Nov; 151(11):1714–5.
    Rec #: 771
  165. Kopala, L. C. and Honer, W. G. The use of risperidone in severely demented patients with persistent vocalizations. Int J Geriatr Psychiatry. 1997 Jan; 12(1):73–7.
    Rec #: 744
  166. Koponen, H. J. Risperidone in the treatment of psychosis and concomitant buccolinguomasticatory dyskinesia in the elderly. Int J Geriatr Psychiatry. 1997 Mar; 12(3):412–3.
    Rec #: 739
  167. Koran, L. M.; Ringold, A. L., and Elliott, M. A. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2000 Jul; 61(7):514–7.
    Rec #: 143
  168. Kozaric-Kovacic, D.; Muck-Seler, D.; Pivac, N.; Vidosic, S., and Tomic, Z. Olanzapine or fluphenazine in patients with psychotic combat-related posttraumatic stress disorder. Int J Neuropsychopharmacol. 2002; 5(Suppl 1).
    Rec #: 1062
  169. Kozaric-Kovacic, D.; Pivac, N.; Muck-Seler, D., and Rothbaum, B. O. Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. J Clin Psychiatry. 2005 Jul; 66(7):922–7.
    Rec #: 1498
  170. Krashin, D. and Oates, E. W. Risperidone as an adjunct therapy for post-traumatic stress disorder. Mil Med. 1999 Aug; 164(8):605–6.
    Rec #: 116
  171. Krishnamoorthy, J. and King, B. H. Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol. 1998; 8(2):107–13.
    Rec #: 695
  172. Kropp, S.; Emrich, H. M.; Bleich, S., and Degner, D. Olanzapine-related hyperglycemia in a nondiabetic. Canadian Journal of Psychiatry. 2001 Jun; 46(5): 457 URL: http://www.cpa-apc.org/Publications/cjpHome.asp; ISSN: 0706–7437 (Print).
    Rec #: 838
  173. Kunwar, A. R. and Megna, J. L. Resolution of risperidone-induced hyperprolactinemia with substitution of quetiapine. Ann Pharmacother. 2003 Feb; 37(2):206–8.
    Rec #: 435
  174. Kurz, A.; Delius-Stute, H.; Rettig, K., and Schwalen, S. [Treatment of behavioral disorders in dementia with risperidone in psychogeriatric out-patients]. MMW Fortschr Med. 2003 Oct 9; 145 Suppl 3:89–95.
    Rec #: 261
  175. Labbate, L. A. and Douglas, S. Olanzapine for nightmares and sleep disturbance in posttraumatic stress disorder (PTSD). Can J Psychiatry. 2000 Sep; 45(7):667–8.
    Rec #: 144
  176. Labbate, Lawrence A. and Douglas, Susan. Re: treatment of posttraumatic stress disorder with olanzapine. Canadian Journal of Psychiatry. 2001 Mar; 46(2): [np] URL: http://www.cpa-apc.org/Publications/cjpHome.asp; ISSN: 0706–7437 (Print).
    Rec #: 837
  177. Laini, V.; Arduini, A.; Critelli, E.; Rossetti, R.; Mapelli, L.; Boscati, L.; Regispani, F.; Orlandi, R.; Papa, P., and Mauri, M. C. (U Milan, Dept of Clinical Psychiatry, Clinical Neuropsychopharmacology Unit, IRCCS Ospedale Maggiore, Milan, Italy). Psychopharmacological treatment with risperidone and psychotherapic-rehabilitative approaches in schizophrenia and personality disorders. New Trends in Experimental & Clinical Psychiatry. 1999 Oct-1999 Dec 31; 15(4): 209–213; ISSN: 0393–5310 (Print).
    Rec #: 878
  178. Laks, J.; Engelhardt, E.; Marinho, V.; Rozenthal, M.; Souza, F. C.; Bacaltchuk, J.; Stoppe, A. Jr; Ferreira, R. C.; Bottino, C., and Scalco, M. Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly. Arq Neuropsiquiatr. 2001 Dec; 59(4):859–64.
    Rec #: 529
  179. Lane, H. Y. and Chang, W. H. Risperidone monotherapy for psychotic depression unresponsive to other treatments. J Clin Psychiatry. 1998 Nov; 59(11):624.
    Rec #: 685
  180. Lane, H. Y.; Chang, Y. C.; Su, M. H.; Chiu, C. C.; Huang, M. C., and Chang, W. H. Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects. J Clin Psychopharmacol. 2002 Feb; 22(1):4–10.
    Rec #: 511
  181. Lane, H. Y.; Chiu, W. C., and Chang, W. H. Risperidone monotherapy for mania and depression. Am J Psychiatry. 1999 Jul; 156(7):1115.
    Rec #: 664
  182. Lane, H. Y.; Guo, S. C.; Hwang, T. J.; Chen, Y. S.; Cheng, J. J.; Lee, Y. C.; Hong, C. J.; Hwu, H. G., and Chang, W. H. Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study. J Clin Psychopharmacol. 2002 Oct; 22(5):530–2.
    Rec #: 463
  183. Lasser, R.; Bossie, C. A.; Gharabawi, G.; Eerdekens, M., and Nasrallah, H. A. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Disord. 2004 Dec; 83(2–3):263–75.
    Rec #: 251
  184. Lasser, R. A.; Bossie, C. A.; Zhu, Y.; Gharabawi, G.; Eerdekens, M., and Davidson, M. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry. 2004 Sep; 19(9):898–905.
    Rec #: 272
  185. Lasser, R. A. and Sunderland, T. Newer psychotropic medication use in nursing home residents. J Am Geriatr Soc. 1998 Feb; 46(2):202–7.
    Rec #: 185
  186. Lavretsky, H. and Sultzer, D. A structured trial of risperidone for the treatment of agitation in dementia. Am J Geriatr Psychiatry. 1998 Spring; 6(2):127–35.
    Rec #: 707
  187. Lee, Hedi; Cooney, John M., and Lawlor, Brian A. (St James’s Hosp, Dublin, Ireland). The use of risperidone, an atypical neuroleptic, in lewy body disease. International Journal of Geriatric Psychiatry. 1994 May; 9(5): 415-417 URL: http://www.interscience.wiley.com/jpages/0885-6230/; ISSN: 0885–6230 (Print); 1099–1166 (Electronic).
    Rec #: 924
  188. Leitner, I.; Praschak-Rieder, N.; Willeit, M., and Kasper, S. Quetiapine in a delusional depressed elderly patient: no EPS and a favourable outcome. Int J Neuropsychopharmacol. 2003 Jun; 6(2):199–200.
    Rec #: 386
  189. Levy, E.; Margolese, H. C.; Sultan, S., and Chouinard, G. Obsessive-compulsive symptoms in schizophrenia induced by risperidone and responding to fluoxetine. Can J Psychiatry. 2003 Nov; 48(10):709–10.
    Rec #: 355
  190. Leyba, C. M. and Wampler, T. P. Risperidone in PTSD. Psychiatr Serv. 1998 Feb; 49(2):245–6.
    Rec #: 708
  191. Licht, Rasmus W.; Arngrim, Torben, and Christensen, Hilmar (Aarhus U Psychiatric Hosp, Mood Disorders Research Unit, Risskov, Denmark; Aarhus U Psychiatric Hosp, Psychiatric Dept South, Risskov, Denmark; Dept of Psychiatry in Randers, Randers, Denmark E-mail: kd.aaa.irtaikysp@lr). Olanzapine-induced galactorrhea. Psychopharmacology. 2002 Jun; 162(1): 94–95 URL: http://link.springer.de/link/service/journals/00213/index.htm; ISSN: 0033-3158 (Print); 1432–2072 (Electronic).
    Rec #: 822
  192. Lindenmayer, J. P. and Patel, R. Olanzapine-induced ketoacidosis with diabetes mellitus. Am J Psychiatry. 1999 Sep; 156(9):1471.
    Rec #: 650
  193. Lipski, P. S. and Death, J. W. (Gosford Hospital, Dept of Geriatric Medicine, Gosford, NSW, Australia). Risperidone in the treatment of agitated and aggressive patients with dementia. Australian Journal on Ageing. 1995 Nov; 14(4): 151-154; ISSN: 0726–4240 (Print).
    Rec #: 920
  194. Lombroso, P. J.; Scahill, L.; King, R. A.; Lynch, K. A.; Chappell, P. B.; Peterson, B. S.; McDougle, C. J., and Leckman, J. F. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry. 1995 Sep; 34(9):1147–52.
    Rec #: 765
  195. Loonen, A. J.; Doorschot, C. H.; Oostelbos, M. C., and Sitsen, J. M. Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. Eur Neuropsychopharmacol. 1999 Dec; 10(1):51–7.
    Rec #: 639
  196. Lu, M. L. and Shen, W. W. Sleep-related eating disorder induced by risperidone. J Clin Psychiatry. 2004 Feb; 65(2):273–4.
    Rec #: 332
  197. Lykouras, L.; Zervas, I. M.; Gournellis, R.; Malliori, M., and Rabavilas, A. Olanzapine and obsessive-compulsive symptoms. Eur Neuropsychopharmacol. 2000 Sep; 10(5):385–7.
    Rec #: 606
  198. MacIntyre, R.; Mancini, D.; McCann, S.; Srinavasan, J., and Kennedy, S. Antidepressant efficacy and tolerability of risperidone and olanzapine in bipolar disorder. Int J Neuropsychopharmacol. 2002; 5(Suppl. 1).
    Rec #: 1059
  199. MacKnight, C. and Rojas-Fernandez, C. Quetiapine for sexually inappropriate behavior in dementia. J Am Geriatr Soc. 2000 Jun; 48(6):707.
    Rec #: 620
  200. Madhusoodanan, S.; Suresh, P.; Brenner, P., and Pillai, R. Experience with the atypical antipsychotics-risperidone and olanzapine in the elderly. Ann Clin Psychiatry. 1999; 11(13):113–8.
    Rec #: 1087
  201. Magnuson, T. M.; Keller, B. K., and Burke, W. J. Extrapyramidal side effects in a patient treated with risperidone plus donepezil. Am J Psychiatry. 1998 Oct; 155(10):1458–9.
    Rec #: 690
  202. Magnuson, T. M.; Roccaforte, W. H.; Wengel, S. P., and Burke, W. J. Medication-induced dystonias in nine patients with dementia. J Neuropsychiatry Clin Neurosci. 2000 Spring; 12(2):219–25.
    Rec #: 602
  203. Mahendran, R. Emergence of compulsive symptoms with olanzapine treatment. Aust N Z J Psychiatry. 2002 Aug; 36(4):565.
    Rec #: 471
  204. ---. Obsessive-compulsive symptoms with risperidone. J Clin Psychiatry. 1999 Apr; 60(4):261–3.
    Rec #: 671
  205. Maina, G.; Albert, U.; Ziero, S., and Bogetto, F. Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued? Int Clin Psychopharmacol. 2003 Jan; 18(1):23–8.
    Rec #: 443
  206. Malhi, G. S. and Checkley, S. A. Olanzapine in the treatment of psychotic depression. Br J Psychiatry. 1999 May; 174:460.
    Rec #: 643
  207. Marangell, L. B.; Johnson, C. R.; Kertz, B.; Zboyan, H. A., and Martinez, J. M. Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study. J Clin Psychiatry. 2002 May; 63(5):391–5.
    Rec #: 485
  208. Marazziti, D. and Pallanti, S. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. Am J Psychiatry. 1999 Nov; 156(11):1834–5.
    Rec #: 645
  209. Marsh, L.; Lyketsos, C., and Reich, S. G. Olanzapine for the treatment of psychosis in patients with Parkinson’s disease and dementia. Psychosomatics. 2001 Nov-2001 Dec 31; 42(6):477–81.
    Rec #: 507
  210. Martin, A.; Koenig, K.; Scahill, L., and Bregman, J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 1999; 9(2):99–107.
    Rec #: 1019
  211. Martin, H.; Slyk, M. P.; Deymann, S., and Cornacchione, M. J. Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia. J Am Med Dir Assoc. 2003 Jul-2003 Aug 31; 4(4):183–8.
    Rec #: 395
  212. Marusic, A. and Farmer, A. Antidepressant augmentation with low-dose olanzapine in obsessive-compulsive disorder. Br J Psychiatry. 2000 Dec; 177:567.
    Rec #: 578
  213. Masi, G.; Cosenza, A.; Mucci, M., and Brovedani, P. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2001 Oct; 40(10):1206–14.
    Rec #: 117
  214. Masi, G.; Cosenza, A.; Mucci, M., and De Vito, G. Risperidone monotherapy in preschool children with pervasive developmental disorders. J Child Neurol. 2001 Jun; 16(6):395–400.
    Rec #: 118
  215. Matthews, J. D.; Bottonari, K. A.; Polania, L. M.; Mischoulon, D.; Dording, C. M.; Irvin, R., and Fava, M. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. J Clin Psychiatry. 2002 Dec; 63(12):1164–70.
    Rec #: 439
  216. McDougle, C. J.; Fleischmann, R. L.; Epperson, C. N.; Wasylink, S.; Leckman, J. F., and Price, L. H. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry. 1995 Nov; 56(11):526–8.
    Rec #: 120
  217. McDougle, C. J.; Holmes, J. P.; Bronson, M. R.; Anderson, G. M.; Volkmar, F. R.; Price, L. H., and Cohen, D. J. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry. 1997 May; 36(5):685–93.
    Rec #: 1175
  218. McElroy, S. L.; Frye, M.; Denicoff, K.; Altshuler, L.; Nolen, W.; Kupka, R.; Suppes, T.; Keck, P. E. Jr; Leverich, G. S.; Kmetz, G. F., and Post, R. M. Olanzapine in treatment-resistant bipolar disorder. J Affect Disord. 1998 May; 49(2):119–22.
    Rec #: 1110
  219. McIntyre, R. S.; Mancini, D. A.; Srinivasan, J.; McCann, S.; Konarski, J. Z., and Kennedy, S. H. The antidepressant effects of risperidone and olanzapine in bipolar disorder. Can J Clin Pharmacol. 2004 Fall; 11(2):e218–26.
    Rec #: 255
  220. McKeith, I. G.; Ballard, C. G., and Harrison, R. W. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet. 1995 Sep 9; 346(8976):699.
    Rec #: 764
  221. McManus, D. Q.; Arvanitis, L. A., and Kowalcyk, B. B. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry. 1999 May; 60(5):292–8.
    Rec #: 1074
  222. Mech A. Assessing benefits of aripiprazole in depressed and bipolar children and adolescents: a naturalistic retrospective chart review study. 18th ECNP Congress; Amsterdam, The Netherlands. 2005: S364.
    Rec #: 1578
  223. Mertens, C. Risperidone in the psychogeriatric patients with behavioural disturbances: an open long-term follow-up study. Janssen Research Foundation. 1990; RIS-BEL-9.
    Rec #: 1426
  224. Mertens, C. Risperidone in the treatment of behavioural disturbances in psychogeriatric patients: a multicentre open dose-finding study. Janssen Research Foundation. 1989; RIS-BEL-6.
    Rec #: 1425
  225. Miller, C. H.; Mohr, F.; Umbricht, D.; Woerner, M.; Fleischhacker, W. W., and Lieberman, J. A. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry. 1998 Feb; 59(2):69–75.
    Rec #: 1234
  226. Miodownik, C. and Lerner, V. Risperidone in the treatment of psychotic depression. Clin Neuropharmacol. 2000 Nov-2000 Dec 31; 23(6):335–7.
    Rec #: 122
  227. Misri, S. and Milis, L. Obsessive-compulsive disorder in the postpartum: open-label trial of quetiapine augmentation. J Clin Psychopharmacol. 2004 Dec; 24(6):624–7.
    Rec #: 254
  228. Mohr, N.; Vythilingum, B.; Emsley, R. A., and Stein, D. J. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2002 Jan; 17(1):37–40.
    Rec #: 509
  229. Monnelly, E. P. and Ciraulo, D. A. Risperidone effects on irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol. 1999 Aug; 19(4):377–8.
    Rec #: 123
  230. Moretti, R.; Torre, P.; Antonello, R. M.; Cazzato, G.; Griggio, S., and Bava, A. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer’s disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003 Jul-2003 Aug 31; 18(4):205–14.
    Rec #: 380
  231. Morikawa, M. and Kishimoto, T. Probable dementia with Lewy bodies and risperidone-induced delirium. Can J Psychiatry. 2002 Dec; 47(10):976.
    Rec #: 434
  232. Morinobu, S.; Yamashita, H.; Yamawaki, S.; Tanaka, K., and Ohkawa, M. Obsessive-compulsive disorder with non-24-hour sleep-wake syndrome. J Clin Psychiatry. 2002 Sep; 63(9):838–40.
    Rec #: 461
  233. Morrison, D.; Clark, D.; Goldfarb, E., and McCoy, L. Worsening of obsessive-compulsive symptoms following treatment with olanzapine. Am J Psychiatry. 1998 Jun; 155(6):855.
    Rec #: 702
  234. Mottard, J. P. and de la Sablonniere, J. F. Olanzapine-induced obsessive-compulsive disorder. Am J Psychiatry. 1999 May; 156(5):799–800.
    Rec #: 669
  235. Mukaddes, N. M. and Abali, O. Quetiapine treatment of children and adolescents with Tourette’s disorder. J Child Adolesc Psychopharmacol. 2003 Fall; 13(3):295–9.
    Rec #: 1347
  236. Murphy, T. K.; Bengtson, M. A.; Soto, O.; Edge, P. J.; Sajid, M. W.; Shapira, N., and Yang, M. Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol. 2005 Sep; 8(3):489–90.
    Rec #: 1559
  237. Murty, Radhika G.; Mistry, Sandeep G., and Chacko, Ranjit C. (Baylor Coll of Medicine, Dept of Psychiatry, Houston, TX, US; Baylor Coll of Medicine, Dept of Psychiatry, Houston, TX, US; Baylor Coll of Medicine, Dept of Psychiatry, Houston, TX, US). Neuroleptic malignant syndrome with ziprasidone. Journal of Clinical Psychopharmacology. 2002 Dec; 22(6): 624–626 URL: http://www.psychopharmacology.com/; ISSN: 0271-0749 (Print).
    Rec #: 824
  238. Narendran, R.; Young, C. M.; Valenti, A. M.; Pristach, C. A.; Pato, M. T., and Grace, J. J. Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. J Clin Psychiatry. 2001 Jul; 62(7):509–16.
    Rec #: 548
  239. Negron, A. E.; Leiderman, E. A.; Parkadavil, M.; Cienfuegos, A., and Javitt, D. C. A naturalistic outcome study of risperidone treatment among hospital patients. Psychiatr Serv. 1996 Oct; 47(10):1118–20.
    Rec #: 749
  240. Negron, A. E. and Reichman, W. E. Risperidone in the treatment of patients with Alzheimer’s disease with negative symptoms. Int Psychogeriatr. 2000 Dec; 12(4):527–36.
    Rec #: 579
  241. Nelson, E. B.; Rielage, E.; Welge, J. A., and Keck, P. E. Jr. An open trial of olanzapine in the treatment of patients with psychotic depression. Ann Clin Psychiatry. 2001 Sep; 13(3):147–51.
    Rec #: 513
  242. Nelson, L. A. and Swartz, C. M. Melancholic symptoms during concurrent olanzapine and fluoxetine. Ann Clin Psychiatry. 2000 Sep; 12(3):167–70.
    Rec #: 145
  243. Nemeroff CB; Simon JS; Forbes A; Carson WH, and McQuade R. Aripiprazole augmentation of SSRIs and SNRIs for the treatment of partial and non-responding patients wiht major depressive disorder. ACNP Annual Meeting.
    Rec #: 1597
  244. Nicolson, R.; Awad, G., and Sloman, L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry. 1998 Apr; 37(4):372–6.
    Rec #: 1006
  245. Nishimura, M.; Hashimoto, T.; Miyazaki, M.; Mori, K., and Kuroda, Y. [An open trial of risperidone in autistic children]. No To Hattatsu. 2003 Nov; 35(6):473–7.
    Rec #: 363
  246. O’Connor, M. and Silver, H. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression. J Clin Psychopharmacol. 1998 Feb; 18(1):89–91.
    Rec #: 124
  247. Ober, S. K.; Hudak, R., and Rusterholtz, A. Hyperglycemia and olanzapine. Am J Psychiatry. 1999 Jun; 156(6):970.
    Rec #: 1377
  248. Onofrj, M.; Paci, C.; D’Andreamatteo, G., and Toma, L. Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol. 2000 Jun; 247(6):443–6.
    Rec #: 1017
  249. Oshimo, T.; Ohta, M.; Ueno, R., and et al. Effects of combined use of serotonin reuptake inhibitor and risperidone for obsessive-compulsive disorders [abstract]. 2003; 18, 185.
    Rec #: 1492
  250. Ostroff, R. B. and Nelson, J. C. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999 Apr; 60(4):256–9.
    Rec #: 125
  251. Oyewole, David; Skerritt, Ursula, and Montgomery, Stuart (Charing Cross & Westminister Medical School, Dept of Psychiatry, London, England). Jaundice associated with the use of risperidone in a case of presenile dementia. International Journal of Geriatric Psychiatry Vol. ISSN: 0885–6230 (Print); 1099–1166 (Electronic) DOI: 10.1002/(SICI)1099–1166(199602)11:2<177::AID-GPS346>3.0.CO;2-G.
    Rec #: 918
  252. Pae, Chi-Un; Kim, Jung-Jin; Lee, Chang-Uk; Chae, Jeong-Ho; Lee, Soo-Jung; Lee, Chul, and Paik, In-Ho (Department of Psychiatry, Catholic University of Korea, College of Medicine, Seoul, Korea; Department of Psychiatry, Catholic University of Korea, College of Medicine, Seoul, Korea; Department of Psychiatry, Catholic University of Korea, College of Medicine, Seoul, Korea; Department of Psychiatry, Catholic University of Korea, College of Medicine, Seoul, Korea; Department of Psychiatry, Catholic University of Korea, College of Medicine, Seoul, Korea; Department of Psychiatry, Catholic University of Korea, College of Medicine, Seoul, Korea; Department of Psychiatry, Catholic University of Korea, College of Medicine, Seoul, Korea). Very low dose quetiapine-induced galactorrhea in combination with venlafaxine. Human Psychopharmacology: Clinical & Experimental. 2004 Aug; 19(6): 433–434 URL: http://www.interscience.wiley.com/jpages/0885-6222/; ISSN: 0885–6222 (Print); 1099–1077 (Electronic).
    Rec #: 789
  253. Papakostas, G. I.; Petersen, T. J.; Kinrys, G.; Alpert, J. E.; Fava, M., and Nierenberg, A. A. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.
    Rec #: 1598
  254. Papakostas, G. I.; Petersen, T. J.; Nierenberg, A. A.; Murakami, J. L.; Alpert, J. E.; Rosenbaum, J. F., and Fava, M. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004 Feb; 65(2):217–21.
    Rec #: 333
  255. Parker, G. Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders. Int Clin Psychopharmacol. 2002 Mar; 17(2):87–9.
    Rec #: 499
  256. Parraga, H. C.; Parraga, M. I.; Woodward, R. L., and Fenning, P. A. Quetiapine treatment of children with Tourette’s syndrome: report of two cases. J Child Adolesc Psychopharmacol. 2001 Summer; 11(2):187–91.
    Rec #: 555
  257. Pascual, J. C.; Oller, S.; Soler, J.; Barrachina, J.; Alvarez, E., and Perez, V. Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services. J Clin Psychiatry. 2004 Sep; 65(9):1281–2.
    Rec #: 269
  258. Patkar AA; Mattila-Evenden M; Peindl K; Mago R, and Masad P. An Open-label, rater-blinded study of aripiprazole as an augmenting agent in patients with treatment-resistant depression.
    Rec #: 1553
  259. Patkar AA; Mattila-Evenden M; Peindl KS; Stein-Marcus K, and Masand PS. Aripiprazole as an augmentation agent in treatment-resistant depression.
    Rec #: 1554
  260. Perry, R.; Pataki, C.; Munoz-Silva, D. M.; Armenteros, J., and Silva, R. R. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc Psychopharmacol. 1997; 7(3):167–79.
    Rec #: 126
  261. Petersen TJ ; Kinrys G; Burns A; Alpert JE; Fava M, and Nierenber AA. Aripiprazole augmentation of SSRIs for treatment-resistant MDD.
    Rec #: 1577
  262. Petrikis, P.; Andreou, C.; Bozikas, V. P., and Karavatos, A. Effective use of olanzapine for obsessive-compulsive symptoms in a patient with bipolar disorder. Can J Psychiatry. 2004 Aug; 49(8):572–3.
    Rec #: 264
  263. Petty, F.; Brannan, S.; Casada, J.; Davis, L. L.; Gajewski, V.; Kramer, G. L.; Stone, R. C.; Teten, A. L.; Worchel, J., and Young, K. A. Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int Clin Psychopharmacol. 2001 Nov; 16(6):331–7.
    Rec #: 146
  264. Pfanner, C.; Marazziti, D.; Dell’Osso, L.; Presta, S.; Gemignani, A.; Milanfranchi, A., and Cassano, G. B. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int Clin Psychopharmacol. 2000 Sep; 15(5):297–301.
    Rec #: 127
  265. Pitchot, W. and Ansseau, M. Addition of olanzapine for treatment-resistant depression. Am J Psychiatry. 2001 Oct; 158(10):1737–8.
    Rec #: 147
  266. Pivac, N.; Kozaric-Kovacic, D., and Muck-Seler, D. Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder. Psychopharmacology (Berl). 2004 Apr 3; (175):451–6.
    Rec #: 322
  267. Popli, Anand; Gupta, Sanjay, and Rangwani, Sunil R. (Porter Starke Counseling Ctrs & Porter Memorial Hosp, Valparaiso, IN, US). Risperidone-induced galactorrhea associated with a prolactin elevation. Annals of Clinical Psychiatry. 1998 Mar; 10(1): 31–33 URL: http://www.tandf.co.uk/journals/titles/10401237.asp; ISSN: 1040-1237 (Print).
    Rec #: 898
  268. Posey, D. J.; Walsh, K. H.; Wilson, G. A., and McDougle, C. J. Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol. 1999; 9(4):273–6.
    Rec #: 1007
  269. Potenza, M. N.; Holmes, J. P.; Kanes, S. J., and McDougle, C. J. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol. 1999 Feb; 19(1):37–44.
    Rec #: 682
  270. Potenza, M. N.; Wasylink, S.; Longhurst, J. G.; Epperson, C. N., and McDougle, C. J. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychopharmacol. 1998 Oct; 18(5):423–4.
    Rec #: 689
  271. Poyurovsky, M.; Dorfman-Etrog, P.; Hermesh, H.; Munitz, H.; Tollefson, G. D., and Weizman, A. Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms. Int Clin Psychopharmacol. 2000 May; 15(3):169–73.
    Rec #: 619
  272. Poyurovsky, M.; Kurs, R., and Weizman, A. Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder. J Clin Psychiatry. 2003 May; 64(5):611.
    Rec #: 409
  273. Prior, T. I. Treatment of posttraumatic stress disorder with olanzapine. Can J Psychiatry. 2001 Mar; 46(2):182.
    Rec #: 576
  274. Privitera, M. R. and Maharaj, K. Mania from dose-related ziprasidone augmentation of an SSRI. J Clin Psychiatry. 2003 Nov; 64(11):1393–4.
    Rec #: 356
  275. Rabinowitz, J.; Bromet, E. J., and Davidson, M. Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study. Schizophr Bull. 2001; 27(4):597–600.
    Rec #: 505
  276. Rainer, M. K.; Masching, A. J.; Ertl, M. G.; Kraxberger, E., and Haushofer, M. Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia. J Clin Psychiatry. 2001 Nov; 62(11):894–900.
    Rec #: 514
  277. Ramasubbu, R.; Ravindran, A., and Lapierre, Y. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs. Pharmacopsychiatry. 2000 Nov; 33(6):236–8.
    Rec #: 593
  278. Ramos, R. H. and Budman, C. L. Emergence of koro after abrupt cessation of olanzapine. J Clin Psychiatry. 1998 Feb; 59(2):86–7.
    Rec #: 715
  279. Rapaport, M.; Canuso, C.; Loescher, A.; Lasser, R., and Gharabawi, G. Preliminary results from ARISe-RD (Augmentation with Risperidone in Resistant Depression) trial [Abstract NR179]. 156th APA Annual Meeting; San Francisco, CA. 2003.
    Rec #: 1044
  280. Rapaport, M. H.; Canuso, C. M.; Rouillon, F., and et al. Treatment augmentation with risperidone for patients with resistant depression [poster]. 44th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU); Phoenix, AZ.
    Rec #: 1477
  281. Ravizza, L.; Barzega, G.; Bellino, S.; Bogetto, F., and Maina, G. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull. 1996; 32(4):677–82.
    Rec #: 129
  282. Ravona-Springer, Ramit; Dolberg, Ornah T.; Hirschmann, Schmuel, and Grunhaus, Leon (Sheba Medical Ctr, Div of Psychiatry, Ramat-Gan, Israel). Delirium in elderly patients treated with risperidone: a report of three cases. Journal of Clinical Psychopharmacology. 1998 Apr; 18(2): 171–172 URL: http://www.psychopharmacology.com/; ISSN: 0271-0749 (Print).
    Rec #: 900
  283. Reddy, S.; Factor, S. A.; Molho, E. S., and Feustel, P. J. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord. 2002 Jul; 17(4):676–81.
    Rec #: 467
  284. Reeves, R. R. and Torres, R. A. Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia. South Med J. 2003 Jul; 96(7):699–701.
    Rec #: 381
  285. Remington, G. and Adams, M. Risperidone and obsessive-compulsive symptoms. J Clin Psychopharmacol. 1994 Oct; 14(5):358–9.
    Rec #: 772
  286. Rigalleau, V.; Gatta, B.; Bonnaud, S.; Masson, M.; Bourgeois, M. L.; Vergnot, V., and Gin, H. Diabetes as a result of atypical anti-psychotic drugs--a report of three cases. Diabet Med. 2000 Jun; 17(6):484–6.
    Rec #: 605
  287. Rocca, P.; Marchiaro, L.; Cocuzza, E., and Bogetto, F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry. 2002 Mar; 63(3):241–4.
    Rec #: 495
  288. Roefaro, J. and Mukherjee, S. M. Olanzapine-lnduced hyperglycemic nonketonic coma. Ann Pharmacother. 2001 Mar; 35(3):300–2.
    Rec #: 580
  289. Rubin, N. J. and Arceneaux, J. M. Intractable depression or psychosis. Acta Psychiatr Scand. 2001 Nov; 104(5):402–5.
    Rec #: 531
  290. Rugino, T. A. and Janvier, Y. M. Aripiprazole in children and adolescents: clinical experience. J Child Neurol. 2005 Jul; 20(7):603–10.
    Rec #: 1570
  291. Sajatovic, M.; Brescan, D. W.; Perez, D. E.; DiGiovanni, S. K.; Hattab, H.; Ray, J. B., and Bingham, C. R. Quetiapine alone and added to a mood stabilizer for serious mood disorders. J Clin Psychiatry. 2001 Sep; 62(9):728–32.
    Rec #: 536
  292. Salmeron, J. M.; Alcantara, A. G., and Barcia, D. [Combination of risperidone and serotonergic antidepressants in refractory obsessive-compulsive disorder]. Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1998 Nov-1998 Dec 31; 26(6):399–402.
    Rec #: 681
  293. Sandor, P. and Stephens, R. J. Risperidone treatment of aggressive behavior in children with Tourette syndrome. J Clin Psychopharmacol. 2000 Dec; 20(6):710–2.
    Rec #: 1008
  294. Sanger, T. M.; Grundy, S. L.; Gibson, P. J.; Namjoshi, M. A.; Greaney, M. G., and Tohen, M. F. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry. 2001 Apr; 62(4):273–81.
    Rec #: 1102
  295. Saran, B. M. Risperidone-induced tardive dyskinesia. J Clin Psychiatry. 1998 Jan; 59(1):29–30.
    Rec #: 717
  296. Sattar, S. P.; Ucci, B.; Grant, K.; Bhatia, S. C., and Petty, F. Quetiapine therapy for posttraumatic stress disorder. Ann Pharmacother. 2002 Dec; 36(12):1875–8.
    Rec #: 447
  297. Saxena, S.; Wang, D.; Bystritsky, A., and Baxter, L. R. Jr. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry. 1996 Jul; 57(7):303–6.
    Rec #: 130
  298. Scalco, M. Z.; Bottino, C. M.; Stoppe Jr, A., and et al. Risperidone oral solution for agitation in dementia. Int Psychogeriatr. 1999; 11((suppl 1)):159.
    Rec #: 1482
  299. Scharre, D. W. and Chang, S. I. Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord. 2002 Apr-2002 Jun 30; 16(2):128–30.
    Rec #: 482
  300. Scheepmaker, A. J.; Horstink, M. W.; Hoefnagels, W. H., and Strijks, F. E. [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine]. Ned Tijdschr Geneeskd. 2003 Jan 4; 147(1):32–5.
    Rec #: 431
  301. Schmitt, A. and Braus, D. F. [Effective treatment of depressive disorder with psychotic symptoms by olanzapine combination therapy]. Dtsch Med Wochenschr. 2000 Dec 15; 125(50):1526–9.
    Rec #: 590
  302. Schneider, L. S.; Katz, I. R.; Park, S.; Napolitano, J.; Martinez, R. A., and Azen, S. P. Psychosis of Alzheimer disease: validity of the construct and response to risperidone. Am J Geriatr Psychiatry. 2003 Jul-2003 Aug 31; 11(4):414–25.
    Rec #: 393
  303. Schnierow, B. J. and Graeber, D. A. Manic symptoms associated with initiation of risperidone. Am J Psychiatry. 1996 Sep; 153(9):1235–6.
    Rec #: 1165
  304. Schreiber, Shaul and Segman, Ronnen H. (Hadassah-Hebrew U, Medical Ctr, Dept of Psychiatry, Jerusalem, Israel). Risperidone-induced galactorrhea. Psychopharmacology. 1997 Apr; 130(3): 300–301 URL: http://link.springer.de/link/service/journals/00213/index.htm; ISSN: 0033-3158 (Print); 1432–2072 (Electronic).
    Rec #: 909
  305. Schulz, S. C.; Camlin, K. L.; Berry, S. A., and Jesberger, J. A. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry. 1999 Nov 15; 46(10):1429–35.
    Rec #: 149
  306. Schwam, J. S.; Klass, E.; Alonso, C., and Perry, R. Risperidone and refusal to eat. J Am Acad Child Adolesc Psychiatry. 1998 Jun; 37(6):572–3.
    Rec #: 1296
  307. Sciro, F. (AstraZeneca Pharmaceuticals, LP). Use of higher-dose quetiapine in elderly inpatients: a chart review study. Presented at the 16th Annual Meeting of the American Association of Geriatric Psychiatry; Waikiki, Oahu, HI.
    Rec #: 1349
  308. Sechi, G.; Agnetti, V.; Masuri, R.; Deiana, G. A.; Pugliatti, M.; Paulus, K. S., and Rosati, G. Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug; 24(6):1043–51.
    Rec #: 599
  309. Selva, K. A. and Scott, S. M. Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr. 2001 Jun; 138(6):936–8.
    Rec #: 1443
  310. Sevincok, L. and Topuz, A. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder. J Clin Psychopharmacol. 2003 Oct; 23(5):448–50.
    Rec #: 375
  311. Sharma, V. and Pistor, L. Treatment of bipolar mixed state with olanzapine. J Psychiatry Neurosci. 1999 Jan; 24(1):40–4.
    Rec #: 1399
  312. Sharpley, A. L.; Bhagwagar, Z.; Hafizi, S.; Whale, W. R.; Gijsman, H. J., and Cowen, P. J. Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. J Clin Psychiatry. 2003 Feb; 64(2):192–6.
    Rec #: 420
  313. Shaw, J. A.; Lewis, J. E.; Pascal, S.; Sharma, R. K.; Rodriguez, R. A.; Guillen, R., and Pupo-Guillen, M. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol. 2001 Winter; 11(4):415–24.
    Rec #: 1348
  314. Shelton, P. S.; Barnett, F. L., and Krick, S. E. Hyperventilation associated with quetiapine. Ann Pharmacother. 2000 Mar; 34(3):335–7.
    Rec #: 612
  315. Shigenobu, K.; Ikeda, M.; Fukuhara, R.; Komori, K., and Tanabe, H. A structured, open trial of risperidone therapy for delusions of theft in Alzheimer disease. Am J Geriatr Psychiatry. 2003 Mar-2003 Apr 30; 11(2):256–7.
    Rec #: 426
  316. Shigenobu, K.; Ikeda, M.; Fukuhara, R.; Maki, N.; Hokoishi, K.; Nebu, A.; Komori, K., and Tanabe, H. Reducing the burden of caring for Alzheimer’s disease through the amelioration of “delusions of theft” by drug therapy. Int J Geriatr Psychiatry. 2002 Mar; 17(3):211–7.
    Rec #: 498
  317. Shiwach, R. S. and Woods, S. Risperidol and withdrawal bruxism in Lewy body dementia. Int J Geriatr Psychiatry. 1998 Jan; 13(1):65–6.
    Rec #: 718
  318. Shulman, L. M.; Singer, C., and Weiner, W. J. Risperidone in Gilles de la Tourette syndrome. Neurology. 1995 Jul; 45(7):1419.
    Rec #: 1096
  319. Simeon, J.; Milin, R., and Walker, S. A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb; 26(2):267–75.
    Rec #: 506
  320. Simon JS; Forbes A; Carson WH, and Nemeroff CB. Aripriprazole augmentation of antidepressants for the treatment of partially-responding and non-responding patients with major depressive disorder. 43rd ACNP Annual Meeting; San Juan, Puerto Rico.
    Rec #: 1576
  321. Singh, H. K.; Markowitz, G. D., and Myers, G. Esotropia associated with olanzapine. J Clin Psychopharmacol. 2000 Aug; 20(4):488.
    Rec #: 611
  322. Sinha, B. N.; Duggal, H. S., and Nizamie, S. H. Risperidone-induced obsessive-compulsive symptoms: a reappraisal. Can J Psychiatry. 2000 May; 45(4):397–8.
    Rec #: 625
  323. Slauson, S. D. and LoVecchio, F. Risperidone-induced priapism with rechallenge. J Emerg Med. 2004 Jul; 27(1):88–9.
    Rec #: 297
  324. Sluys, M.; Guzelcan, Y.; Casteelen, G., and de Haan, L. Risperidone-induced leucopenia and neutropenia: a case report. Eur Psychiatry. 2004 Apr; 19(2):117.
    Rec #: 324
  325. Sobów, Tomasz M. and Kloszewska, Iwona (AM Klinika Psychiatryczna, Lodz, Poland). Risperidon w ambulatoryjnym leczeniu zaburzen zachowania u chorych z otepieniem typu alzheimera: analiza retrospektywna. Psychiatria Polska. 2001 Nov-2001 Dec 31; 35(6): 1033–1045; ISSN: 0033-2674 (Print).
    Rec #: 843
  326. Sokolski, K. N.; Denson, T. F.; Lee, R. T., and Reist, C. Quetiapine for treatment of refractory symptoms of combat-related post-traumatic stress disorder. Mil Med. 2003 Jun; 168(6):486–9.
    Rec #: 396
  327. Soler, J.; Campins, M. J.; Perez, V.; Puigdemont, D.; Perez-Blanco, E., and Alvarez, E. [Olanzapine and cognitive-behavioural group therapy in borderline personality disorder]. Actas Esp Psiquiatr. 2001 Mar-2001 Apr 30; 29(2):85–90.
    Rec #: 570
  328. Solomons, K. and Geiger, O. Olanzapine use in the elderly: a retrospective analysis. Can J Psychiatry. 2000 Mar; 45(2):151–5.
    Rec #: 1092
  329. Spina, E.; D’Arrigo, C.; Migliardi, G.; Morgante, L.; Zoccali, R.; Ancione, M., and Madia, A. Plasma risperidone concentrations during combined treatment with sertraline. Ther Drug Monit. 2004 Aug; 26(4):386–90.
    Rec #: 291
  330. Stamenkovic, M.; Aschauer, H., and Kasper, S. Risperidone for Tourette’s syndrome. Lancet. 1994 Dec 3; 344(8936):1577–8.
    Rec #: 1095
  331. Stamenkovic, M.; Schindler, S. D.; Aschauer, H. N.; De Zwaan, M.; Willinger, U.; Resinger, E., and Kasper, S. Effective open-label treatment of tourette’s disorder with olanzapine. Int Clin Psychopharmacol. 2000 Jan; 15(1):23–8.
    Rec #: 1018
  332. Steele, M. and Couturier, J. A possible tetracycline-risperidone-sertraline interaction in an adolescent. Can J Clin Pharmacol. 1999 Spring; 6(1):15–7.
    Rec #: 652
  333. Stein, D. J.; Bouwer, C.; Hawkridge, S., and Emsley, R. A. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry. 1997 Mar; 58(3):119–22.
    Rec #: 131
  334. Stephens, R. J.; Bassel, C., and Sandor, P. Olanzapine in the treatment of aggression and tics in children with Tourette’s syndrome--a pilot study. J Child Adolesc Psychopharmacol. 2004 Summer; 14(2):255–66.
    Rec #: 279
  335. Stern RG; Petti TA; Bopp K, and Tobia A. Aripiprazole for the treatment of schizophrenia with co-morbid social anxiety- a preliminary report.
    Rec #: 1580
  336. Stigler, K. A.; Posey, D. J., and McDougle, C. J. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004 Fall; 14(3):455–63.
    Rec #: 1575
  337. Stoll, A. L. and Haura, G. Tranylcypromine plus risperidone for treatment-refractory major depression. J Clin Psychopharmacol. 2000 Aug; 20(4):495–6.
    Rec #: 132
  338. Storch, Daniel D. Risperidone-induced retrograde ejaculation. Journal of the American Academy of Child & Adolescent Psychiatry. 2002 Apr; 41(4): 365–366; ISSN: 0890–8567 (Print).
    Rec #: 829
  339. Street, J. S.; Clark, W. S.; Juliar, B. E.; Feldman, P. D.; Kadam, D. L., and Breier, A. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with alzheimer’s dementia. JNS. 2001; 187(Suppl 1). CODEN: RCT; ISSN: CN-00339926.
    Rec #: 952
  340. Street, J. S.; Clark, W. S.; Kadam, D. L.; Mitan, S. J.; Juliar, B. E.; Feldman, P. D., and Breier, A. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer’s dementia. Int J Geriatr Psychiatry. 2001 Dec; 16 Suppl 1:S62–70.
    Rec #: 523
  341. Swensen, E. and Ravasia, S. Ziprasidone-induced lupus erythematosus. Can J Psychiatry. 2004 Jun; 49(6):413–4.
    Rec #: 283
  342. Szigethy, E. M. and Schulz, S. C. Risperidone in comorbid borderline personality disorder and dysthymia. J Clin Psychopharmacol. 1997 Aug; 17(4):326–7.
    Rec #: 727
  343. Takahashi, H.; Yoshida, K.; Higuchi, H., and Shimizu, T. Development of parkinsonian symptoms after discontinuation of carbamazepine in patients concurrently treated with risperidone: two case reports. Clin Neuropharmacol. 2001 Nov-2001 Dec 31; 24(6):358–60.
    Rec #: 508
  344. Takahashi, H.; Yoshida, K.; Sugita, T.; Higuchi, H., and Shimizu, T. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry. 2003 May; 27(3):549–53.
    Rec #: 411
  345. Tani, K.; Takei, N.; Kawai, M.; Suzuki, K.; Sekine, Y.; Toyoda, T.; Minabe, Y., and Mori, N. Augmentation of milnacipran by risperidone in treatment for major depression. Int J Neuropsychopharmacol. 2004 Mar; 7(1):55–8.
    Rec #: 343
  346. Tariot, P. N.; Salzman, C.; Yeung, P. P.; Pultz, J., and Rak, I. W. Long-Term use of quetiapine in elderly patients with psychotic disorders. Clin Ther. 2000 Sep; 22(9):1068–84.
    Rec #: 1075
  347. Tarraga, L.; Gil, P., and Buron, J. A. Long-term efficacy and safety of risperidone treatment in patients with behavioral and psychological symptoms associated with dementia. American Psychiatric Nurses Association Annual Meeting; Dallas, TX.
    Rec #: 1485
  348. Tarsy, Daniel (Harvard Medical School, Boston, MA, US). Risperidone and neuroleptic malignant syndrome. JAMA: Journal of the American Medical Association. 1996 Feb; 275(6): 446; ISSN: 0098-7484 (Print).
    Rec #: 912
  349. Teich, Jeffrey. Side effects of ziprasidone. American Journal of Psychiatry. 2003 Jul; 160(7): 1355–1356 URL: http://ajp.psychiatryonline.org/; ISSN: 0002-953X (Print).
    Rec #: 812
  350. Terao, T.; Shimomura, T.; Izumi, Y., and Nakamura, J. Two cases of quetiapine augmentation for donepezil-refractory visual hallucinations in dementia with Lewy bodies. J Clin Psychiatry. 2003 Dec; 64(12):1520–1.
    Rec #: 344
  351. Teter, Christian J.; Early, John J., and Frachtling, Richard J. (Dorothea Dix Hosp, Raleigh, NC, US). Olanzapine-induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric institution. Journal of Clinical Psychiatry. 2000 Nov; 61(11): 872–873; ISSN: 0160-6689 (Print).
    Rec #: 862
  352. Took, K. J. and Buck, B. J. Enuresis with combined risperidone and SSRI use. J Am Acad Child Adolesc Psychiatry. 1996 Jul; 35(7):840–1.
    Rec #: 1186
  353. Trivedi, M. H.; Gharabawi, G. M.; Canuso, C. M., and et al. Predictors of symptom resolution with risperidone augmentation in patients with resistant depression [abstract]. 2005; 57, 1S–212S.
    Rec #: 1479
  354. Troost, P. W.; Lahuis, B. E.; Steenhuis, M. P.; Ketelaars, C. E.; Buitelaar, J. K.; van Engeland, H.; Scahill, L.; Minderaa, R. B., and Hoekstra, P. J. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry. 2005 Nov; 44(11):1137–44.
    Rec #: 1529
  355. Turner, M.; Eerdekens, E.; Jacko, M., and Eerdekens, M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol. 2004 Jul; 19(4):241–9.
    Rec #: 1353
  356. van der Linden, C.; Bruggeman, R., and van Woerkom, T. C. Serotonin-dopamine antagonist and Gilles de la Tourette’s syndrome: an open pilot dose-titration study with risperidone. Mov Disord. 1994 Nov; 9(6):687–8.
    Rec #: 1009
  357. Vercellino, F.; Zanotto, E.; Ravera, G., and Veneselli, E. Open-label risperidone treatment of 6 children and adolescents with autism. Can J Psychiatry. 2001 Aug; 46(6):559–60.
    Rec #: 1010
  358. Veznedaroglu, B.; Ercan, E. S.; Kayahan, B.; Varan, A., and Bayraktar, E. Reduced short-term obsessive-compulsive symptoms in schizophrenic patients treated with risperidone: a single-blind prospective study. Hum Psychopharmacol. 2003 Dec; 18(8):635–40.
    Rec #: 353
  359. Vieta, E.; Gasto, C.; Colom, F.; Martinez, A.; Otero, A., and Vallejo, J. Treatment of refractory rapid cycling bipolar disorder with risperidone. J Clin Psychopharmacol. 1998 Apr; 18(2):172–4.
    Rec #: 1290
  360. Vieta, E.; Gasto, C.; Colom, F.; Reinares, M.; Martinez-Aran, A.; Benabarre, A., and Akiskal, H. S. Role of risperidone in bipolar II: an open 6-month study. J Affect Disord. 2001 Dec; 67(1–3):213–9.
    Rec #: 1038
  361. Vieta, E.; Goikolea, J. M.; Corbella, B.; Benabarre, A.; Reinares, M.; Martinez, G.; Fernandez, A.; Colom, F.; Martinez-Aran, A., and Torrent, C. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry. 2001 Oct; 62(10):818–25.
    Rec #: 1053
  362. Villareal G; Calais LA; Lundy SL; Pickard J; Toney G; Ghoma R, and Canive JM. Efficacy of Aripiprazole monotherapy in the treatment of posttraumatic stress disorder.
    Rec #: 1600
  363. Villeneuve, E. and Lemelin, S. Quetiapine treatment of borderline personality disorder. Nr 275. 156th Annual Meeting of the American Psychiatric Association; San Francisco, CA.
    Rec #: 1277
  364. Virkkunen, M.; Wahlbeck, K.; Rissanen, A.; Naukkarinen, H., and Franssila-Kallunki, A. Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study. Pharmacopsychiatry. 2002 May; 35(3):124–6.
    Rec #: 474
  365. Walker, C.; Thomas, J., and Allen, T. S. Treating impulsivity, irritability, and aggression of antisocial personality disorder with quetiapine. Int J Offender Ther Comp Criminol. 2003 Oct; 47(5):556–67.
    Rec #: 374
  366. Walker, Z.; Grace, J.; Overshot, R.; Satarasinghe, S.; Swan, A.; Katona, C. L., and McKeith, I. G. Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry. 1999 Jun; 14(6):459–66.
    Rec #: 665
  367. Wancata, J. Efficacy of risperidone for treating patients with behavioral and psychological symptoms of dementia. Int Psychogeriatr. 2004 Mar; 16(1):107–15.
    Rec #: 166
  368. Wang, H. S. and Kuo, M. F. Tourette’s syndrome in Taiwan: an epidemiological study of tic disorders in an elementary school at Taipei County. Brain Dev. 2003 Dec; 25 Suppl 1:S29–31.
    Rec #: 339
  369. Warnock, J. K.; Burke, W. J., and Hueter, C. Self-injurious behavior in elderly patients with dementia: four case reports. Am J Geriatr Psychiatry. 1999; 7:166–170.
    Rec #: 1487
  370. Webster, P. and Wijeratne, C. Risperidone-induced neuroleptic malignant syndrome. Lancet. 1994 Oct 29; 344(8931):1228–9.
    Rec #: 1134
  371. Weisler, R. H.; Ahearn, E. P.; Davidson, J. R., and Wallace, C. D. Adjunctive use of olanzapine in mood disorders: five case reports. Ann Clin Psychiatry. 1997 Dec; 9(4):259–62.
    Rec #: 151
  372. Weiss, E. L.; Potenza, M. N.; McDougle, C. J., and Epperson, C. N. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry. 1999 Aug; 60(8):524–7.
    Rec #: 649
  373. White, R. E.; Travers, J.; Edell, W. S.; Adams, B. E., and Jensik, S. E. Effectiveness of atypical antipsychotic medications for maladaptive behaviors in geropsychiatric inpatients.
    Rec #: 1432
  374. Worthington, J. J. 3rd; Kinrys, G.; Wygant, L. E., and Pollack, M. H. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol. 2005 Jan; 20(1):9–11.
    Rec #: 244
  375. Yamauchi, K.; Ohta, K.; Taniguchi, T., and Ohmori, T. A case of social phobia with obsessive-compulsive symptoms improved by paroxetine in combination with risperidone. Gen Hosp Psychiatry. 2004 May-2004 Jun 30; 26(3):242–3.
    Rec #: 314
  376. Yeung, P. P. and Liu, S. Low incidence of persistent tardive dyskinesia with quetiapine. Institute of Psychiatric Services Meeting; Philadelphia, PA.
    Rec #: 1438
  377. Yoon, J. S.; Kim, J. M.; Lee, H.; Shin, I. S., and Choi, S. K. Risperidone use in Korean patients with Alzheimer’s disease: optimal dosage and effect on behavioural and psychological symptoms, cognitive function and activities of daily living. Hum Psychopharmacol. 2003 Dec; 18(8):627–33.
    Rec #: 354
  378. Zannino, G.; Gargiulo, A.; Lamenza, F.; Marotta, M. G.; Barzotti, T.; Silvestri, A.; Ettorre, E., and Marigliano, V. The management of psychogeriatric patient. Arch Gerontol Geriatr Suppl. 2004; (9):465–70.
    Rec #: 298
  379. Zarate, C. A. Jr; Baldessarini, R. J.; Siegel, A. J.; Nakamura, A.; McDonald, J.; Muir-Hutchinson, L. A.; Cherkerzian, T., and Tohen, M. Risperidone in the elderly: a pharmacoepidemiologic study. J Clin Psychiatry. 1997 Jul; 58(7):311–7.
    Rec #: 728
  380. Zarate, C. A. Jr; Rothschild, A.; Fletcher, K. E.; Madrid, A., and Zapatel, J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry. 2000 Mar; 61(3):185–9.
    Rec #: 624
  381. Zullino, D. and Baumann, P. Olanzapine for mixed episodes of bipolar disorder. J Psychopharmacol. 1999; 13(2):198.
    Rec #: 1400
  382. Zullino, D. F.; Quinche, P.; Hafliger, T., and Stigler, M. Olanzapine improves social dysfunction in cluster B personality disorder. Hum Psychopharmacol. 2002 Jul; 17(5):247–51.
    Rec #: 451

REJECTED: Study-Design - Non-Systematic Review

  1. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations. J Clin Psychiatry. 1998; 59 Suppl 12:41–5.
    Rec #: 692
  2. Consensus development on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004; 27(2):596–01.
    Rec #: 1384
  3. Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. J Clin Psychiatry. 1998; 59 Suppl 12:46–52.
    Rec #: 691
  4. Alevizos, Basil; Lykouras, Lefteris; Zervas, lannis M., and Christodoulou, George N. (Athens University, Department of Psychiatry, Eginition Hospital, Athens, Greece; Athens University, Department of Psychiatry, Eginition Hospital, Athens, Greece; Athens University, Department of Psychiatry, Eginition Hospital, Athens, Greece; Athens University, Department of Psychiatry, Eginition Hospital, Athens, Greece E-mail: rg.aou.dem@zivelav). Reply to “risperidone-induced obsessive-compulsive symptoms: serotonin-dopamine imbalance?”. Journal of Clinical Psychopharmacology. 2004 Oct; 24(5): 549–549 URL: http://www.psychopharmacology.com/; ISSN: 0271-0749 (Print).
    Rec #: 788
  5. Alexopoulos, G. S.; Streim, J.; Carpenter, D., and Docherty, J. P. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004; 65 Suppl 2:5–99; discussion 100–102; quiz 103–4.
    Rec #: 169
  6. ---. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004; 65 Suppl 2:5–99; discussion 100–102; quiz 103–4.
    Rec #: 1572
  7. Askenasy, J. J. Sleep disturbances in Parkinsonism. J Neural Transm. 2003 Feb; 110(2):125–50.
    Rec #: 427
  8. Baker R, Tohen M Risser R Stauffer V Breier A Tollefson G. Depression during mania: treatment response to olanzapine or placebo. Journal of the European College of Neuropsychopharmacology (Abstracts of the 13th ECNP Congress, Munich, September 9–13, 2000). 2000; 10(Suppl 3):S246. CODEN: RCT; ISSN: CN-00304342.
    Rec #: 960
  9. Ballard, C. G. and Margallo-Lana, M. L. The relationship between antipsychotic treatment and quality of life for patients with dementia living in residential and nursing home care facilities. J Clin Psychiatry. 2004; 65 Suppl 11:23–8.
    Rec #: 285
  10. Baskys, A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004; 65 Suppl 11:16–22.
    Rec #: 286
  11. Beasley, C. M. Jr; Tollefson, G. D., and Tran, P. V. Safety of olanzapine. J Clin Psychiatry. 1997; 58 Suppl 10:13–7.
    Rec #: 1453
  12. Benazzi, F. Fluoxetine and olanzapine for resistant depression. Am J Psychiatry. 2002 Jan; 159(1):155–6.
    Rec #: 137
  13. Blin, O. A comparative review of new antipsychotics. Can J Psychiatry. 1999 Apr; 44(3):235–44.
    Rec #: 670
  14. Buckley, P. F. Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry. 2001 Dec 1; 50(11):912–24.
    Rec #: 527
  15. Carson, W.; Archibald, G.; Phil, M., and et al. Short-term efficacy of aripiprazole on depression/anxiety in schizophrenia [poster]. Presented at the 156th American Psychiatric Association Meeting; San Francisco, CA.
    Rec #: 1340
  16. Cummings, J. L.; Frank, J. C.; Cherry, D.; Kohatsu, N. D.; Kemp, B.; Hewett, L., and Mittman, B. Guidelines for managing Alzheimer’s disease: Part II. Treatment. Am Fam Physician. 2002 Jun 15; 65(12):2525–34.
    Rec #: 479
  17. Daniel, D. G. Antipsychotic treatment of psychosis and agitation in the elderly. J Clin Psychiatry. 2000; 61 Suppl 14:49–52.
    Rec #: 592
  18. David, S. R.; Beasley, C. M. Jr., and Alaka, K. Analysis of the QTC interval in acutely agitated patients with schizophrenia, bipolar mania, or dementia treated with intramuscular (IM) olanzapine vs. IM placebo or IM haloperidol. European Neuropsychopharmacology. 2001; 11(3):276. CODEN: RCT; ISSN: CN-00370660.
    Rec #: 949
  19. De Deyn, P. P (U Antwerp, Lab of Neurochemistry & Behavior, Antwerpen, Belgium). Risperidone in the treatment of behavioral and psychological symptoms of dementia. International Psychogeriatrics. 2000; 12(Suppl1): 263–269 URL: http://titles.cambridge.org/journals/journal_catalogue.asp?historylinks=ALPHA&m nemonic=IPG; ISSN: 1041-6102 (Print).
    Rec #: 875
  20. De Deyn, P. P. and Katz, I. R. Control of aggression and agitation in patients with dementia: efficacy and safety of risperidone. Int J Geriatr Psychiatry. 2000 Jul; 15 Suppl 1:S14–22.
    Rec #: 632
  21. Falsetti, A. E. Risperidone for control of agitation in dementia patients. Am J Health Syst Pharm. 2000 May 1; 57(9):862–70.
    Rec #: 622
  22. Fava, M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am. 1997 Jun; 20(2):427–51.
    Rec #: 730
  23. Fernandez, H. H.; Wu, C. K., and Ott, B. R. Pharmacotherapy of dementia with Lewy bodies. Expert Opin Pharmacother. 2003 Nov; 4(11):2027–37.
    Rec #: 371
  24. Finkel, S. I. Behavioral and psychologic symptoms of dementia. Clin Geriatr Med. 2003 Nov; 19(4):799–824.
    Rec #: 1217
  25. Firoz, A. H.; Rahman, A. H.; Chowdhury, W. A., and Mamun, A. A. Brief report on Ziprasidone. Mymensingh Med J. 2002 Jul; 11(2):129–32.
    Rec #: 454
  26. Geodon. Prescribing information (ziprasidone HCl).
    Rec #: 1455
  27. Glazer, W. M. Olanzapine and the new generation of antipsychotic agents: patterns of use. J Clin Psychiatry. 1997; 58 Suppl 10:18–21.
    Rec #: 743
  28. Goldstein, J. M. and Zhong, K. (AstraZeneca Ppharmaceuticals LP). Tolerance to somnolence with quetiapine: preclinical mechanisms and clinical evidence. Presented at the 157th Annual Meeting of the American Psychiatric Association; Newy York, NY.
    Rec #: 1345
  29. Goodnick, P. J. and Barrios, C. A. Use of olanzapine in non-psychotic psychiatric disorders. Expert Opin Pharmacother. 2001 Apr; 2(4):667–80.
    Rec #: 568
  30. Green, B. Focus on aripiprazole. Curr Med Res Opin. 2004; 20(2):207–13.
    Rec #: 331
  31. Greenspan, A; Eerdekens, M., and Mahmoud, R. Risk of cerebrovascular adverse events, Including mortality, with risperidone in elderly patients. Int Psychogeriatrics. 2003; (Suppl. 2):261–2.
    Rec #: 1320
  32. Grossman, F.; Okamoto, A.; Turkoz, I., and Gharabawi, G. Risperidone in the treatment of elderly patients with psychosis of Alzheimer’s disease and related dementias. J Am Geriatr Soc. 2004 May; 52(5):852–3.
    Rec #: 320
  33. Hallmayer, J. F. Olanzapine and women with borderline personality disorder. Curr Psychiatry Rep. 2003 Jul; 5(3):175.
    Rec #: 346
  34. Harvey, P. D. Ziprasidone and cognition: the evolving story. J Clin Psychiatry. 2003; 64 Suppl 19:33–9.
    Rec #: 345
  35. Jackson-Siegal, J. M.; Schneider, L. S.; Baskys, A., and Haupt, D. W. Recognizing and responding to atypical antipsychotic side effects. J Am Med Dir Assoc. 2004 Jul-2004 Aug 31; 5(4 Suppl):H7–10.
    Rec #: 293
  36. Jeste, D. V. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry. 2004; 65 Suppl 9:21–4.
    Rec #: 302
  37. Jimenez-Jimenez, F. J. and Garcia-Ruiz, P. J. Pharmacological options for the treatment of Tourette’s disorder. Drugs. 2001; 61(15):2207–20.
    Rec #: 517
  38. Kasckow, J. W.; Mulchahey, J. J., and Mohamed, S. The use of novel antipsychotics in the older patient with neurodegenerative disorders in the long-term care setting. J Am Med Dir Assoc. 2004 Jul-2004 Aug 31; 5(4):242–8.
    Rec #: 296
  39. Kaufer, D. [Treatment of neuropsychiatric symptoms in Alzheimer’s disease]. Rev Neurol. 2002 Nov 1-2002 Nov 15; 35(9):846–50.
    Rec #: 450
  40. Keck, P. E.; Reeves, K. R.; Harrigan, E. P., and Ziprasidone Study Group. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol. 2001; 21:27–35.
    Rec #: 1460
  41. Keck, P. E. Jr; Strakowski, S. M., and McElroy, S. L. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry. 2000; 61 Suppl 3:4–9.
    Rec #: 634
  42. Kennedy, J. S.; Bymaster, F. P.; Schuh, L.; Calligaro, D. O.; Nomikos, G.; Felder, C. C.; Bernauer, M.; Kinon, B. J.; Baker, R. W.; Hay, D.; Roth, H. J.; Dossenbach, M.; Kaiser, C.; Beasley, C. M.; Holcombe, J. H.; Effron, M. B., and Breier, A. A current review of olanzapine’s safety in the geriatric patient: from pre-clinical pharmacology to clinical data. Int J Geriatr Psychiatry. 2001 Dec; 16 Suppl 1:S33–61.
    Rec #: 524
  43. Kennedy, S. H. and Lam, R. W. Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. Bipolar Disord. 2003; 5 Suppl 2:36–47.
    Rec #: 350
  44. Kieszek, S. [Trials and perspectives in pharmacotherapy of Alzheimer’s disease]. Psychiatr Pol. 1999 May-1999 Jun 30; 33(3):331–40.
    Rec #: 630
  45. Kumar, V. and Brecher, M. (Florida Inst of Neurosciences & Clinical Research, Venice, FL, US). Psychopharmacology of atypical antipsychotics and clinical outcomes in elderly patients. Journal of Clinical Psychiatry. 1999; 60(Suppl 13): 5–9; ISSN: 0160-6689 (Print).
    Rec #: 890
  46. Lawlor, B. A. Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics. J Clin Psychiatry. 2004; 65 Suppl 11:5–10.
    Rec #: 288
  47. Lieberman, J. A. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004; 18(4):251–67.
    Rec #: 327
  48. Madhusoodanan, S. and Brenner, R. Update on risperidone use in elderly patients: a review. Clin Geriatr. 2001; 9:32–43.
    Rec #: 1035
  49. Madhusoodanan, S.; Sinha, S.; Brenner, R.; Gupta, S., and Bogunovic, O. Use of olanzapine for elderly patients with psychotic disorders: a review. Ann Clin Psychiatry. 2001 Dec; 13(4):201–13.
    Rec #: 491
  50. Manning, J. S. Difficult-to-treat depressions: a primary care perspective. J Clin Psychiatry. 2003; 64 Suppl 1:24–31.
    Rec #: 422
  51. Marek, G. J.; Carpenter, L. L.; McDougle, C. J., and Price, L. H. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology. 2003 Feb; 28(2):402–12.
    Rec #: 428
  52. Masand, P. S. Side effects of antipsychotics in the elderly. J Clin Psychiatry. 2000; 61 Suppl 8:43–9; discussion 50–1.
    Rec #: 628
  53. Masand, P. S. and Gupta, S. Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs Aging. 2003; 20(15):1099–110.
    Rec #: 360
  54. McDougle, C. J. Update on pharmacologic management of OCD: agents and augmentation. J Clin Psychiatry. 1997; 58 Suppl 12:11–7.
    Rec #: 724
  55. McDougle, C. J.; Epperson, C. N., and Price, L. H. Obsessive-compulsive symptoms with-neuroleptics. J Am Acad Child Adolesc Psychiatry. 1996 Jul; 35(7):837–8.
    Rec #: 1194
  56. McDougle, C. J.; Scahill, L.; McCracken, J. T.; Aman, M. G.; Tierney, E.; Arnold, L. E.; Freeman, B. J.; Martin, A.; McGough, J. J.; Cronin, P.; Posey, D. J.; Riddle, M. A.; Ritz, L.; Swiezy, N. B.; Vitiello, B.; Volkmar, F. R.; Votolato, N. A., and Walson, P. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am. 2000 Jan; 9(1):201–24.
    Rec #: 1267
  57. McGavin, J. K. and Goa, K. L. Aripiprazole. CNS Drugs. 2002; 16(11):779–86; discussion 787–8.
    Rec #: 456
  58. McIntyre, R. and Katzman, M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord. 2003; 5 Suppl 2:20–35.
    Rec #: 351
  59. Mintzer, J. E. Underlying mechanisms of psychosis and aggression in patients with Alzheimer’s disease. J Clin Psychiatry. 2001; 62 Suppl 21:23–5.
    Rec #: 539
  60. Motsinger, C. D.; Perron, G. A., and Lacy, T. J. Use of atypical antipsychotic drugs in patients with dementia. Am Fam Physician. 2000 Jun 1; 67(11):2335–40.
    Rec #: 404
  61. Nasrallah, H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003 Jan; 28 Suppl 1:83–96.
    Rec #: 1415
  62. Nasrallah, H. A. (Department of Psychiatry, University of Cincinnati Medical Center, Cincinnati, OH, US). Use of adjunctive medication in patients taking long-acting risperidone. Journal of Clinical Psychiatry. 2004 Jan; 65(1): 130–131; ISSN: 0160-6689 (Print).
    Rec #: 797
  63. Nemeroff, C. B. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry. 1997; 58 Suppl 10:45–9.
    Rec #: 742
  64. Parnetti, L. Therapeutic options in dementia. J Neurol. 2000 Mar; 247(3):163–8.
    Rec #: 181
  65. Parnetti, L.; Amici, S.; Lanari, A., and Gallai, V. Pharmacological treatment of non-cognitive disturbances in dementia disorders. Mech Ageing Dev. 2001 Nov; 122(16):2063–9.
    Rec #: 537
  66. Peuskens, J.; Van Baelen, B.; De Smedt, C., and Lemmens, P. Effects of risperidone on affective symptoms in patients with schizophrenia. Int Clin Psychopharmacol. 2000 Nov; 15(6):343–9.
    Rec #: 1064
  67. Pringsheim, T.; Davenport, W. J., and Lang, A. Tics. Curr Opin Neurol. 2003 Aug; 16(4):523–7.
    Rec #: 390
  68. Raskind, M. A. and Peskind, E. R. Alzheimer’s disease and related disorders. Med Clin North Am. 2001 May; 85(3):803–17.
    Rec #: 566
  69. Reynolds, P. L. and Strayer, S. M. Neuroleptics for behavioral symptoms of dementia. J Fam Pract. 2000 Jan; 49(1):78–9.
    Rec #: 182
  70. Rothschild, A. J. Management of psychotic, treatment-resistant depression. Psychiatr Clin North Am. 1996 Jun; 19(2):237–52.
    Rec #: 752
  71. Ryan, J. Michael (Monroe Community Hospital, Rochester, NY, US). Newer-generation antipsychotics for the management of psychosis in older patients with dementia. Journal of Clinical Psychiatry. 2003 Nov; 64(11): 1388–1390; ISSN: 0160-6689 (Print).
    Rec #: 779
  72. Sajatovic, M. Treatment for mood and anxiety disorders: quetiapine and aripiprazole. Curr Psychiatry Rep. 2003 Aug; 5(4):320–6.
    Rec #: 1550
  73. Salzman, C. Treatment of the agitation of late-life psychosis and Alzheimer’s disease. Eur Psychiatry. 2001 Jan; 16 Suppl 1:25s–28s.
    Rec #: 545
  74. Schatzberg, A. F. New approaches to managing psychotic depression. J Clin Psychiatry. 2003; 64 Suppl 1:19–23.
    Rec #: 423
  75. Schneider, L. S. Pharmacologic management of psychosis in dementia. J Clin Psychiatry. 1999; 60 Suppl 8:54–60.
    Rec #: 668
  76. Schulz SC; Adityanjee, and Romine A. Atypicla Antipsychotic Medications for borderline personality Disorder: What’s the Story? Current Psychosis and Therapeutics Report. 2004; 2:93–98.
    Rec #: 1247
  77. Schweitzer, I. Does risperidone have a place in the treatment of nonschizophrenic patients? Int Clin Psychopharmacol. 2001 Jan; 16(1):1–19.
    Rec #: 589
  78. Sharif, Z. A. Overview of safety and tolerability of atypical antipsychotics used in primary care. Primary Care Companion. J Clin Psychiatry. 2003; 5((Suppl 3)):14–21.
    Rec #: 1386
  79. Shelton, R. C. The combination of olanzapine and fluoxetine in mood disorders. Expert Opin Pharmacother. 2003 Jul; 4(7):1175–83.
    Rec #: 398
  80. Siris, S. G. Suicide and schizophrenia. J Psychopharmacol. 2001 Jun; 15(2):127–35.
    Rec #: 1612
  81. Soares, J. C. and Gershon, S. Therapeutic targets in late-life psychoses: review of concepts and critical issues. Schizophr Res. 1997 Oct 30; 27(2–3):227–39.
    Rec #: 186
  82. Stoppe, G.; Brandt, C. A., and Staedt, J. H. Behavioural problems associated with dementia: the role of newer antipsychotics. Drugs Aging. 1999 Jan; 14(1):41–54.
    Rec #: 680
  83. Stoppe, G. and Staedt, J. [Psychopharmacotherapy of behavioral disorders in patients with dementia]. Z Gerontol Geriatr. 1999 Jun; 32(3):153–8.
    Rec #: 659
  84. Sumitani, S. and Ohmori, T. [The treatment of OCD]. Ryoikibetsu Shokogun Shirizu. 2003; (38):442–5.
    Rec #: 388
  85. Targum, S. D. New Rx for psychoses in Alzheimer’s, Parkinson’s. Contemp Longterm Care. 2001 Jan; 24(1):39–40.
    Rec #: 588
  86. Tariot, P. N. and Ismail, M. S. Use of quetiapine in elderly patients. J Clin Psychiatry. 2002; 63 Suppl 13:21–6.
    Rec #: 433
  87. Tariot, P. N.; Profenno, L. A., and Ismail, M. S. Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry. 2004; 65 Suppl 11:11–5.
    Rec #: 287
  88. Thase, M. E. What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry. 2002 Feb; 63(2):95–103.
    Rec #: 501
  89. Tollefson, G. D. and Kuntz, A. J. Review of recent clinical studies with olanzapine. Br J Psychiatry Suppl. 1999; (37):30–5.
    Rec #: 673
  90. Trivedi, M. H. Treatment-resistant depression: new therapies on the horizon. Ann Clin Psychiatry. 2003 Mar; 15(1):59–70.
    Rec #: 392
  91. Tune, L. E. Risperidone for the treatment of behavioral and psychological symptoms of dementia. J Clin Psychiatry. 2001; 62 Suppl 21:29–32.
    Rec #: 538
  92. Verma, S. D.; Davidoff, D. A., and Kambhampati, K. K. Management of the agitated elderly patient in the nursing home: the role of the atypical antipsychotics. J Clin Psychiatry. 1998; 59 Suppl 19:50–5.
    Rec #: 1233
  93. Weimer, E.; Braus, D. F.; Cavus, I., and Thome, J. [Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression]. Fortschr Neurol Psychiatr. 2002 Apr; 70(4):210–7.
    Rec #: 492
  94. Wooltorton, E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ. 2004 Apr 27; 170(9):1395.
    Rec #: 317
  95. ---. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2002 Nov 26; 167(11):1269–70.
    Rec #: 448
  96. Wragg, R. E. and Jeste, D. V. Neuroleptics and alternative treatments. Management of behavioral symptoms and psychosis in Alzheimer’s disease and related conditions. Psychiatr Clin North Am. 1988 Mar; 11(1):195–213.
    Rec #: 1022
  97. Yatham, L. N. Efficacy of atypical antipsychotics in mood disorders. J Clin Psychopharmacol. 2003 Jun; 23(3 Suppl 1):S9–14.
    Rec #: 397
  98. Yatham, L. N.; Calabrese, J. R., and Kusumakar, V. Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord. 2003 Apr; 5(2):85–97.
    Rec #: 414
  99. Zaudig, M. A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia. Drug Saf. 2000 Sep; 23(3):183–95.
    Rec #: 601

REJECTED: Study Design - Review/Meta-Analyses

  1. Adityanjee and Schulz, S. C. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry. 2002; 63 Suppl 13:32–8.
    Rec #: 432
  2. Aubry, J. M.; Simon, A. E., and Bertschy, G. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. J Clin Psychiatry. 2000 Sep; 61(9):649–55.
    Rec #: 1078
  3. Battaglia, J.; Lindborg, S. R.; Alaka, K.; Meehan, K., and Wright, P. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med. 2003 May; 21(3):192–8.
    Rec #: 402
  4. Bhana, N. and Spencer, C. M. Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia. Drugs Aging. 2000 Jun; 16(6):451–71.
    Rec #: 608
  5. Breder C; Kostic D; Forbes A; Marcus R; Goyvaerts H; Swanink R, and Carson W. Overall Safety of ARipiprazole in triasl of patients with psychosis of Alzheimer’s dementia. American Psychiatric Association 158th Meeting; Atlanta, GA.
    Rec #: 1541
  6. Byerly, M. J.; Weber, M. T.; Brooks, D. L.; Snow, L. R.; Worley, M. A., and Lescouflair, E. Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging. 2001; 18(1):45–61.
    Rec #: 586
  7. Caley, C. F. and Cooper, C. K. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother. 2002 May; 36(5):839–51.
    Rec #: 1419
  8. Correll, C. U.; Leucht, S., and Kane, J. M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004 Mar; 161(3):414–25.
    Rec #: 225
  9. Davis, J. M. and Chen, N. Clinical profile of an atypical antipsychotic: risperidone. Schizophr Bull. 2002; 28(1):43–61.
    Rec #: 481
  10. De Deyn, P.; Katz, I., and Brodaty, H. Risperidone reduces aggressive symptoms associated with dementia independent of its antipyschotic effect of induction of somnolence. Presented at the 11th Congress of International Pschogeriatric Association. Int Psychogeriatr. 2003; 15((Suppl 2)):330.
    Rec #: 1469
  11. De Deyn, P. P.; Katz, I. R.; Brodaty, H.; Lyons, B.; Greenspan, A., and Burns, A. Management of agitation, aggression, and psychosis associated with dementia: A pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg. 2005 May 24.
    Rec #: 1287
  12. DeVane, C. L. and Mintzer, J. Risperidone in the management of psychiatric and neurodegenerative disease in the elderly: an update. Psychopharmacol Bull. 2003; 37(4):116–32.
    Rec #: 313
  13. Fineberg, N. A.; Gale, T. M., and Sivakumaran, T. A review of antipsychotics in the treatment of obsessive compulsive disorder. J Psychopharmacol. 2006 Jan; 20(1):97–103.
    Rec #: 1624
  14. Fountoulakis, K. N.; Nimatoudis, I.; Iacovides, A., and Kaprinis, G. Off-label indications for atypical antipsychotics: A systematic review. Ann Gen Hosp Psychiatry. 2004 Feb 18; 3(1):4.
    Rec #: 170
  15. Ghaemi, S. N. New treatments for bipolar disorder: the role of atypical neuroleptic agents. J Clin Psychiatry. 2000; 61 Suppl 14:33–42.
    Rec #: 1106
  16. Glick, I. D.; Murray, S. R.; Vasudevan, P.; Marder, S. R., and Hu, R. J. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res. 2001 May-2001 Jun 30; 35(3):187–91.
    Rec #: 189
  17. Greenspan, A.; Brodaty, H.; Katz, I., and et al. Risperidone is effective in treating psychotic symptoms in patients with psychosis of Alzheimer’s disease. Poster presented at the American Association for Geriatric Psychiatry Annual Meeting; San Diego, California.
    Rec #: 1495
  18. Greenspan, A.; Eerdekens, M.; Mahalchick, L., and et al. Risperidone treatment in psychosis of Alzheimer’s disease with and without prominent agitation/aggression. Poster presented at teh ICGP Annual Meeting; Basal, Swtizerland.
    Rec #: 1497
  19. Herrmann, N. and Lanctot, K. L. Do atypical antipsychotics cause stroke? CNS Drugs. 2005; 19(2):91–103.
    Rec #: 1515
  20. Hoeh, N.; Gyulai, L.; Weintraub, D., and Streim, J. Pharmacologic management of psychosis in the elderly: a critical review. J Geriatr Psychiatry Neurol. 2003 Dec; 16(4):213–8.
    Rec #: 172
  21. Howard, R.; Ballard, C.; O’Brien, J., and Burns, A. Guidelines for the management of agitation in dementia. Int J Geriatr Psychiatry. 2001 Jul; 16(7):714–7.
    Rec #: 179
  22. Katz, I.; De Deyn, P. P.; Brodaty, H., and et al. Risperidone is effective in the treatment of behavioural and psychological symptoms in patients with psychosis of Alzheimer’s disease and related dementias. Annual meeting of teh American Geriatrics Society.; Las Vegas, NV.
    Rec #: 1499
  23. Kennedy, E.; Song, F.; Hunter, R.; Clarke, A., and Gilbody, S. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2000; (2):CD000440.
    Rec #: 1310
  24. Kindermann, S. S.; Dolder, C. R.; Bailey, A.; Katz, I. R., and Jeste, D. V. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience. Drugs Aging. 2002; 19(4):257–76.
    Rec #: 1072
  25. Kostic D; Breder C; Marcus R; Forbes A; Pikalov A; Swanink R, and Goyvaerts H. Aripiprazole for Treatment of Agitation in inpatients with psychosis of Alzheimer’s dementia. American Psychiatric Association 158th Annual Meeting; Atlanta, GA.
    Rec #: 1543
  26. Kujawa MJ; Marcus R; Breder C; Kostic D; Swanink R; Iwamoto T; Carson WH, and Yamamoto Y. Safety and tolerability profile of aripiprazole in elderly patients wiht psychosis of alzheimer’s dementia: A pooled analysis.
    Rec #: 1594
  27. Lee, P. E.; Gill, S. S.; Freedman, M.; Bronskill, S. E.; Hillmer, M. P., and Rochon, P. A. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ. 2004 Jul 10; 329(7457):75.
    Rec #: 165
  28. Lindborg, S. R.; Beasley, C. M.; Alaka, K., and Taylor, C. C. Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Res. 2003 Jul 15; 119(1–2):113–23.
    Rec #: 391
  29. Lykouras, L.; Alevizos, B.; Michalopoulou, P., and Rabavilas, A. Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry. 2003 May; 27(3):333–46.
    Rec #: 412
  30. Marder, S. R.; Davis, J. M., and Chouinard, G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997 Dec; 58(12):538–46.
    Rec #: 1037
  31. McClellan, J. M. and Werry, J. S. Evidence-based treatments in child and adolescent psychiatry: an inventory. J Am Acad Child Adolesc Psychiatry. 2003 Dec; 42(12):1388–400.
    Rec #: 365
  32. Mintzer J; DeVane L; West B; Pultz J; Pikalov A; Marcus R; Gutierrez-Esteinou R, and Crandall D. Aripiprazole effects on highly agitated patients with alzheimers’s disease and associated psychosis. American College of Neuropsychopharmacology; Waikoloa, Hawaii.
    Rec #: 1544
  33. Peuskens, J.; Moller, H. J., and Puech, A. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol. 2002 Aug; 12(4):305–10.
    Rec #: 473
  34. Rabinowitz, J.; Katz, I. R.; De Deyn, P. P.; Brodaty, H.; Greenspan, A., and Davidson, M. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. J Clin Psychiatry. 2004 Oct; 65(10):1329–34.
    Rec #: 260
  35. Rachid, F.; Bertschy, G.; Bondolfi, G., and Aubry, J. M. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J Clin Psychiatry. 2004 Nov; 65(11):1537–45.
    Rec #: 252
  36. Rendell, J. M.; Gijsman, H. J.; Keck, P.; Goodwin, G. M., and Geddes, J. R. Olanzapine alone or in combination for acute mania. Cochrane Database Syst Rev. 2003; (3):CD004040.
    Rec #: 154
  37. Sareen, J.; Kirshner, A.; Lander, M.; Kjernisted, K. D.; Eleff, M. K., and Reiss, J. P. Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms? A systematic review. J Affect Disord. 2004 Oct 15; 82(2):167–74.
    Rec #: 164
  38. Schatz, R. A. Olanzapine for psychotic and behavioral disturbances in Alzheimer disease. Ann Pharmacother. 2003 Sep; 37(9):1321–4.
    Rec #: 383
  39. Schneider, L. S.; Dagerman, K., and Insel, P. S. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006 Mar; 14(3):191–210.
    Rec #: 1628
  40. Schneider, L. S.; Dagerman, K. S., and Insel, P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005 Oct 19; 294(15):1934–43.
    Rec #: 1509
  41. Schoenfeld, F. B.; Marmar, C. R., and Neylan, T. C. Current concepts in pharmacotherapy for posttraumatic stress disorder. Psychiatr Serv. 2004 May; 55(5):519–31.
    Rec #: 1225
  42. Schooler N; Loebel A, and Yang R. Long-Term Depressive Symptoms Improvement after switch to ziprasidone. Pfizer, Inc.
    Rec #: 1533
  43. Simard, M. and van Reekum, R. Dementia with Lewy bodies in Down’s syndrome. Int J Geriatr Psychiatry. 2001 Mar; 16(3):311–20.
    Rec #: 573
  44. Sink, K. M.; Holden, K. F., and Yaffe, K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005 Feb 2; 293(5):596–608.
    Rec #: 1283
  45. Siris, S. G. Depression in schizophrenia: perspective in the era of “Atypical” antipsychotic agents. Am J Psychiatry. 2000 Sep; 157(9):1379–89.
    Rec #: 1610
  46. Snowden, M.; Sato, K., and Roy-Byrne, P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc. 2003 Sep; 51(9):1305–17.
    Rec #: 174
  47. Stock E; Breader C; Goyvaerts H, and et al. Safety profile of aripiprazole in psychosis of Alzheimer’s dementia: pooled analysis. Poster. American Psychiatric Association Annual Meeting; New York, NY.
    Rec #: 1518
  48. Toren, P.; Laor, N., and Weizman, A. Use of atypical neuroleptics in child and adolescent psychiatry. J Clin Psychiatry. 1998 Dec; 59(12):644–56.
    Rec #: 683
  49. Tulloch, K. J. and Zed, P. J. Intramuscular olanzapine in the management of acute agitation. Ann Pharmacother. 2004 Dec; 38(12):2128–35.
    Rec #: 163
  50. Williams, R. Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry. 2001 Apr; 62(4):282–9.
    Rec #: 562
  51. Zajacka J; Murray S; Ramey T, and Mandel F. Efficacy of ziprasidone in dysphoric mania: Analysis of 3 double-blind studies. Pfizer, Inc.
    Rec #: 1532

REJECTED: Study Design - Descriptive

  1. Aakhus, E. [Ziprasidone and dementia]. Tidsskr Nor Laegeforen. 2004 Aug 26; 124(16):2155–6; author reply 2155–6.
    Rec #: 275
  2. Baker, R. W. Possible dose-response relationship for risperidone in obsessive-compulsive disorder. J Clin Psychiatry. 1998 Mar; 59(3):134.
    Rec #: 711
  3. Berigan, T. R. and Harazin, J. S. Response to risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry. 1996 Dec; 57(12):594–5.
    Rec #: 745
  4. Bernhard, R. Can risperidone be antidepressive and also inhibit aggression? J Neuropsychiatry Clin Neurosci. 1997 Fall; 9(4):627–8.
    Rec #: 722
  5. Chaplin, R. H. Risperidone, tardive dyskinesia, and the elderly. Am J Psychiatry. 2001 Aug; 158(8):1336–7.
    Rec #: 550
  6. Croarkin, P. E. and Bain, B. K. “Risperidone-associated diabetic ketoacidosis”: reply. Psychosomatics: Journal of Consultation Liaison Psychiatry. 2001 May-2001 Jun 30; 42(3): 280 URL: http://psy.psychiatryonline.org/; ISSN: 0033-3182 (Print).
    Rec #: 858
  7. Duggal, H. S. Risperidone-induced obsessive-compulsive symptoms in two children. J Child Adolesc Psychopharmacol. 2004 Spring; 14(1):155–6.
    Rec #: 312
  8. ---. Risperidone-induced obsessive-compulsive symptoms: serotonin-dopamine imbalance? J Clin Psychopharmacol. 2003 Dec; 23(6):681–2.
    Rec #: 366
  9. Edleman, R. J. (St Mary’s Children & Family Services, Syosset, NY, US). Td from risperidone? Journal of the American Academy of Child & Adolescent Psychiatry. 1997 Jul; 36(7): 867; ISSN: 0890-8567 (Print).
    Rec #: 907
  10. Haupt, D. W. and Newcomer, J. W. Risperidone-associated diabetic ketoacidosis. Psychosomatics. 2001 May-2001 Jun 30; 42(3):279–80.
    Rec #: 564
  11. Iruela, L. M. Risperidone and obsessive-compulsive symptoms. J Clin Psychopharmacol. 1996 Feb; 16(1):85–6.
    Rec #: 756
  12. Mahmoud, R. and Greenspan, A. (Janssen Pharmaceutica, Titusville, NJ, US; Janssen Pharmaceutica, Titusville, NJ, US). “Early alzheimer’s disease”: comment. New England Journal of Medicine. 2004 Jan; 350(1): 81; ISSN: 0028-4793 (Print).
    Rec #: 800
  13. Malek-Ahmadi, P. and Simonds, J. F. Olanzapine for autistic disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1998 Sep; 37(9):902.
    Rec #: 1016
  14. Mowat, D.; Fowlie, D., and MacEwan, T. CSM warning on atypical psychotics and stroke may be detrimental for dementia. BMJ. 2004 May 22; 328(7450):1262.
    Rec #: 309
  15. Onalaja, D. and Jainer, A. K. Re: Chan et al. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 16: 1156–162. Int J Geriatr Psychiatry. 2002 Nov; 17(11):1076-7; author reply 1077.
    Rec #: 452
  16. Parker, G. and Malhi, G. Are the atypical antipsychotic drugs antidepressants? J Clin Psychopharmacol. 2002 Feb; 22(1):94–5.
    Rec #: 510
  17. Ramasubbu, R. Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent. Arch Gen Psychiatry. 2002 May; 59(5):472; author reply 472–3.
    Rec #: 489
  18. Scahill, L.; McCracken, J.; McDougle, C. J.; Aman, M.; Arnold, L. E.; Tierney, E.; Cronin, P.; Davies, M.; Ghuman, J.; Gonzalez, N.; Koenig, K.; Lindsay, R.; Martin, A.; McGough, J.; Posey, D. J.; Swiezy, N.; Volkmar, F.; Ritz, L., and Vitiello, B. Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. J Child Adolesc Psychopharmacol. 2001 Winter; 11(4):377–88.
    Rec #: 1279
  19. Scahill, L.; MCracken, J. T.; McDougle, C. J., and et al. Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. J Chil Adolesc Psychopharmacol. 2001; 11(4):377–88.
    Rec #: 1327
  20. Schneider, L. S.; Tariot, P. N.; Lyketsos, C. G.; Dagerman, K. S.; Davis, K. L.; Davis, S.; Hsiao, J. K.; Jeste, D. V.; Katz, I. R.; Olin, J. T.; Pollock, B. G.; Rabins, P. V.; Rosenheck, R. A.; Small, G. W.; Lebowitz, B., and Lieberman, J. A. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry. 2001 Fall; 9(4):346–60.
    Rec #: 528
  21. Shelton, R. C. Dr. Shelton replies. American Journal of Psychiatry. 2002 Jan; 159(1): 155–156 URL: http://ajp.psychiatryonline.org/; ISSN: 0002-953X (Print).
    Rec #: 836
  22. Tariot, P. N. Clinical effectiveness of atypical antipsychotics in dementia. J Clin Psychiatry. 2004; 65 Suppl 11:3–4.
    Rec #: 289
  23. Viner, M. W.; Chen, Y.; Bakshi, I., and Kamper, P. Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation. J Clin Psychopharmacol. 2003 Feb; 23(1):104–6.
    Rec #: 436
  24. Wolfgang, S. A. Olanzapine in whole, not half, tablets for psychosis from Alzheimer’s dementia. Am J Health Syst Pharm. 1999 Nov 1; 56(21):2245–6.
    Rec #: 646

REJECTED: Study Design - Cohort

  1. Adson, D. E.; Kushner, M. G., and Fahnhorst, T. A. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord. 2005 May; 86(1):99–104.
    Rec #: 1549
  2. Brown, E. S.; Jeffress, J.; Liggin, J. D.; Garza, M., and Beard, L. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry. 2005 Jun; 66(6):756–60.
    Rec #: 1568
  3. Heimburger GE. Open-label trial of aripiprzole in Tourette’s syndrome children: Young Adults.
    Rec #: 1560
  4. Ketter TA; Wang PW; Chandler RA; Culver JL, and Alarcon AM. Aripiprazole in treatment-resistant bipolar depression. 43rd Annual Meeting of American College of Neuropsychopharmacology; San Juan, Puerto Rico.
    Rec #: 1555
  5. Loonen, A. J.; Loos, J. C., and Van Zonneveld, T. H. Outcomes and costs of treatment with risperidone in adult and elderly patients: the Delta patient using risperidone study. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Dec; 26(7–8):1313–8.
    Rec #: 442
  6. Margolese, H. C.; Annable, L., and Dion, Y. Depression and dysphoria in adult and adolescent patients with Tourette’s disorder treated with risperidone. J Clin Psychiatry. 2002 Nov; 63(11):1040–4.
    Rec #: 449
  7. Mukaddes, N. M.; Abali, O., and Gurkan, K. Short-term efficacy and safety of risperidone in young children with autistic disorder (AD). World J Biol Psychiatry. 2004 Oct; 5(4):211–4.
    Rec #: 1505
  8. Noordsy, D. L.; O’Keefe, C.; Mueser, K. T., and Xie, H. Six-month outcomes for patients who switched to olanzapine treatment. Psychiatr Serv. 2001 Apr; 52(4):501–7.
    Rec #: 577
  9. Papakostas, G. I.; Petersen, T. J.; Kinrys, G.; Burns, A. M.; Worthington, J. J.; Alpert, J. E.; Fava, M., and Nierenberg, A. A. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry. 2005 Oct; 66(10):1326–30.
    Rec #: 1547
  10. Rothschild, A. J.; Bates, K. S.; Boehringer, K. L., and Syed, A. Olanzapine response in psychotic depression. J Clin Psychiatry. 1999 Feb; 60(2):116–8.
    Rec #: 148
  11. Simon, J. S. and Nemeroff, C. B. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry. 2005 Oct; 66(10):1216–20.
    Rec #: 1548

REJECTED: Study Design - Other

  1. Clarnette R, Brodaty H Ames D Snowdon J Lee E Woodward M Kirwan J Lyons B Grossman F. Risperidone in the treatment of agitation, aggression and psychosis of dementia. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum, June 23–27 2002, Montreal, Canada). 2002; 5(Suppl 1):S91. CODEN: CCT; ISSN: CN-00393219.
    Rec #: 944
  2. Condren, R. M. and Cooney, C. Use of drugs by Old Age Psychiatrists in the treatment of psychotic and behavioural symptoms in patients with dementia. Aging Ment Health. 2001 Aug; 5(3):235–41.
    Rec #: 544
  3. Dube, S.; Andersen, S., and Tohen, M. et al. Onset of action of olanzapine-fluoxetine combination for bipolar depression [Abstract P.1.077]. J Eur Coll Neuropsychopharmacol. 2002; 12(Suppl. 3):S202.
    Rec #: 1041
  4. Grohmann, R.; Engel, R. R.; Geissler, K. H., and Ruther, E. Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry. 2004 Mar; 37 Suppl 1:S27–38.
    Rec #: 323
  5. Hellings, J. A.; Zarcone, J. R.; Crandall, K.; Wallace, D., and Schroeder, S. R. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol. 2001 Fall; 11(3):229–38.
    Rec #: 216
  6. Kinon, B. J.; Stauffer, V. L.; McGuire, H. C.; Kaiser, C. J.; Dickson, R. A., and Kennedy, J. S. The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients. J Am Med Dir Assoc. 2003 Jul-2003 Aug 31; 4(4):189–94.
    Rec #: 394
  7. Liperoti, R.; Mor, V.; Lapane, K. L.; Pedone, C.; Gambassi, G., and Bernabei, R. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry. 2003 Sep; 64(9):1106–12.
    Rec #: 188
  8. Voris, J. C. Glazer W. M. Use of risperidone and olanzapine in outpatient clinics at six veterans affairs hospitals. Psychiatric Serv. 1999; 50:163–4.
    Rec #: 1491
PubReader format: click here to try

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (9.7M)

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...